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Introduction: Tibolone as Hormone Replacement 
Therapy (HRT), a comparison with continuous 
combined HRT and Raloxifene. 
1.1 History and definition of the study objectives 
The menopause is defined as the time at which a woman has her final menstruation. The 
average age at menopause is 51 years. In contrast to the decreased age at which menarche 
takes place. the age at menopause remained constant over the last century (McKinlay et aL 
1992). In the early 18" century. life expectancy of (upper class) women increased from 55 to 
65 years (Cope. 1976). It is unsurprising that the first reports concerning the climacteric 
period date from that period (Titus, 1710; anonymous. 1727). At that time the problems of 
postmenopausal women were attributed to the cessation of menstrual blood flow leading to 
accumulation of poisons in the body. In the 19" century Tilt published a work which 
hypothesised that menopausal problems were caused by ovarian failure (Tilt. 1857). The 
previous theory of poisons accumulation was abandoned. At the end of the 19th century. 
Maintzer was the first practitioner to treat young ovariectornised women with bovine ovarian 
extracts (Maintzer, 1896). At the beginning of the 20th century Starling introduced his concept 
of "'hormones··. Subsequently. the knowledge of ovarian function increased. After the 
isolation of the first estrogen (oestron) from theburine of pregnant women in 1929 
(Butenandt. 1929), the concept of estrogen deficiency and "postmenopausal syndrome " was 
fairly well established. by around 1930. After isolation of estradiol in 1940. commercial 
hormone replacement therapy (HRT) preparations became available from the 1950s onwards. 
HRT became more popular after publication of the book "fentinine forever" in 1966. a rather 
uncritically advocate for the use of estrogens. Interest in HRT faced a serious blow in 1975 
when unopposed estrogen therapy was associated with a higher risk of endometrial carcinoma 
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in non-hysterectomised women (Ziel et al., 1975; Smith et aL, 1975). From then on the use of 
progestins to protect the endometrium from estrogen-induced hyperplasia was mandatory. 
During the last decade, the positive effect of long term HRT on osteoporosis became 
apparent. In addition, active research into the mechanism of action of estrogens on the 
cardiovascular and nervous systems is underway. However. in spite of benefits of long-term 
HRT, compliance with treatment is poor. Scheduled withdrawal bleeding substantially 
reduces the acceptability of and compliance with HRT (Groeneveld et al.. 1998). Since it is 
the anti estrogenic effect rather than the shedding of the endometrium that is the important 
factor in preventing atypical hyperplasia or endometrial carcinoma, strategies to avoid 
withdrawal bleedings are now under development. A first approach is to add a progestin 
continuously to the estrogen administration in order to induce endometrial atrophy. Although 
spotting in the first months of therapy is frequent, about 90 % of the postmenopausal women 
will achieve amenorrhoea. More recently. effects of direct intrauterine administration of 
progestin. using a levonorgestrel releasing intrauterine device. have been studied. In addition 
to the protective effects on the endometrium and contraceptive properties. this device also 
reduces menstrual blood flow. which makes it especially suitable for use in perimenopausal 
women. Another approach to eliminating progestin-induced withdrawal bleeding is to develop 
target tissue specificity. The ideal compound would have the positive effects of estrogens on 
climacteric symptoms, bone and lipid profile, but would lack a stimulatory effect on the 
endometrium or breast. Tibolone is at present the only target tissue specific compound that 
alleviates postmenopausal symptoms without the need for withdrawal bleeding. 
Another important factor contributing to low compliance is the association of long-term 
HRT with breast cancer. When HRT is used for longer than 5 years there is a somewhat 
increased risk (relative risk 1.3) of breast cancer (Beral et al .. 1997). In this respect, the 
development of selective estrogen receptor modulators is of special interest. Raloxifene is first 
SERM to be developed that has no stimulatory effect on the endometrium and breast but has 
an estrogen-like effect on bone. The target tissue specificity of tibolone and SERMs will be 
discussed in the next section. In the present chapter. tibolone will be compared with 
continuous combined HRT and with raloxifene with respect to the most important aspects of 
HRT. 
The frrst aim of this thesis is to evaluate the effect of two different doses of tibolone on 
early postmenopausal bone loss. Furthermore. data on the incidence of vaginal bleeding and 
effect on the endometrium are presented. Thirdly. bone loss after discontinuation of treatment 
with tibolone is assessed. Finally, tibolone and its effect on bone will be reviewed. 
3 
1.2 Mixed hormonal profile and target tissue specificity of tibolone and raloxifene. 
Tibolone is a Cl9 derived synthetic progestin. An oral dose of tibolone is rapidly absorbed. 
appearing in the plasma within 30 minutes. and peaking at 4 hours. It is extensively 
metabolised by the liver into three metabolites: 3a(OH)tibolone. 3~(0H)tibolone and its .M 
isomer (Sandker et aL. 1994). The elimination half-life is about 45 hours. which is 
comparable to norethisteron (48-72 hours) and norgestrel (36 hours) (Anonymous. 1991). 
Endocrinological studies in rats and rabbits showed that tibolone has weak progestagenic 
estrogenic and androgenic effects (Visser et al.. 1984). In classical in vivo endocrinological 
assays. the estrogenic potency of tibolone is about 1/50"' that of ethinyl estradioL the 
progesragenic potency 1/Sth that of norethisteron, and the androgenic potency about l/3th that 
of norethisteron (Vies era!.. 1987). 
These actions are receptor mediated, as evident from the inhibitory effects of anti-
estrogens and anti-progestins. Therefore the effects of ti.bolone at the receptor level are 
complex as progestins reduce estrogen-receptor levels. while estrogens increase progestin-
receptor concentrations (Markiewicz eta!.. 1994). The complexity is increased by the fact that 
the three metabolites of tibolone show different estrogenic and progestagenic capabilities in 
vitro. Furthermore. the concentrations of metabolites differ depending on the target tissue. It 
is therefore likely that the estrogenic or progestagenic capabilities of tibolone differ. 
depending on the target tissue. For example. tibolone and its Ll.4 isomer stimulate 17~ 
dehydrogenase activity and glycogen accumulation in proliferative endometrium comparable 
to stimulation by progesterone. In contrast. the 3a(OH)- and 3~(0H) metabolites increase 
prostaglandin output in proliferative endometrium (i.e. an estrogenic effect). Furthermore. it 
was shown that tibolone was extensively metabolised to its .6.4 isomer in the endometrium by 
3~ hydroxylase/isomerase (Tang et al.. 1993). These findings suggest a complex receptor-
mediated as well as metabolic regulation of the activity of tibolone at the target tissue leveL 
which probably accounts for tissue specificity in the relative estrogenic/progestagenic 
activities (Markiewicz eta!.. 1990). In other words. the tissue specific action of tibolone may 
be caused by differences in metabolism in combination with the presence of various receptor 
types and their density. 
In contrast to tibolone. SERMs produce tissue specific agonist/antagonist effects after 
binding to the estrogen receptor (ER) through a mechanism that has not yet been elucidated. 
An important step in explaining the differential effects of SERMs may be the discovery of a 
4 
second ER. ER~ (Kuiper et al.. 1996: Mosselman et al.. 1996). The classic ER has been 
renamed ERa. As reviewed recently (Nilsson et al.. 1998), these two ERs appear to have 
unique tissue distributions and their own specific set of functions. Furthermore, in contrast to 
17~ estradiol (E2). raloxifene (a benzothiophene SERM) showed an ERa selective partial 
agonist/antagonist function but acted as a pure antagonist through ERj3 (Barkhem et al., 
1998). The precise mechanism by which SERMs produce their tissue selective 
agonist/antagonist effect after binding to the ER. which is distinct from that of 17j3 E2 since it 
behaves as an estrogen agonist in all tissues, is now the subject of intensive research. It is 
thought that when a SERM binds to the ER. a specific conformation of the receptor-ligand is 
induced. Then. depending on structure of the gene-promotor and the sets and concentrations 
of the co-regulatory proteins present. produces a cell-specific antagonist/agonist effect 
(Barkhem et al.. 1998: McDonnell. 1998). Raloxifene is the first SERM available for 
prescription that has no stimulatory effect on the endometrium while having an estrogenic 
effect on bone. A comparison of raloxifene with continuous combined HRT and with tibolone 
in respect to its effects in postmenopausal women will be made in the present chapter. 
1.3 Climacteric symptoms 
1.3.1 Hot flushes and nocturnal sweats 
The hallmark symptom of the menopause is the hot flush. A hot flush is a sudden. transient 
sensation ranging from warmth to intense heat that spreads over the upper part of the body. 
typically accompanied by flushing. perspiration and often followed by a chill. In some 
instances, there are palpitations and a feeling of anxiety. Whether referred to as hot flashes. 
hot flushes. night sweats or vasomotor symptoms (terms that are used interchangeably) these 
episodic events can disrupt a woman's sense of well-being. Although hot flushes are the 
predominant complaint of western peri- and postmenopausal women. it was not until 1975 
that their objective existence was demonstrated (Molnar. 1975). One should bear in mind that 
several conditions share some clinical features with hot flushes. particularly flushing and 
sweating. These conditions include hyperthyroidism. panic attacks. carcinoid syndrome and 
pheochromocytoma. 
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As many as 75% of all postmenopausal women experience vasomotor symptoms. For 65% 
these last longer than a year and in 20%, these symptoms continue for more than 5 years 
(Brenner, 1988). A drop in estrogen levels rather than a steady low estrogen level is 
associated with hot flushes. The observation that women with gonadal dysgenesis (Turner's 
syndrome) who never had adult estrogen levels do not experience hot flashes unless they 
previously used HRT. supports this contention (Casper et al.. 1985). Furthermore 
premenopausal women using gonadotrophin releasing hormone (GnRH)-agonists experience 
vasomotor symptoms and postmenopausal women on HRT often experience the return of hot 
flushes when they discontinue medication. Hypotheses about the definitive explanation of the 
hot flush also include the role of a-adrenergic mechanisms, endogenous opioid peptide and 
GnRH (Casper et al.. 1985). As yet, however. the aetiology of the hot flush remains unknown. 
Usually within a few weeks of starting replacement therapy vasomotor symptoms are reduced. 
The effect of continuous combined HRT on vasomotor symptoms has been reviewed 
recently (Udolff et al.. 1995). Thirteen studies specifically examined vasomotor 
symptomatology. Of these only four studies used the Kuppennan index. All four studies 
revealed a significant treatment -associated decline in Kupperman scores. The remaining 9 
studies made use of diaries or interview to record the incidence and severity of hot flushes. 
Similarly these studies noted a reduction in the rate of complaints. Furthermore. recently 
introduced low-dose continuous combined HRT (25jlg 17f3E2 administrated transdennally or 
lmg 17[3E2 orally) seem to be as effective as continuous combined HRT with 2mg 17f3E2 in 
alleviating vasomotor symptoms in women 2-3 years after menopause (Stadberg et al.. 1996: 
Mattson et al.. 1999). 
Tibolone. at a dose of 2.5mg/d has been proven to alleviate vasomotor symptoms when 
compared with placebo. There are 6 randomised placebo-controlled trials (Aloysio et al., 
1987) of which 5 were blinded (Kicovic et al.. 1982; Trevoux et al., 1983; Nevinny-Stickel, 
1983; Benedek-Jaszmann, 1987. Hammar et al.. 1996). All used diaries scoring the incidence 
and/or severity of flushes. Follow-up varied from 12-52 weeks. All studies found a significant 
reduction in vasomotor symptoms compared with placebo. In a non-randomised study in 
which patients with more severe vasomotor symptoms chose treaunent with tibolone 2,5 
mg/d. the number of hot flushes was reduced from 5 to less than 1 per day. (Rymer et al., 
1994). The effect of tibolone on vasomotor symptoms was as effective as sequential HRT 
regimens (Volpe et al .. 1986; Crona er al., 1988; Egarter et al., 1996). Two studies directly 
compared the effect of tibolone on vasomotor symptoms with that of continuous combined 
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HRT. One double-blind. placebo-controlled trial (Hanunar et al.. 1998) involving 423 
patients, and an open labeL randontised study of 148 women (Al-Azzawi et al.. 1999) showed 
that both treatments effectively reduced vasomotor symptoms. However. in one study there 
was a small but significant difference in favour of continuous combined HRT (Hammar et al., 
1998). 
Raloxifene increases hot flushes. In a large prospective randomised trial involving more 
than 7700 elderly postmenopausal women (Ettinger et al.. 1999). 10% of the women with 
ra!oxifene 60 mg/d reported hot flushes compared to 6% in the placebo group. Although the 
incidence of hot flushes was increased. only 1% of the women withdrew from the study for 
this reason. Another study pooled the treatment groups of 8 randontized parallel clinical trials 
comparing the adverse effects of raloxifene 60 mg/d with HRT. unopposed estrogen therapy 
and placebo (Davies et al.. 1999). These 8 studies enrolled a total of 2789 women. Twenty-
four percent of women on raloxifene reported hot flushes compared with 18% of women in 
the placebo group. However, discontinuation rates were not increased. 
fu summary. satisfactory relief of hot flushes was universally reported for continuous 
combined HRT as well as for tibolone. Unfortunately this effect is solely based on subjective 
(patient) reporting since no study used objective biophysical monitoring. Although one direct 
comparative study showed a small but significant difference in favour of continuous 
combined-HRT, the efficacy of tibolone and continuous combined as well as sequential HRT 
seem to be comparable for combating vasomotor symptoms. As one might suspect. there is a 
slight increase in vasomotor symptoms in women using raloxifene. However, data suggest 
that discontinuation rates are not substantially increased by this adverse event. 
1.3.2 Mood and libido 
Data on the relationship between changes in the endocrine milieu and psychological 
symptoms are conflicting. Epidentiological studies in the USA and Europe have failed to 
document an increase in depressive symptoms around the time of menopause (HallstrOm et 
al., 1985; McKinlay et al.. 1992). In contrast. other studies of non-clinical populations 
showed an increased incidence of depressive symptoms in peri- and postmenopausal women 
(Bungay et al., 1980; Hunter et al.. 1986). Interestingly. a longitudinal survey of ntiddle-aged 
women in the USA showed that depressive symptoms increase after surgical menopause but 
not after natural menopause (McKinlay et al.. 1987). Fnrthermore. up to 89% of women 
attending menopause clinics have depressive symptoms (Montgomery et al.. 1987). Plasma 
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levels of estrogens and testosterone are associated with positive moods in healthy non-
depressed women who had undergone bilateral oophorectomy (Sherwin. 1988). However. the 
positive effect of estrogens on mood seems to be dampened by the concomitant use of 
progestins. which can be attenuated by higher doses of estrogens (Holst et al.. 1989: Sherwin. 
1991). 
There are 3 studies evaluating the effect of tibolone on mood. In a short. randornised cross-
over trial involving healthy postmenopausal women. tibolone showed no statistically 
significant effect on mood compared with placebo (Nevinny-Stickel. 1983). However. in 
women who had undergone bilateral oophorectomy tibolone as well as unopposed estrogens. 
had a statistical significant positive effect on mood (Crona et a/..1988). Tibolone. proved to 
be significantly better than continuous combined HRT for improving mood (Egarter et al.. 
1996). The effects of raloxifene on mood were assessed in women using raloxifene 60 or 120 
mg/d. Raloxifene showed no effect on mood compared with placebo (Nickelsen et al.. 1999). 
Sexual problems seem to be associated with the menopause and not with ageing per se. 
Epidentiological data serve to point out that between one third and one half of menopausal 
women recruited from general populations complain of a problem in one or more aspects of 
sexual functioning (Sherwin, 1994). Since the integrity of the tissues of the female 
reproductive tract depend on estrogens, degenerative changes due to the hypo-estrogenic state 
may adversely affect sexual functioning in postmenopausal women. For example. decreased 
vaginal lubrication or atrophic vaginitis may result in dyspareunia. The positive effect of 
androgens rather than estrogens on libido or sexual motivation is now well established 
(Sherwin, 1994). For example. women who complained of loss of libido that had not been 
relieved by unopposed estrogen therapy reponed significant symptomatic relief following 
treatment with a combined estrogens/testosterone implant (Burger et al.. 1987). In this respect 
it is of interest whether tibolone is superior to HRT. since it possesses weak androgenic 
proprieties. Five studies evaluated the effect of tibolone on libido and sexual desire. Three of 
them showed a significant increase in libido compared to placebo or no treatment (Kicovic et 
a/..1982: Rymer et al.. Maturitas 1994: Palacios et al.. 1995). The studies showing no 
difference to placebo had either a short follow-up (Nevinny-Stickel. 1983) or low baseline 
scores for loss of libido (Genazzani et al.. 1987). These factors seem important since two 
randomised studies which intensively studied sexuality showed lager effects at longer 
duration of treatment and women with the lowest sexual desire scores were shown to have the 
greatest improvement over one year (Palacios et al.. 1995; Nathorst-Boos et al. 1997). 
Comparison between tibolone and sequential HRT showed that both treatments increased 
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libido without a significant difference between treatment groups. However. tibolone was 
found to be superior in improving all seven items assessing sexual life when compared with 
continuous combined HRT (Nathorst-Boos et al. 1997). 
In summary, there some evidence that tibolone has a positive effect on mood. libido and 
sexual desire in postmenopausal women. In this respect tibolone seems to be superior to 
continuous combined HRT but not to sequential HRT or unopposed estrogens. Assessments 
with raloxifene show no influence on mood compared with placebo (Nickelsen et al.. 1999). 
VI Genital atrophy 
Estrogen loss due to follicular depletion in the postmenopausal ovary is the major cause of 
vulvovaginal dysfunction in older women. accounting for most of the anatomic. cytologicaL 
bacteriologic and physiologic genital changes that occur. The most common presentations of 
vulvovaginal complaints are: vaginal dryness/irritation (27-40%) dyspareunia (25%) and 
urinary frequency and urgency (25%) (Oldenbave et al.. 1993: Geelen et al.. 1996). 
Systemic or topical administration of estrogens has been shown to alleviate symptoms of 
urogenital atrophy. In general. a minimum treatment period of 3 months is advised for 
alleviation of the symptoms of vaginal atrophy. In addition. estrogen therapy considerably 
reduces the incidence of urogenital infections (Raz et al., 1993). Although a significant effect 
on subjective improvement of all types of incontinence has been demonstrated for estrogen 
therapy compared with placebo (Fantl et al.. 1994). there is no conclusive evidence that 
estrogens objectively improve incontinence (Formosa et al., 1994). However, a combination 
of estrogen and a-adrenergic drugs seems to improve genuine stress incontinence subjectively 
as well as objectively (Hilton et al.. 1990). 
For continuous combined HRT. specific data on the effect of urogenital atrophy are 
lacking. Only one study of 59 healthy postmenopausal women states that .. all patients noted 
improvement of their climacteric symptoms and vaginal atrophy .. (AinM.elk. 1996). A total of 
7 studies evaluate the effect of tibolone on the vagina (Punnonen et al., 1984; De Aloyoisio et 
al.. 1987; Rymer et al.. 1994: Siseles et a/..1995: Egarter et al.. 1996: Botsis et al.. 1997: 
Hammar et al .. 1998). None of the studies compating tibolone with placebo or no treatment 
were double-blinded. Only one double-blind randornised study compared the effect of 
tibolone on the vagina with continuous combined HRT (Hammar et al.. 1998). Outcomes of 
these studies were either the maturation index of the vaginal epithelium and/or subjective 
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symptoms scoring (diaries) of vaginal dryness and dyspareunia. When tibolone was compared 
to no treatment or placebo there was a significantly increased maturation of the vaginal 
epithelium and significantly less complaints of vaginal dryness and dyspareunia. When 
tibolone was compared to other HRT regimens. vaginal dryness. dyspareunia and signs of 
atrophic vaginitis all improved with both treatments. Tibolone seems as effective as 
conventional HRT in this respect. Like continuous combined HRT. data on the effect of 
tibolone on urinary incontinence are lacking. For raloxifene. data on the effect on urogenital 
atrophy are not yet available. When adverse experiences of raloxifene were compared to 
placebo or HRT, the incidence of events related to vaginal atrophy did not differ (Davies et 
al.. 1999). 
LS Bone density 
1.5.1 Prevention and treatment of osteoporosis 
Osteoporosis is defined as a systemic skeletal disease characterised by low bone mass and 
rn.icroarchitectural deterioration of bone tissue, that leads to an increase in bone fragility and 
susceptibility to fracture (anonymous Am J Med; 1993). In contrast with earlier consensus 
statements this definition no longer requires the presence of non-traumatic fractures. Primary 
osteoporosis occurs in the absence of known causes for bone loss. The exception to the rule is 
postmenopausal osteoporosis. Although estrogen deficiency after menopause is a well-known 
cause for increased bone turnover and accelerated bone loss, postmenopausal osteoporosis is 
still classified as primary osteoporosis. Other representatives of primary osteoporosis are: age-
related osteoporosis, idiopathic osteoporosis and juvenile osteoporosis. When another disease, 
condition or medication is the cause of accelerated bone loss leading to low bone mass it is 
referred to as secondary osteoporosis (Table 1). 
fu the USA. osteoporosis gives rise to approximately 1.5 million fractures annually. 
Vertebral fractures are most frequent: 700.000 each year. Of all fractures due to osteoporosis, 
hip fractures are the most serious. Between 10-15% of 250.000 hip fractures victims die 
within a year of their fracture. Only about half of the survivors are able to return to fully 
independent living. and approximately a third become pennanent nursing home residents 
(Ray et al.. 1997). In the Netherlands the age-adjusted incidence of hip fractures in women 
over 50 years of age is about 350 per 100.000. The number of hospital admissions for hip 
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Table 1 Proposed risk factors for osteoporosis. 
Factor 
Genetic 
Nutritional 
Life-style 
Endocrine 
Disease 
Drugs 
Example 
Race, sex, familial prevalence 
Low calcium intake, high intake of: 
alcohol, caffeine, sodium or animal 
protein 
Cigarette use, low physical activity 
Menopausal age (oophorectomy), body 
composition, low premenopausal 
estrogen levels (anorexia nervosa, 
hypogonadism), hyper(para)thyreoidy, 
hypercortisolism. 
Malabsorption, liver cirrhosis, myeloma, 
connective tissue disorder. 
Corticosteroids 
fractures in Dutch inhabitants of 65 years and older is expected to double between 1990 and 
2010 (Boereboom et al.. 1992). Postmenopausal white women are most commonly affected 
because at any age they have lower bone mass than men and white people have a lower bone 
mass than other ethnic groups. 
Postmenopausal bone mass depends on the peak bone mass and the subsequent loss of 
bone. Bone mass depends on many hereditary and environmental factors. Although various 
risk factors for osteoporosis have been proposed (Table 1). it has been shown that patient 
history. anthropomorphic measurements and biomarkers of bone metabolism cannot be used 
to identify those women at risk for osteoporosis (Slemenda et al.. 1990: Cooper et al.. 1991: 
Berning et al .. 1993). At fhis moment the best available method of assessing fracture risk. 
especially in early postmenopausal women without previous fractures, is the performance of a 
bone mass measurement (Wasnich et al.. 1985: Gardsell et al .. 1993: Cummings et al.. 1995). 
The current "'gold standard'" method of bone density testing is Dual Energy X-ray 
Absorptiometry (DEXA) of the spine and hip (Bracker et al .. 1998). 
Bone mass is expressed as T -scores. This is defined as the difference in standard deviations 
of the individual bone mass, compared to the mean peak bone mass of a reference population. 
A T -score of -1 to -2.5 is considered to indicate osteopenia. A T -score of less than -2.5 is 
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considered as osteoporosis and. with fractures, it is considered to indicate severe osteoporosis. 
For each standard deviation reduction in bone mass there is an approximately 2-fold increase 
in the risk of fracture (Marshall et al., 1996). 
In theory. the prevention of osteoporosis could be achieved by either increasing peak bone 
mass, or by decreasing subsequent bone loss. However, except for a healthy active life style. 
no definite strategy for increasing peak bone mass has yet identified. In elderly prevention of 
fall may reduce the risk of hip fracmre considerably. Although risk factors for falling have 
been identified (Grisso et al., 1991) there is no specific intervention that has been proven to 
be widely effective. General measures including an adequate intake of calcium and vitamin D 
and an active life style can be recommended to everyone. whether or not they present with 
osteoporosis. A recent study (Kannus et al.. 2000) in elderly people (mean age 82 yrs) showed 
a reduction of 60% of hip fracmres with the use of hip protectors. However, an important goal 
for prevention and therapy of osteoporosis is the restoration of bone resorption and formation 
to premenopausal levels. 
Estrogens are generally considered to be the agent of choice for both treatment and 
prevention of osteoporosis. The epidemiological and observational studies on reduction of 
fracmre risk are numerous (Weiss et al., 1980; Krieger et al.. 1982; Ettinger et al., 1985; Kiel 
et al.. 1987; Naessen et al., 1990; Kanis et al., 1992; Cauley et al.. 1995). To date there are 
three randomised placebo controlled studies showing that HRT reduces the incidence of 
vertebral fracmres (Lufkin et al .. 1992), non-vertebral fracmres (Koumalainen et al., 1998) 
and forearm fractures (Mosekilde et al.. 2000). 
Biphosphanates are a class of compounds that are resistant to enzymatic hydrolysis and 
therefore have a long skeletal half-life. resulting in reduced bone resorption. In the 
Netherlands etidronate and alendronate are generally in use for the treatment of osteoporosis. 
Etidronate has been shown effective for treatment of postmenopausal osteoporosis in two 
large prospective. randomized controlled trials (Watts et al., 1990; Miller et al.. 1997). In 
addition, etidronate showed to be effective in preventing early postmenopausal bone loss 
(Herd et al., 1997). In phase lJI trials. including almost 1.000 osteoporotic patients, 
alendronate showed an increase of spinal bone density up to 10% (Liberman et al.. 1995). In 
the fracmre intervention trial (Black et al.. 1996). involving over 2.000 osteoporotic women 
with pre-existing fractures. alendronate significantly reduced the frequency of vertebral. wrist 
and hip fractures. In women without pre-existing fractures alendronate significantly reduced 
vertebral (Cummings et al.. 1998) and non-vertebral fractures (Pols et al.. 1999). Results from 
the early intervention cohort indicates that alendronate in a dose of 5 mg/d prevents 
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posunenopausal bone loss in women under 60 years of age nearly to the same extent than 
estrogen-progestin (Hosking et al .. 1998). 
The effect of continuous combined HRT on bone density in healthy postmenopausal 
women has been studied in 12 studies. which are listed in Table 2. Five of these studies where 
double-blind and placebo-controlled. Meaningful comparison of these studies is hampered 
due to different methods of bone mass measurements and sites measured. In addition various 
combinations and doses of estrogens and progestins were involved. Duration of treaunent 
ranged from 1-10 years. Generally the studies showed a significant increase or maintenance of 
bone density. This positive effect was seen even after a follow-up of 10 years. 
For tibolone. 8 randomised studies (listed in Table 2) showed that with a dose of 2.5mg/d 
there was an increase in spinal and appendicular bone density in early and late 
postmenopausal women. Furthermore. a dose of 1.25 mg/d seems to be effective in prevention 
of postmenopausal bone loss especially in older women. In two large multicentre trials 1.25 
mg/d of tibolone seems the preferred dose for preventing early postmenopausal bone loss. 
These studies will be discussed in detail in chapter 3. Raloxifene in a dose ranging between 30 
mg/d and 150 mg/d has been shown to increase bone density in hip and spine ranging from 1-
2.2% (see Table 2). Compared to placebo all doses seem to be effective in preventing 
postmenopausal bone mass. Studies evaluating the effect of continuous combined HRT, 
tibolone and raloxifene on bone density in osteoporotic postmenopausal women are listed in 
Table 3. Tibolone and continuous combined HRT seem to increase bone density in hip and 
spine to the same extent. Data from a large multicentre trial on multiple outcomes of 
raloxifene (the MORE study) (Ettinger eta! .. 1999) shows an increase in bone density. which 
is somewhat less than seen with tibolone or continuous. combined HRT. However. this trial 
showed a significant reduction of vertebral fracture risk of 50% in women with no pre-
existing fracture and 30% in women with pre-existing fractures who used raloxifene 60 mg. 
Data on the reduction of fracture risk are not available for continuous combined HRT and 
tibolone. There are no comparative studies with respect to bone density between tibolone and 
continuous combined HRT. As will be discussed in chapter 3. the effect of tibolone on 
postmenopausal bone density is comparable with unopposed estrogens or sequential HRT. 
In conclusion. tibolone. continuous combined HRT and raloxifene are capable of 
increasing bone density in healthy and osteoporotic postmenopausal women. For continuous 
combined HRT this effect has been proven to last for up to 10 years. Although there are no 
direct comparative studies, the effect on bone density of the three treatment modalities seem 
to be in the same order of magnitude. Only for raloxifene it has been shown that fracture risk 
Table 2 Effect,;of preventive treatment of osteoporosis for continuouscombined (9c) HRT, tibolone andralo~ifene. 
- -r~,o~-~= 
yrs since 
technigue# Reference medication subjects number design meno~ause site thera~y placebo duration 
cc-HRT: 
Riis 2mg E2 pmp 21/22 db-bl-pc 0.5-3 SPA/DPA distal radius no change -7.5% 2 yrs 
etal., 1988 1mg NET proximal radius +1.0% -4.5% 
spine L2-4 +5.4% -3.7% 
Christiansen 2mg E2 pmp 18119 controlled 0.5-3 SPA distal radius no change -10% 5 yrs 
el al,. 1990 1mg NET proximal radius no change -10% 
Williams 5~tg EE pmp 12110 randomized 1-5 seQCT spine L2-3 +6.8% no change 1 yr 
elal., 1990 0.5mg NET controlled 
5~tg EE 14/10 seQCT spine l2-3 +7.8% 
1mg NET 
10pg EE 13/10 seQCT spine L2-3 +11.2% 
0.5mg NET 
10pg EE 14/10 seQCT spine L2-3 +10.2% 
1mg NET 
20pg EE 12110 seQCT spine L2-3 +13% 
1mg NET 
Marslew 2mg E2V pmp 19/24 db·bl·pc 0.5-3 SPA distal radius +1.9% -4.8% 2 yrs 
et al., 1992 1mgCPA DEXA spine L2-4 +3.9% -2.4% 
Fuleihan 0.625mg GEE pmp 7/0 randomized 1·20 DPA hip no change N.A. 1 yr 
et al., 1992 2.5mgMPA comparative spine L2-4 no change 
0.625mg CEE 0/0 DPA hip no change N.A. 
5.0mgMPA spine L2-4 no change 
Luciano 0.625mg CEE pmp 7/0 randomized 2·13 DPA spine L2-4 no change N.A. 
etal., 1993 2.5mg MPA comparative 
0.625mg CEE 6/0 DPA spine L2-4 +5.2% N.A. 
5.0mg MPA 
Maclennan 0.3 or 0.625mg pmp db·bl HO 1 yr 
etal., 1993 CEE with comparative 
2.5 mg MPA or 25/0 SPA forearm no change N.A. 
0.35mg NET or 25/0 SPA forearm no change N.A. 
0.03mg LNG or 25/0 SPA forearm no change N.A. 
Table Zv~E:!Lects of E!!:YI31llive treatment of ost~(3.'?E()~~sis for~ontirl[J9US combined (cc1J:If'1I·~ti~()IOne and ralo~ll13!1E!J!:.<?!llinuedL_ 
yrs since 
techniguelt Reference medication subjects number design fr_1~_f_1_5J28US9 site thera2)1 ~~ ~~ ~ 2iacebo duration ____ 
Eiken 2mg 17~ E2 pmp 19/25 controlled 0.5~2 SPA proximal radius no change -17.6% 10 yrs 
etal., 1996 1mg NET DPA spine L2-4 +15.9% -4.7% 
Bush (PEPI) 0.625mg GEE pmp 168/163 db-bl-pc 1~1 0 DEXA hip +2.0% -2.2% 3yrs 
et al., 1996 2.5mgMPA ovx spine L2-4 +5.0% -2.8% 
Speroff 1Jl9 EE2 pmp 139/137 db-bl-pc 1~5 seOCT spine L2-3 no change -7.4% 2 yrs 
et al., 1996 0.2mg NET 
2.5~g EE2 136/137 seOCT spine L2-3 no change 
O.Smg NET 
5~g EE2 146/137 seOCT spine l2-3 +2.2% 
1mg NET 
10~tgEE2 145/137 seOCT spine l2-3 +4.2% 
1mg NET 
Hart 2mg 17~ E2 pmp 27/0 prospective 0~2 OPAl spine L2-4 +5.5% N.A 10yrs 
et al. 1998 1mg NET ovx observational DEXA 
Recker 0.3mg GEE pmp 54/53 db-bl-pc DEXA hlp no change no change 3.5yrs 
elal., 1999 2.5mg MPA (Ca spine +3.2% no change 
vi!. D) forearm no change no change 
tlbolone 
Lindsay 2.5mg pmp 33/30 db-bt-pc 0.5~3 SPA metacarpal no change -3.6°/o 2 yrs 
elal., 1980 ovx 
Rymer 2.5mg pmp 46/45 controlled 0.5~3 DPA hip +3.5% ·2.5% 2 yrs 
el al., 1994 spine L2-4 +2.5% -3.5% 
Lyritis 2.5mg ovx 15/10 randomized SPA distal radius no change -12.4% 1 yr 
et al., 1995 1g Ca all controlled proximal radius no change -15.2% 
_!able 2 Effects ol preventive treatment of osteoporosis for~continuol;!scombi~,ed (cc) HRT, tib~e and r~oxifene (c'?ntinued). ~ 
yrs since 
Reference medication subjects number· design menopause technique# site theraQY. __ Qiacebo duration 
Berning 2.5mg pmp 35/23 db-bl-pc 1-3 MOM phalanx +5.5% no change 2 yrs 
et al., 1996 seQCT spine L2-4 +9.1% -6.4% 
1.25mg 36/23 MOM phalanx +3.1% 2 yrs 
seQCT spine L2-4 +4.0% 
Bjarnason 2.5mg pmp 28/13 db-bl-pc >10 SPA distal radius +1.9% -2.1% 2 yrs 
et aL, 1996 OEXA spine L2-4 +5.1% no change 
1.25mg 29113 SPA distal radius +2.2% 
OEXA spine L2-4 +5.9% 
Gallagher 0.3mg pmp total of 770 db-bl-pc ? OEXA spine study 1111 1 2.6%3/2.6%3 -1.6%/-3.0% 2 yrs 
etal., 1999 0.5mg Ca mean age 52 hip study 1111 0.7%3/1.3%3 -2.0%/-3.2°/o 
0.625mg OEXA spine study 1/11 2.1%?/1.8%3 
0.5mg Ca hip study Jill 0.4%?/0.6%3 
1.25mg OEXA spine study 1/11 0.7%2/1.5%3 
0.5mg Ca hip study Jill 0.8%3/-1.4% 
2.5mg OEXA spine study Jill -0.6%/-0.2%3 
0.5mg Ca hip study 1/ll 0.5%2/-1.0%1 
Breadsworth 2.5mg pmp 22120 randomized 1-? OEXA hip no change -3.9% 2 yrs 
etal., 1999 controlled spine L2-4 +3.7% no change 
raloxJfene 
Delmas 30mg pmp 1521150 db-bl-pc 2-8 DEXA hip +1.0% -0.8% 2 yrs 
eta!., 1997 spine L2-4 +1.3% -0.8% 
60mg 1521150 OEXA hip +1.6% 
spine L2-4 +1.6% 
150 mg 147/150 OEXA hip +1.5% 
spine L2-4 +2.2% 
0.4-0.6g Ca all 
'-~---~~. ~-~'""" ___ - -~~-~--~~ .. ~-~~-""~-----
'treatment group/glacebo ~roup; #: for BMD assessment; pmp: postmenopausal; ovx: ovariectomized; db-bl-pc: double-blind placebo-controlled; 12 identical independent 
studies; 1P<0.05; P<0.01; P<0.001, treatment versus placebo. 
E2: 17~ estradiol; NET: norethisterone; EE: ethinyl estradiol; E2V: estradiol valerate; CPA: cyproterone acetate; CEE: conjugated equine estradiol; MPA: 
medroxyprogesterone acetate; LNG: levonorgestrel. 
SPA: single photon absorptiometry; DPA: dual photon absorptiometry; seQCT: single energy quantitative computed Tomography; DEXA: dual energey X-ray 
absorptiometry. 
Table 3 Effects of_ tibolone, continuous combinedjQQ)_ HRT, and raloxifene for treatment of osteoeorosis, .. 
concurrent subject. 
Reference medication treatment number duration design Technique# site therapy______Qiacebo Fracture risk 
tlbolone 
Geusens 2.5mg 14/17 2 yrs db-bl-pc SPA/DPA distal radius no change no change NS 
eta!., 1990 proximal radius no change no change 
spine L2·4 +8.0% -4.0% 
Pavlov 2.5mg 63/43 2 yrs db-bl-pc DEXA hip +7.2% no change not done 
etal., 1996 spine L2-4 +2.6% no change 
Studd 2.5mg Ca1g 31/36 2 yrs db-bl-pc DEXA hip +2.7% +1.4% not done 
eta!., 1996 spine L2-4 +6.9% +2.7% 
cc-HRT: 
Christiansen 2mg E2 Ca 0.5g 16/15 1 yr db-bl-pc SPA/DPA distal radius +8.0% no change not done 
et al., 1990 1mg NET proximalradius no change no change 
spine 12-4 +8.0% no change 
Grey 0.3-0.625mg 44/19 1/6-3 yrs retrospective DEXA hip +3.0°/o no change not done 
et al., 1994 CEE+5mgMPA controlled spine L2-4 +7.0% no change 
50~g E2 7/19 DEXA hip +7.2% no change 
5mgMPA spine l2-4 no change no change 
raloxlfene 
Ettinger 60mg Ca 0.5g + 2557/2576 3 yrs db-bl-pc DEXA hip +1.0% -1.1% AA 0.5 (95%Cf 0.3-0.d 
et al., 1999 400-600 IU vii. D spine L2-4 +3.1% +0.5% RR 0.7 (95%CI 0.6-0.9)' 
120mg 2572/2576 +1.3% -1.1% RR 0.5 (95%CI 0.4-0.6)1 
+2.9% +0.5% AA 0.6 (95%CI 0.4-0.9)2 
*: treatment group/placebo group; #for BMD assessment 
pmp: postmenopausal; ovx: ovariectomized; db-bl-pc: dubb!e blind placebo controlled N.S.: not significant 
E2: 17!3 estradiol; NET: norethisterone; EE: ethinyl estradiol; E2V: estradiol valerate; CPA: cyproterone acetate; GEE: conjugated equine estradiol; MPA: 
medroxyprogesterone acetate; LNG: !evonorgeslrel; Ca: elementary calcium; vii. D: vitamin D. 
SPA: single photon absorptiometry; DPA: dual photon absorptiometry; seQCT: single energy quantitative computed Tomography; DEXA: dual energy X-ray 
absorpliometry. 
1
: relative risk and 95% confidence interval in subjects without preexisting fractures; 2: relative risk and 95% confidence interval in subjects with preexisting fractures 
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is reduced by 30-40% in (severe) osteoporotic women (Ettinger eta! .. 1999). Data on fracture 
risk are lacking for continuous combined HRT and tibolone. However, numerous 
epidemiological and observational studies as well as three random.ised trials show that 
unopposed estrogens and conventional HRT regimens reduce fracture risk. Since the effect of 
tibolone on posunenopausal bone density is comparable to estrogens, it is likely that tibolone 
will reduce fracture risk. However. the magnitude of fracture risk reduction by tibolone 
remains to be determined. 
1.5.2 Add-back therapy in GnRH-agonist treated patients 
Gonadotrophin-releasing hormone (GnRH) is a decapeptide. secreted by the hypothalamus 
into the portal circulation. GnRH controls the release of luteinising hormone (LH) and follicle 
stimulating hormone (FSH) from the gonadotroph cells of the anterior lobe of the pituitary 
gland. The pituitary response depends to some extent on the frequency of the GnRH pulse. 
Continuous infusion will result in the inhibition of pituitary secretion. GnRH-agonists are 
GnRH-analogues with a longer half-life due to their resistance to cleavage by endopeptidases. 
causing pituitary down regulation. This ''medical castration"' results in suppression of gonadal 
steroids levels. This medication is therefore used for steroid-dependent diseases such as 
uterine fibroids and endometriosis. Their short-term use in women is of proven benefit in the 
assisted reproduction and prior to endometrial ablation. Of the long-term indications the 
management of endometriosis is the most important. Since endometriosis is a chronic disease 
long-term use of GnRH-agonists would be favourable. However, because of the hypo-
estrogenic state and subsequent rapid reduction in bone density. the use of GnRH-agonists is 
limited to a 6-month course. 
Since the oestrogen-dependent growth in endometriosis is believed to respond to cyclical 
changes in circulating estrogens. this adds weight to the idea that. low steady state oestrogen 
levels do not stimulate the growth of endometriosis. This in turn leads to the rationale that 
HRT regimens and tibolone could be used as add back. or replacement. therapy. to reduce the 
adverse effects of bone loss and vasomotor symptoms, while not altering the therapeutic 
effect of the GnRH-agonists. GnRH-agonist induced bone loss averages 1% per month during 
a 6-month course (Pickersgill 1998). which much greater than an average loss of 2-3% 
annually during the first years after natural menopause (Riggs et al., 1986). Although most 
studies indicate that bone mass is partially or completely restored after cessation of GnRH-
agonist therapy (Pickersgill. 1998) it can be argued that adverse changes in trabecular bone 
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structure may occur during bone loss. which could lead to permanently reduced bone strength 
even when the total bone mass has been restored (Compston et al.. 1995). Therefore the 
importance of preventing GnRH-agonist induced bone loss is emphasised. 
Studies using HRT regimens with commonly used doses for the prevention of 
postmenopausal bone loss. do not entirely prevent GnRH-a induced bone loss (Maheux et al .• 
1992: Moghissi et al.. 1996: Maheux et al.. 1991: Sugimoto et al.. 1993). In contrast. a higher 
dose of estrogens (Leather et al.. 1993: Simber et al.. 1996: Makarainen et al.. 1996) 
protected against significant bone loss during GnRH-agonist treatment. 
When continuous combined HRT regimens are considered. transdermal 25!J.g 17~ E2 with 
5mg medroxyprogestrone acetate did not prevent bone loss at the lumbar spine completely 
(Howel et al.. 1997). In contrast. 1.25mg conjugated estrogens with Smg medroxyprogestrone 
acetate or 1 mg 17~ E2 with 0.5 mg norethisterone was effective in preserving lumbar spine 
bone density in a 6-month course with a GnRH-agonist (Gregoriou et al., 1997~ Franke eta!., 
2000). In a study of 12 months'duration in patients treated with a GnRH-agonist, 
norethisterone in a daily dose of 5mg alone or in combination with conjugated estrogens 
0.625 or 1.25mg maintained bone density and alleviated vasomotor symptoms (Hornstein et 
al .. 1998). Another continuous combined HRT regimen with 20!J.g of ethinyl estradiol with 
0.15mg desogestrel reduces vasomotor symptoms but also the efficacy of GnRH-a treatment 
for endometriosis (Gnoth et al .. 1999). 
A prospective. randomised. placebo-controlled trial with tibolone 2.5 mg/d in patients 
treated for 6 months with a GnRH-agonist, showed that tibolone prevented GnRH-agonist 
induced bone loss and alleviated vasomotor symptoms without altering the efficacy of the 
GnRH-agonist (Lindsay et al.. 1996). When compared to data from other studies, tibolone 
appears at least as effective as high doses of norethisterone or estrogen-progestagen 
combinations. In addition histomorphometric studies in trabecular (Compston et al., 1995) 
and cortical (Bell et al.. 1997) bone showed that increased bone turnover as well as adverse 
structurally changes can be counteracted by 2.5 mgld tibolone. There are no studies using 
raloxifene as add-back therapy as it does not alleviate vasomotor symptoms. However. it 
would be interesting what effect raloxifene may have on endometriosis itself. 
In summary. proven regimens preventing GnRH-agonist induced bone loss for up to 6 
months include: 2mg estradiol valerate. lOOJ.Lg transdermal 17~ E2 with sequential progestin, 
conjugated estrogens 1.25mg/d with 5mg/d medroxyprogestrone acetate. lmg 17~ estradiol 
and 0.5 mg norethisteron, or 2.5 mg/d tibolone, without altering the efficacy of a the GnRH-
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agonist in treating endometriosis. Up to 12 months this is proven for 5mg/d norethisterone 
alone or in combination 'Nith conjugated estrogens. 
1.6 Safety and compliance aspects 
1.6.1 Endometrium and vaginal bleeding 
Since unopposed estrogens increase the risk of endometrial cancer, sequential progesterone 
should be administered to women who have not had a hysterectomy (Grady et al., 1995). One 
disadvantage of sequential HRT is withdrawal bleeding, which may result in premature 
cessation of HRT (Groenveld et al.. 1998). Long cycle HRT reduces the frequency from 12 to 
4 scheduled bleeding episodes a year and may be an attractive alternative towards meeting the 
needs of postmenopausal women (Ettinger et al., 1994). Although a 2-year study of 1 or 2 
mg/d E2 for 84 days with 50!-lg gestodene for 12 days showed no hyperplasia (Boerrigter et 
al., 1996). to date no detailed studies determined conclusively long-term safety of long-cycle 
HRT (Ettinger et a/.,1994: Williams et al., 1994: Hirvonen et al.. 1995). In a discontinued. 
randomised, multicentre trial of 240 women. there was a significant increase in incidence of 
simple and complex hyperplasia in women using a long-cycle regimen compared to monthly 
withdrawal bleeds. This was seen at the 2-3 year point in a planned 5 year study (Studd et al.., 
1997). Obviously. long-term data as well as data on the optimum dose and duration of 
administration of estrogens and progestins are needed before such a long-cycle treatment can 
be safely reco=ended to all women requesting this kind of HRT. 
One approach to the elimination of undesirable uterine bleeding and protection against 
endometrial hyperplasia is to use continuous combined HRT. Continuous combined HRT 
involves the use of a lower dose of progestin continuously every day (administrated orally or 
by a progestin containing intra uterine device) with the aim of rendering the endometrium 
atrophic and subsequently achieving amenorrhoea (Udoff et al.. 1995). 
Another approach is that of target tissue specificity. The ideal compound should have the 
positive effect of estrogens on climacteric symptoms, bone and lipid profile, without a 
stimulatory effect on endometrium or breast. Tibolone is a synthetic steroid with combined 
estrogenic progestagenic and androgenic activity. It effectively alleviates climacteric 
symptoms and prevents postmenopausal bone loss. In the endomerrium tibolone is 
transformed in its ~4 metabolite, which has no estrogenic activity. Hence, there is no need for 
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progestin-induced withdrawal bleeding. Another group of compounds. which has either 
estrogenic or anti-estrogenic effects depending on the target tissue. are so called SERM' s. The 
first SERM available on prescription. without stimulatory effects on the endometrium. is 
raloxifene. Data on endometrial effects as well as incidence of vaginal bleeding of continuous 
combined HRT, tibolone and raloxifene will be discussed. 
The effects of various continuous combined HRT regimens on the endometrium has been 
recently reviewed (Udoff et al., 1995) and, since then data from an additional two large 
clinical trials (CHART study and PEP!-Trial) have been published (Speroff et al., 1996: The 
writing group for the PEP!-Trial, 1996). Almost all studies, regardless of the hormonal 
preparations used, reported endometrial atrophy rates between 90-l 00%, even after only 3 
months of treatment (Udoff et aL 1995: AinMelk et aL 1996: Stadberg et al., 1996). The 
endometrial atrophy rates reported represent the number of patients with atrophic 
endometrium or insufficient tissue for diagnosis. divided by the total number of patients 
sampled. It should be stated that, by uncertainty as to whether all patients with insufficient 
tissue for diagnosis have atrophic endometrium. the endometrial atrophy rates could be falsely 
elevated. However. with regard to endometrial hyperplasia the three largest studies involving 
a total of almost 1800 women on a continuous combined HRT regimen reported less than 1% 
hyperplasia_ which was significantly less than with unopposed estrogen therapy, and 
comparable to that in placebo groups ('N oodruff et al., 1994: Speroff et aL 1996: The writing 
group for the PEPI-Trial, 1996). The estrogen doses used were 0.625 mg/d conjugated 
estrogens or 1-1 Oj.lg ethinyl estradiol. while the daily progestin dose was as low as 2.5mg 
medroxyprogesteron acetate or 0.5mg norethisteron. 
Thirty-two studies, which evaluated the bleeding patterns of various continuous combined 
HRT regimens, showed that vaginal bleeding was relatively common during the first months 
of treatment (Udoff et aL 1995). The incidence of vaginal bleeding varied widely ranging 
from 0 to 93% in the first 6 months. After 6 months the incidence of vaginal bleeding was less 
than 25% in 22 out of 23 studies with a follow-up longer than 6 months (range 0-38%). Data 
also suggest that the incidence of bleeding is inversely related to the number of years since 
menopause (Archer eta!.. 1994). The different dosages and types of estrogens and progestins 
used hamper comparison of these results. Moreover. whereas some studies used doses fixed. 
other varied the dose in an attempt to decrease vaginal bleeding. Data on the effects of 
different estrogen and progestin doses on the incidence of breakthrough bleedings are 
conflicting. Some studies show that lower estrogen dose was associated with higher rates of 
amenorrhoea whilst others reported the opposite. For progestins. some studies found no 
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relation between progestin dose and amenorrhoea while others reported higher rates of 
amenorrhoea with increasing progestin dose (Udoff et al.. 1995). Interestingly, the occurrence 
of breakthrough bleeding during continuous combined HRT with estradiol and 
dydrogesterone in postmenopausal women was related to serum estradiol levels rather than to 
dydrogesterone levels. However. further studies are needed to test the hypothesis that 
oestrogen is a major factor in incidence of vaginal bleeding during continuous combined HRT 
(Weijer vd et al.. 1999). 
More recently adverse progestagenic effects were reduced to a minimum when 
postmenopausal patients using unopposed estrogen therapy were switched to a levonorgestrel-
containing intrauterine device (LNG-IUD). Atrophic endometrium was seen in all 
postmenopausal women using LNG-IUD in combination with 1.5 mg/d percutaneous 17~ E2 
for 1 year (Suvanto Luukkonen et al., 1998). In another study of postmenopausal women 
using subdermal implants of 17J3 E2 and a LNG-IUD. 72% were amenorrhoeic for at least 3 
months after 1 year of treatment (Suhonen eta!., 1995). Since it was found that the LNG-IUD 
reduces blood loss considerably (Anderson et al.. 1990), the LNG-IUD would be especially 
advantageous in perimenopausal women who have a high incidence of irregular and heavy 
menstrual blood loss due to anovulatory and hypoprogestagenic cycles (Metcalf eta!., 1981). 
In addition. the use of these intrauterine devices bridge the gap between contraception and 
estrogen replacement therapy. In perimenopausal patients. frequent and irregular spotting will 
trouble the first 6 months of use. However. after 12 months. amenorrhoea has been reported in 
61-83% of perimenopausal women using LNG-IUD (W oUter Svenson et al., 1997: Andersson 
et al.. 1992). 
Clinical studies of tibolone, which include data on the endometrium and vaginal bleeding 
compared to placebo or no treatment, are listed in Table 4. In all these studies there was no 
evidence of endometrial stimulation by tibolone. In total there were 2 women with 
endometrial cancer, of whom one had hyperplasia at the baseline endometrial biopsy 
(Ginsburg et aL 1996). There was no evidence that these malignancies were directly caused 
by tibolone. Furthermore, an incidence of 2 out of 434 postmenopausal women (Ginsburg er 
a!., 1996) using tibolone is no more than might normally be expected in the light of the 
calculated ''presumed"' occurrence of 2-3 cases of endometrial cancer per 300 women 
(Dadelszen et al .. 1994). World wide at that time, six cases of endometrial hyperplasia and 
adenocarcinoma in patients on tibolone have been reported (Dadelszen et al.. 1994). All of 
these women presented with vaginal bleeding. Two out of four women who had endometrial 
cancer in that series also had other significant risk factors for cancer (one being obese and the 
Table 4 Clinical studies of tibolone with data on endometrium and/or vaginal bleeding." 
vaginal bleeding endometrial thickness pathology or other 
Reference studyde~n duration Q02ulation treatment {incidence} or histology measurements 
Punnonen nonrandomized, 14wks 69 postmenopausal 2,5mg/d tibolone one subject (1 ,4%•) atrophic 54 subjects; slightly 
et al., 1984 open, women proliferative 13 subjects, of 
non-comparative whom 11 had an atrophic 
endometrium at baseline 
De Aloyosio randomized, open 16wks 168 postmenopausal 2,5mg/d tibotone, 3 drop outs due to bleeding. No alterations In endometrium 
et al., 1987 parallel group women placebo or no treatment No incldence given. Total of morphology in all subjects 
54% drop outs in Org OD 14 
group. 
Rymer non randomized, 104 wks 100 women mean 2,5mg/d tibo!one or no Hbo!one:12 (20%) No evidence of endometrial 
et al., 1994 open parallel group. age 50 yrs treatment. no treatment: 5 (9%) stimulation at 52 and 104 wks. 
Hablba observational N.A. 37 women bleeding 2,5mg/d tibolone 63% began to bleed within 6 no hyperplasia 10 women polyps, 
eta!., 1996 on tibo!one mths 4 had fibroids and 
2 subseptate 
uterus 
Ginsburg et observational mean 35 mths 47 women bleeding 2,5mg/d tibolone (12.6%) simple hyperplasia In 2 women 11 women polyps, 
al., 1996 on tibolone out of early adenocarcinoma in 2 7 had fibroids 
434 women. women 
Bjarnason db·bl·pC 104 wks 91 women >10 yrs 2,5mg/d tibolone (n=o-35) (20%) 
et al., 1996 alter menopause 1 ,25mg/d tibolone (11%) 
(n=36) placebo (n=20) (5%) 
Gallagher db·bl·pc 104 wks 770 early 1st yr Endometrial hyperplasia in 3 
eta!., 1999 postmenopausal 0,3-2,5mg/d tibolone (27-42%} women (1 in placebo and 2 in 
women (mean age placebo (13%) the 2,5 mg/d tibolone) 
52 yrs) 2nd yr 
0,3-2,5mg/d tibolone (18·35%) 
placebo (12%) 
Berning db·bl-pc 104 wks 94 women 1-3 yrs 2,5mg/d tibolone (n=35) (SP/o) No evidence of endometrial 1 woman with 
etal.,2000 after menopause 1 ,25mg/d tibolone (44%) stimulation in women who bled uterine fibroids 
(n=36) (22%) during treatment or placebo. 
~lacebo (n=23~ 
""Wks: weeks; ffiths: mori"i'hs; N.A.: not appl-icable; db-bl-pc: double-blind placebo-controlled-. · =~'"' ···--··""-
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other having been on unopposed estrogens for 15 yrs)~ none of these women had endometrial 
biopsies prior to starting therapy. Two women in the series were diagnosed as having 
endometrial hyperplasia in an endometrial polyp, whilst the rest of the endometrimn was 
atrophic or reported as normal. 
Earlier studies state that vaginal bleeding does occur in women taking 2.5 mg/d tibolone. 
but no incidence was given (Genazzani eta!.. 1991; Lindsay et al., 1980). In 1994, Rymer 
(Rymer et al., 1994) reported for the first time the incidence of bleeding during a 2 year non-
randomised study in one hundred early postmenopausal women. They found a 20% incidence 
in the tibolone group compared to 9,4% in the group which did not receive medication. 
Furthermore. women who bled in the tibolone group were younger at menopause. were 
recently menopausal and may have had remaining endogenous estrogen production. This was 
not confirmed by a recent double-blind placebo controlled study (Berning et al., 2000). In a 
report in which the majority of women were more than 5 years past their menopause 
(Ginsburg et al., 1996), the incidence of vaginal bleeding was 13%, suggesting that vaginal 
bleeding may be less in late postmenopausal women. In the recently reported prelhninary data 
from 2 double-blind placebo-controlled dose finding (0,3-25 mg/d tibolone) studies, 
involving 770 early postmenopausal women (Gallagher et a!.. 1999). vaginal 
bleeding/spotting ranged from 27-42% in the frrst year in the active treatment groups. Berning 
et al. reported an incidence of vaginal bleeding of 51% and 44% for 25 mg/d and 1.25 mg/d 
tibolone, respectively (Berning et a!.. 2000). About 50% of the bleeding will occur within 3 
months; by 9 months 90% of all first bleedings have occurred (Berning et a!.. 2000). 
Furthermore, bleeding episodes is dose related and statistical significant for L25mg/d and 
25mg!d tibolone compared to placebo (Berning et at.. 2000). In late postmenopausal women 
the incidence of vaginal bleeding is less (20%) (Bjarnason eta!.. !996). 
Two observational studies on postmenopausal women who had vaginal bleeding while 
taking tibolone showed that in about 50% uterine pathology could be found (Habiba et al., 
1996; Ginsburg et al., 1996). Therefore it is concluded that, as with any "bleed-free" HRT 
regimen, investigation of the endometrium is mandatory if late onset vaginal bleeding occurs. 
Clinical studies that directly compare tibolone to sequential HRT or continuous combined 
HRT are listed in Table 5. Again tibolone showed no stimulatory effect on the endometrimn 
as judged by endometrial thlclmess and/or endometrial biopsies. Interestingly, when tibolone 
was compared to continuous combined HRT the incidence of vaginal bleeding in the frrst 
three months and during the total study period was less for tibolone. Furthermore, 
discontinuation from both studies due to vaginal bleeding was less in women using tibolone 
Table 5 Comparative studies of tibolone with sequential or continuous combined HRT in respect to data on endometrium and/or vaginal 
bleeding. ~~~~ '"'M-~~~==,; ---------- ------~-"~; ... w~..,~~· .... v~:gTn~r b~ed·i·ng·~~~~~~-~endometrTaTth!Ckness~~~--~~-~~Pathorogy·-~-r-other 
Reference study design duration population ~~~~tm~IlL__ (incidence) or histology measurements 
Ergarter 
et al.,1996 
Hanggi 
etal., 1997 
Botsls 
et al., 1997 
Hammar 
eta!., 1998 
AI Azzawi 
et al., 1999 
randomized, 26 wks 
open, 
parallel group 
randomized, open 104 wks 
parallel group 
randomized, open 24 wks 
parallel group 
randomized, db- 48 wks 
bl, parallel group 
randomized, open 48 wks 
parallel group 
Wks: weeks; mths: months 
N.A.: not applicable 
db·bl-pc: double-blind placebo-controlled. 
129 postmenopausal 
women, mean age 53 
yrs 
85 postmenopausal 
women, mean age 52 
yrs 
72 postmenopausal 
women with atrophic 
vaginitis 
315 postmenopausal 
women >53 yrs 
235 postmenopausal 
women, mean age 
53.8 yrs 
2,5mg/d tibolone or 
conjugated estrogens 
2,5mg/d tibolone, no 
treatment, oral or 
transdermal estrogen 
2,5mg/d tibolone or 
intravaginal estrogens 
Occurrence of vaginal 
bleeding was significantly 
lower with tibolone than with 
conjugated estrogens afler 
one month. At 6 mths rates 
were 4% with tibolone and 
27% with conjugated 
estrogens. 
No difference between tibolone 
and no treatment at 12 and 24 
mths for endometrial thickness. 
AU tibolone patients had inactive 
endometrial samples at 24 mths. 
One woman experienced No change in endometrial 
vaginal bleeding with tibolone. thickness with tibolone. 
2,5mg/d tibolone or (34%) 
estradiol-norethlsterone (58%) 
2,5mg/d tibolone or 
estradiol-norethisterone 
Drop outs for bleeding 2% 
with Ubolone, 12% with 
estradiol-norethlsterone 
(15%, alter 3 mths) 
(20%, alter 3 mths) 
No change in 
uterine dimensions 
with tibolone or 
controls 
No change in 
uterine dimensions 
with tibolone. 
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Figure 1 
Treatment cycles 
Cumulative number of women who discontinued treatment due to 
unacceptable bleeding or spotting in postmenopausal women treated with 
tibolone or continuous combined estradiol (E2)/norethisterone (NET). 
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(Figure 1), suggesting that in terms of compliance t:ibolone is superior to continuous 
combined HRT regimens (Hammar et al., 1998). 
The SERM, raloxifene is chemically distinct from tarnoxifen and estradiol. It binds to ERs 
to completely block estrogen-induced DNA transcription in the breast and endometrium 
(Grese et aL 1997; Brzozowski et al., 1997). Io animal studies, ra!oxifene antagonises the 
mitogenic effects of both estrogen and tam.oxifen in the uterus (Sato et al.. 1996: Kleinman et 
al., 1996). A double-blind placebo-controlled study with ra!oxifene (30, 60 or !50 mg/d) 
involving over 600 women (Delmas et al., 1996) showed no difference in endometrial 
thickness in any of the four study groups. Furthermore. vaginal bleeding occurred in 2-3% of 
the women taking raloxifene. which was not different from the placebo group. All women 
who bled while taking raloxifene had an endometrial thickness of less than 5 mm. When 
adverse experiences of raloxifene were compared to placebo or HR T. the incidence of vaginal 
bleeding in women on raloxifene was comparable with the placebo group and significantly 
less than in women using other HRT regimens (Davies et al.. 1999). In the MORE study 
involving 7705 women. there were 10 cases with endometrial cancer. 4 in the placebo group 
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and 6 in the raloxifene group within the first 3 years of the trial (Etringer et al .. 1999). For 
those women who had transvaginal ultrasonography. there was a slight increase in 
endometrial thickness of 0.3 mm. Endometrial thickness exceeded 5 mm in 4% more of those 
in the raloxifene group than in those in the placebo group. Fluid in the endometrial cavity was 
seen in 2% more women on raloxifene. The latter is assumed to be a benign fmding that 
sometimes occurs in healthy postmenopausal women (Vuento et al.. 1996; Goldstein. 1994). 
Lastly. in women who had an endometrial biopsy. there were a total of 6 cases of hyperplasia 
of which 3 were in the placebo group. 
In summary, data from clinical studies show that various continuous combined HRT 
regimens (with doses of progestins as low as 2.5mg/d MP A or 0.5mg/d NET). tibolone and 
raloxifene do not stimulate the endometrium in postmenopausal women. For continuous 
combined HRT and tibolone breakthrough bleeding during the first months of treatment is 
common. After one year of treatment amenorrhoea is achieved in the majority of the patients. 
Data from direct comparative studies between tibolone and continuous combined HRT 
suggest that the incidence and severity of vaginal bleeding is less with tibolone than with 
continuous combined HRT. Furthermore, in women using tibolone or continuous combined 
HRT, the incidence of vaginal bleeding lessens the further a woman is beyond the onset of 
menopause. As might be expected, the incidence of vaginal bleeding in women using 
raloxifene is low and comparable to placebo. One should bear in mind that with any "bleed 
free'' HRT regimen. investigation of the endometrium is mandatory if late onset vaginal 
bleeding occurs. 
1.6.2 Breast. 
Breast cancer is the most common cancer in women in developed countries, affecting up to 1 
in 10 women. One major concern among both women and physicians is the fact that the use of 
HRT may increase the risk of developing breast cancer. Out of approximately 50 
observational studies only four have shown significant increases in relative risk. of between 
1.6 and 1.9 (Bergl:vist. 1997). Similarly. out of six meta-analyses that have been published 
only one (Colditz et al .• 1993) found an increased risk of 1.4 for ever users (Bergkvist. 1997). 
However, the best evidence of the effect of HRT on breast cancer comes from a collaborative 
re-analysis of individual patient data from 51 epidemiological studies covering about 90% of 
the worldwide epidemiological data on this topic (Beral. 1997). The results demonstrated that 
a 35% increase in risk for the diagnosis of breast cancer in postmenopausal women using 
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HRT for 5 years or more. There was an increased risk of about 2% for each year of HRT use. 
which was found to be comparable with the effect on breast cancer of delayed menopause. 
Five years after stopping HRT there was no longer an increased risk of breast cancer. 
Although the increased risk for breast cancer was highly significant, the excess number of 
women with breast cancer after 5. 10 or 15 years of use was small: 1-3. 3-9 and 5-20 cases. 
per 1000 women who began HRT between 50-70 years of age. Finally. the overall risk was 
similar when estrogen plus progestins was used. 
Because the number of women receiving tibolone compared with conventional HRT 
regimens worldwide is relatively smalL no epidemiological studies have directly compared 
the effect of tibolone on the incidence of breast cancer. However. some evidence can be 
sought from experimental studies in tumour models of breast cancer. In vitro. the effect of 
tibolone on the growth ofMCF-7 tumor cell lines and subclones A and A ofT47-D cells was 
studied (Kloosterboer et al.. 1994). In general. the effect of tibolone on cell proliferation was 
substantially less than that of estrogens. 
In vivo. the influence of tibolone on dimethylbenzanthracene (DMBA)-induced mammary 
tumor in rats was studied (Kloosterboer et al., 1994). As preventive treatment in rats that 
received DMBA. there was a marked reduction in tumour load when tibolone or one of its 
metabolites was given for 10 weeks. As therapeutic treatment in rats with DMBA-induced 
mammary tumours. tibolone stabilised the tumour load to a similar extent as tamoxifen. while 
tumour load increased markedly in control rats. In humans. estrogen is one of the most 
imponant factors supporting the growth and evolution of breast cancer. In postmenopausal 
women with breast cancer. breast tissue contains high levels of estrogens (Pasqualini et al., 
1997). Two main pathways are involved in the local production of estrogens. Firstly. the 
aromatase pathway which converts androgens into estrogens. Secondly. the sulphatase 
pathway that transforms estron-sulphate into estron. The latter is assumed to be the most 
important source of estrogens in breast cancer tissue (Pasqualini eta!.. 1997). Tibolone and its 
metabolites have been shown to have an intense inhibitory effect on the sulphatase pathway in 
hormone-dependent breast cancer cells (Chetrite et al.. 1997). 
Tissue homeostasis is the result of a balance between proliferation, differentiation and 
apoptosis. or programmed cell death. and is thought to play a major role in the growth of both 
normal and tumor tissue. Tibolone decreases cell proliferation. promotes 1713 hydroxysteroid 
dehydrogenase activity (a marker of epithelial cell differentiation) and increases apoptosis in 
normal as well as in breast cancer cells (Gompel et a!.. 1997). These finding suggest that 
tibolone may have potential for the treatment of breast cancer. A small study of 14 women 
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with terminal stage breast cancer who received t:ibolone after appropriate treatment for their 
cancer, noted that one woman developed cancer in the other breast, one woman improved and 
the other women showed no change. Therefore. the significance of this, if any, is as yet 
unclear (O'Brien et al.. 1996). 
Finally. density on mammography is a marker for increased risk: in several studies 
increased breast density predicted a two-fold increased risk of breast cancer (Boyd et al.. 
1995). A small prospective study of mammographic changes in women taking tibolone 
showed minor changes in tv.ro out of 25 women: one of increased parenchymal density and 
one of rnicrocalcifications. The authors quote a frequency of increases in mammographic 
density with estrogens of 11-27% (Ere! et al.. 1998). 
Tamoxifen. a SERM that inhibits the action of oestrogen on breast tissue, improves 
disease-free survival among women with hormone-dependent breast cancer (Fisher et aL 
1989) and reduces the risk of contralateral breast cancer (Early Breast Cancer Trialists 
Collaborative Group. 1998). The largest study on preventive treatment for breast cancer 
showed a reduction in risk of about 50% for women using tamoxifen (Fisher et al., 1998). 
Raloxifene. a SERM that is chemically distinct from tarnoxifen. binds to ERs to competitively 
block estrogen-induced DNA transcription in the breast and endometrium (Grese et al.. 1997: 
Brzozowski et al.. 1997). In animal studies. raloxifene inhibits the estrogen-stimulated growth 
of mammary cancers (Anzano et al.. 1996). In the MORE study. in which 7705 
postmenopausal women received raloxifene 60 or 120 mg or placebo. the raloxifene group 
showed a significant reduction in breast cancer risk after 3 years of treatment (Cummings et 
al.. 1999). There was an overall relative risk of 0.24 (95% CI: 0.13-0.44). Consequently. to 
prevent one case of breast cancer, 126 women would need to be treated. The reduction in risk 
for ER positive cancer was 90%, whereas no significant reduction in risk was found for ER 
negative breast cancer. As noted by Cummings et aL breast cancer requires several years to 
grow to a clinically detectable stage. Therefore. the reduction of 40 months of treatment with 
raloxifene probably represents suppression or regression of subclinical cancer. Consequently, 
it is important to assess the long-term effects of raloxifene (and other SERM's) on breast 
cancer risk. Only if treatment continues to safely reduce the risk of breast cancer as long as it 
is taken, would it be worthwhile to use raloxifene in a broader spectrum of women than is 
currently practised (namely women at high risk for osteoporotic fractures). 
In summary, the use of unopposed estrogens for more than 5 years is associated with an 
increased risk for the diagnosis of breast cancer (RR: 1.35). Use of estrogens in combination 
with progestins (HRT) has a similar overall risk as compared to estrogens alone. This 
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increased risk disappears within 5 years after cessation of therapy. No epidemiological data 
on the risk of breast cancer with the use of tibolone are available. The preclinical effects on 
breast epithelium cells and breast cancer cells give no cause for concern and are in fact 
encouraging. Treatment for 40 months with raloxifene showed a marked reduction in risk for 
the diagnosis breast cancer in a large prospective randomised placebo-controlled trial. 
However. before raloxifene can be used for primary prevention of breast cancer. the long-term 
effects on risk reduction need to be established. 
1.6.3 Cardiovascular disease 
Cardiovascular disease (CVD) is the most common cause of death in women above the age of 
60 in western countries (Wenger et aL. 1993). However. the risk of CVD in women is low 
until the age of sixty (Tunstal-Pedoe. 1998). The lower risk of women compared with age-
matched men. and the disparity in the incidence of CVD between pre- and postmenopausal 
women, suggests a protective effect for estrogens. However. the factors that influence the risk 
of CVD are many; they include geographic. ethnic, dietary. lifestyle, environmental and 
biochemical factors, any of which may also interact with each other. 
Nearly every observational study has found a decreased risk of CVD in women who ever 
used estrogen. A recent meta-analysis found a summary relative risk of 0.70 for CVD in 
women who used unopposed estrogens. fu studies that separately assessed HRT. the risk 
estimate was 0.66 (Barret-Connor et al.. 1998). Cardioprotection by estrogens is plausible 
since a growing number of studies on the surrogate markers of CVD risk (see Table 6) 
showed beneficial effects from HRT. In sharp contrast. the recently published Heart and 
Estrogen/progestin Replacement Study (HERS). the first randomised placebo controlled trial 
with hard cardiovascular end-points among women with a history of CVD. did not show a 
favourable effect. with a trend towards an increased risk of CVD in the first year of treatment. 
However. after the first year of treatment. there is a decreased risk of events (Hulley et al.. 
1998). Summarising, epidemiological and various experimental data gave biological 
plausibility to a protective cardiovascular impact of HRT. whereas the first randornised 
clinical trial did not support this. 
Baal (Baal van et al.. 1999) and Moore (Moore, 1999) recently reviewed the effects of 
continuous combined HRT and tibolone on various surrogate markers of risk for CVD. Table 
7 summarises their conclusions. The effects of raloxifene on serum lipids and coagulation 
factors (Walsh et al.. 1998; Delmas et al .. 1997) are also summarised in Table 7. 
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Table 6 Surrogate marker for risk of cardiovascular disease. 
Classical cardiovascular risk factors: 
Lipids: cholesterol: 
triglycerides I 
Lipoproteine (a) I 
Blood pressure I 
Glucose metabolism: 
Low Density Lipoprotein I 
High Density Lipoprotein .j. 
insulin resistance I 
glucose tolerance .J. 
Newly established cardiovascular risk factors: 
Factor VII I 
Fibrinogen I 
Plasminogen activator inhibitor-1 I 
Tissue-type plasminogen activator I 
Homocysteine I 
For continuous combined HRT there is an overall beneficial effect on serum lipids. However, 
in continuous combined HRT with noretbisterone, high-density lipoprotein (HDL) is lowered 
and triglycerides are increased in continuous combined HRT regimens with 
medroxyprogesteronacetate as well as norethisterone. For tibolone. the potentially deleterious 
effect of reduced HDL may be balanced by the beneficial effects of reduced triglycerides and 
lipoprotein(a). Furthermore, in cholesterol-fed ovariectomised rabbits. the arterial wall was 
completely protected against atherosclerotic processes by tibolone (Zandberg et a!., 1998). 
For raloxifene changes in serum lipids are beneficial although the magnitude of changes seem 
somewhat less. Raloxifene was shown to prevent atherosclerosis in cholesterol-fed 
ovariectomised rabbits (Bjarnason et al., 1997) but not in postmenopausal monkeys (Clarkson 
et al., 1998). 
In conclusion, data presented in Table 7 and animal studies give an incomplete view of the 
overall picture. Only large-scale clinical trials and epidemiological surveys can illnminate the 
effect of continuous combined HRT, tibolone and raloxifene on the incidence of 
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Table 7 Surrogate makers of risk of cardiovascular disease: influence of continuous 
combined (cc) hormonal replacement therapy (HRT) with 
medroxyprogesteron acetate (MPA) or norethisteron acetate (NET), 
tibolone and raloxifene. 
Surrogate maker 
Blood pressure 
Glucose metabolism 
Lipids: 
Total Cholesterol 
High Density Lipoprotein 
Low Density Lipoprotein 
Triglycerides 
Lipoprotein (a) 
Fibrinogen 
Fibrinolysis/coagulation 
balance 
Homocysteine 
Reference a: Baal van et al., 1999 
b: Moore, 1999 
c: Delmas et al., 1997 
d: Wlash et al., 1998 
cc-HRT 
MPNNETa 
-1-
-?/-? 
.J.. 
- 1/.J.. 
.l..!.l.. 
lit 
W.J...J.. 
.1..- ?I? 
-7 
?I? 
tiboloneb Raloxifenec,d 
-? -? 
.1..- .J.. 
.J.. 
.J.. 
.J.. 
.J...J.. .J.. 
.1..-? .1..? 
f- -? 
? 
cardiovascular disease. For continuous combined HRT (Women Health Initiative) and 
raloxifene (Raloxifene Use for The Heart) such large-scale clinical trials are now ongoing. 
1.6.4 Venous thromboembolism 
Exogenous estrogens used in the combined oral contraceptive pill have been recognised as 
factors in the pathogenesis of venous thromboembolism (VTE) (Spitzer et al .. 1996). HRT 
also exposes women to exogenous estrogen. but was not considered to be associated with 
VTE (Devor et al.. 1992: Lobo. 1992). The difference between these preparations was 
attributed to ·'physiological" doses of natural estrogens. which contrasted. with the 
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.. pharmacological .. doses of synthetic estrogens of high potency in the pill (Lobo, 1992). 
However, recent case control studies have shown a modest increase in the relative risk (range: 
2-4) of VTE in women on unopposed estrogens or HRT (Daly eta!., 1996; Grodstein eta! .. 
1996: Jick et a! .. Gutrhann et a! .. !997). Furthermore, the HERS study, involving 2763 
women with coronary heart disease, showed a relative risk for VTE of 2.89 (95% confidence 
interval between 1.5 and 5.6) in women using HRT compared to placebo (Hulley et al .. 1998). 
The mechanism whereby replacement therapy provokes an increased risk of VTE is 
unclear. Unopposed estrogens and HRT appear to be associated with a shift in the 
procoagulant-anticoagulant balance towards a procoagulant state. An effective increase in 
fibrinolytic activity is not consistently observed in randomised trials (Baal van eta!.. !999). 
This may be relevant in explaining the increased risk of VTE associated with unopposed 
estrogens and HRT. However, the frequency of VTE might be expected to be higher when 
these haemostatic changes would appear to be the sole or even the major mechanism for 
replacement therapy associated VTE. since these changes occur in virtually all women on 
medication. The potential role of the progestin component was highlighted when an increased 
risk of VTE was associated with certain third generation progestins (Spitzer et aL !996), but 
there are no clues as to the exact mechanism of the thrombosis. At present. there are no data 
from randomised trials concerning the role of progestins and whether a difference exists 
between oral and transdermal administration in respect to the balance of the procoagulant and 
anti-coagulant state (Baal van et al., !999). The epidemiological data relate VTE to the first 
year of unopposed estrogens or HRT exposure. This raises the possibility that replacement 
therapy unmasks one of the congenital thrombophilias, namely anti-thrombin Ill deficiency, 
protein SIC deficiency, Factor V Leiden or acquired thrombophilic defect such as anti-
phospholipid antibody syndrome, lupus anti-coagulant or hyperhomocysteinemia. Finally, in 
absence of recognised congenital thrombophilic defects. a combination of risk factors for 
VTE (THRIFT Consensus Group, 1992) may exist in a women, which, when coupled with 
unopposed estrogens or HRT. leads to thrombosis. 
No data are available on the incidence of VTE in women using tibolone. Short-term studies 
on haemostatic factors found decreases in fibrinogen. increases in anti-thrombin ill (A Till). 
plasminogen (Walker et aL 1985) and increased fibrinolytic activity on fibrin plates (Walker 
et al., 1985; Cortes-Prieto. 1987). More recently, studies showed a significant fall in tissue 
plasminogen activator and plasminogen activator inhibitor- I and an increase in plasmin-anti-
plasmine complexes over I to 2 years (Bjarnason et aL 1997: Wersch et aL 1994) indicating 
increased fibrinolysis. without affecting other clotting factors (fibrinogen. ATIIL thrombin-
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anti-thrombin complexes. Factor VII and Factor X) (Parkin et al.. 1987; Wersch et al.. 1994; 
Bjarnason et al.. 1997; Hiinggi et al.. 1997). Comparison of tibolone with transdermal or oral 
E2 showed little difference for fibrinogen and ATIII (Hanggi et al.. 1997). A separate 
comparison with oral estrogens v.rith cyproterone acetate showed changes indicative of 
enhanced fibrinolysis in women using tibolone. In contrast estrogens with cyproterone 
acetate had no effect on markers of fibrinolysis (Wersch et al.. 1994). These studies of 
haemostatic factors show a trend for tibolone towards increased fibrinolysis without affecting 
coagulation. Therefore. in contrast to unopposed estrogens or HRT. tibolone may alter the 
balance between pro-coagulant and anti-coa.:,oulant state in the direction of the anti-coagulant 
state. Although interpretation with respect to clinical relevance of various changes in 
haemostatic factors is difficult. in general the effect of tibolone on the balance of coagulation 
and fibrinolysis can be considered to be advantageous. Eventually. only large scale trials and 
epidemiological surveys can illuminate the effect of tibolone on VTE. As for estrogen 
containing HRT. the incidence of VTE is increased in women using raloxifene. Data from the 
MORE-study (Ettinger et al.. 1999) involving 7705 postmenopausal osteoporotic women 
showed a RR 3.1 (CI: 1.5-6.2). which is comparable to the increased risk seen with estrogens 
(Hulley et al.. 1998). At present data regarding the effect of raloxifene on coagnlation factors 
is lintited. 
In summary. estrogen-containing HRT and raloxifene are associated with a moderate 
increased risk of VTE. No data on the association between tibolone and VTE exists. 
However. in contrast to HRT. the balance between the pro-coagnlant and the anti-coagulant 
states in women using ti.bolone seems to be altered in the direction of the anti-coagulant state. 
Women starting HRT or raloxifene should have a personal and family history taken for VTE 
as well as an assessment of additional risk factors for VTE. Women with a personal or family 
history of VTE should undergo thrombophilia screening before starting treatment (Greer et 
al.. 1999). 

2 
Clinical studies 
2.1 DETERMINANTS OF LUMBAR BONE MINERAL DENSITY 1N NORMAL 
WEIGHT, NON-SMOKING WOMEN SOON AFTER MENOPAUSE. A STUDY 
USING CLINlCAL DATA AND QUANTITATIVE COMPUTED 
TOMOGRAPHY. 
2.1.1 Introduction 
Postmenopausal bone mass depends on the amount of peak bone mass and the subsequent bone 
loss. Peak bone mass is influenced by many hereditary and environmental factors. In the 
literature there is controversy about the effect of oral contraceptive use, parity and lactation on 
bone mass. This is partly due to differences in study populations and in the skeletal sites 
measured. 
The primary cause of postmenopausal bone loss of bone mass is the cessation of ovarian 
reproductive function resulting in low serum estrogen levels. It has been documented that 
hormonal replacement therapy can reduce the incidence of both hip and vertebral fractures ('N eis 
et al., 1980; Lindsay et al .. 1980; Krieger et al., 1982; Naessen et al., 1990) by preserving bone 
mass (Lindsay et al.. 1976; Christiansen et al .• 1980). Since there is. at present. no simple and 
effective method to restore lost bone mass. prevention of bone loss is the most rational approach 
in reducing the incidence of fractures related to osteoporosis. 
The major problem in prevention of osteoporosis is the selection of women who need 
preventive medication. At present bone mass measurements provide the best prediction of 
fracture risk (Hui et al .. 1989; Wasnich et al .. 1989; Gardsell et al.. 1991) . It could be claimed 
that medication should be restricted to women with an elevated fracture risk for the following 
reasons: at first. uncertainty remains in respect to the incidence of breast cancer and 
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cardiovascular disease during combined hormonal replacement therapy. Secondly, information 
about fracture risk is mandatory in case women are only v.rilling to accept hormonal replacement 
therapy if their fracture risk is augmented. Finally. prediction of fracture risk could be useful to 
enbance both the cost-effective use and compliance of preventive therapy. 
This cross-sectional study was designed to discuss the following questions: Is there an 
influence of oral contraceptive use. parity and lactation on early postmenopausal bone mass? Is 
assessment of reproductive history. body weight in combination with routine biochemical 
markers of bone metabolism suitable to predict lumbar bone mass soon after menopause in 
women without any obvious risk factors? In order to answer these questions non-smoking. 
normal weight. healthy postmenopausal women within three years after their natural menopause 
- a period in which a decision concerning preventive medication should be made- were selected. 
To our knowledge, this is the first cross-sectional study using Single energy Quantitative 
Computer Tomography (seQCT) which exclusively measures trabecular bone mineral density 
(B:tv.ID) of the spine in a homogeneous population of early postmenopausal women. 
2.1.2 Materials and Methods 
Subjects and study protocol: The study protocol was approved by the Ethics Review 
Committee of the Erasmus University Rotterdam, and informed consent was obtained from each 
participant. Ninety-four healthy white women were recruited through announcements in the local 
media. All women were amenorrheic, due to spontaneous menopause, for at least 12 months 
with a maximum of 36 months. All participants were between 45 and 60 yrs of age and had a 
body mass index (BMI) between 18 and 27 kg/m2 See Table 1 for further clinical characteristics. 
None of the participants smoked. abused alcohol (more than 4 units/day). or used any medication 
considered to affect bone/calcium metabolism (such as gonadal steroids. calcitonin. thyroxin, 
biphosphanates. fluorides. corticosteroids. vitamin D. insulin. anticonvulsants. heparin. diuretics. 
antacids, calcium supplements and long-term use of antibiotics). 
Gynaecological parameters and exclusion criteria used in this study were based on factors 
suggested by various reviews (Riggs et al., 1986~ Lam et al .. 1988). Age at menarche, months 
after menopause. oral contraceptive (OAC) use (years). number of pregnancies. parity (number 
ofbirths).lactation (episodes exceeding 2 weeks) and its duration (weeks) was assessed through 
interview performed by the same physician (BB). Height was measured using a wall-mounted 
headboard. Weight was measured with a mechanic weightscale. The BMI was calculated as 
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weight (kg) divided by height' (m). Venous blood samples were taken between 12:00 and 16:00 
h. After overnight fasting, urine samples of second morning voids were collected two hours after 
drinking 300 ml of water. 
Bone Measurements: SeQCT (Somatom Plus. Siemens AG. Erlangen. Gennany) was used for 
estimation of trabecular and cortical Bone Mineral Density (BMD) of the lumbar vertebral body 
(Ll-L3). Midvertebral slices were determined by an automated procedure as published 
previously (Kalender et al.. 1988). For measurement within the vertebrae a computerised 
selection of the trabecular and cortical area was used (Sandor et al .. 1985). BMD was expressed 
as milligram calcium (Ca) hydroxyapatite per cm3. using a standard reference device (Kalender 
et al.. 1987). Scanning parameters were: 80 kVp 125 mAs with 10 mm slice thickness. 
Coefficient of variation is less than l percent as measured with COMAC-BME phantom 
(Kalender et al .. 1991). The in vivo precision is generally reported to be less than 2% in clinical 
trials (Faulkner et al.. 1991). 
Laboratory Measurements: For biochemical estimation of bone metabolism the following 
markers were used. Albumin (ALB). Alkaline Phosphatase (AP) and serum Ca were measured 
with a Bayer Technicon Chem-1 system according to the manufacturers instructions. Urinary Ca. 
creatinine and hydroxyproline were measured with commercial kits: creatinine and Ca with 
Merek kits (creatinine Mercko-test A and Ca ERIS-test respectively) and hydroxyproline with a 
Hypronosticon kit (Organon Teknika. The Netherlands). Urinary ratios of hydroxyproline-
creatinine (OH-index) and Ca-creatinine (Ca-index) were calculated in mmol per mol. Corrected 
serum Ca (Ca-corr) was calculated by the equation: Ca-corr = Ca- 0.025 ALB + I mmol. 
Statistical analysis: All variables were tested for normal distribution. If appropriate (i.e. AP and 
OR-index) logarithmic transformation was performed. Only for continuous normally distributed 
variables. Pearson's correlation coefficient and the Student-t test was used. For all other variables 
Spearman's correlation coefficient and the Mann-Whitney test were performed. Analysis of 
OAC-use. parity and duration of lactation was done by dividing the study population according 
to these parameters (Table 2). Further analysis of the gynaecological parameters. age. BML 
biochemical markers was performed by dividing the study population in a group with low 
trabecular and low cortical bone mineral density (defined as bone mass measurements within the 
lower tertile) and the remainder of the study population. Correlations were calculated between 
these variables and bone tuass measurements (Table 3). Multiple regression analysis (Table 4) 
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was performed to determine the extend of interrelationships among variables and to calculate a 
linear model for the best prediction of trabecular and cortical BMD. All values are presented as 
median and range with exception of table 2. A P-value below 0.05 was considered significant. 
All presented P-values are two tailed. Statistical calculations were performed in Statgraphics 
version 4.0 (STSC Inc .. Rock-ville. Md.). 
2.1.3 Results 
The study population characteristics are shown in Table I. The measurements of trabecular and 
cortical lumbar BMD were highly correlated (""'0.77). 
The values of trabecular and cortical BMD after dividing the study population according 
OAC-use. parity or duration of lactation are shown in Table 2. The trabecular and cortical BMD 
of women who used OAC did not differ from that of non-users. The nulliparous women did not 
differ in respect to trabecular and cortical BMD from the parous women studied. Women who 
breast fed more than 2 weeks had no significantly different trabecular and cortical BMD 
compared to parous women who had not breast fed. However, trabecular B:MD was significantly 
(P=0.02) higher in women who had lactated more than 24 weeks compared with parous women 
who lactated 24 weeks or less (Table 2). 
Only AP was significantly higher in women with low trabecular (:> 107 mg/cm3) and low 
cortical (:> 267 mg/cm3) BMD (P=0.02) as compared with the remainder of the study population. 
OH-index was slightly lower in the low trabecular BMD group but this difference did not reach 
the level of statistical significance (P=0.06). In respect to the other variables (as mentioned in 
Table 1\ women with low trabecular and cortical BMD did not differ significantly from the 
remainder of the study population. 
Most of the variables showed no individually significant correlation with trabecular or cortical 
BMD (Table 3). A significant correlation with trabecular lumbar BMD existed for AP (""'·0.31, 
P=0.003). parity (""'0.26. P=O.OI) and duration of lactation (r=0.29, P=0.005). AP (""'·0.30. 
P=0.004) and parity (r=0.22. P=0.04) correlated significantly with cortical lumbar BMD. The 
correlation between duration of lactation and cortical BMD (""'0.20) was of borderline 
significance (P=0.05). Between variables no significant correlations were found. with exception 
of AP and Ca-index (r=-0.29, P=0.006) and between pregnancies, parity. duration of lactation 
and number of breast-fed children. Multiple regression analysis showed that parity does not 
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Table 1 Clinical and biochemical characteristics of 94 women 1-3 yrs after spontaneous 
menopause. 
Variables 
Age (yrs) 
Height (m) 
Weight (kg) 
BMI (kglm2) 
Gynecological parameters: 
Age at Menarche (yrs) 
OAC-use (yrs) (n=73) 
Parity" (n=85) 
Lactation (n=62) 
(Number of children) 
(weeks) 
Months since Menopause 
Biochemical markers: 
OH-index (mmoVmol) 
190) 
Ca-index (mmoVmol) 
AP (U/L) 
Ca-corr (mmoiA) 
LumbarBMD: 
Trabecular (mglcm3) 
Cortical (mg/cm3) 
anumber of births, only parous women included 
median (range) 
52.9 (45.7-60.0) 
1.64 (1.48-1.77) 
64.5 (47.0-80.5) 
24.3 (18.2-27.0) 
14 (10-18) 
10(1-30) 
2 (1-4) 
1 (1-4) 
12 (2-120) 
20 (12-36) 
28 (1 0-
338 (39-1186) 
54 (27-141) 
2.21 (2.00-2.40) 
120 (55-230) 
288 (186-409) 
relate to trabecular (P=0.52) or cortical (P=0.52) BMD when duration of lactation was taken into 
account (Tahle 4: model 2). Furthermore, inclusion of nulliparous women did not change the 
slope or significance of the simple regression of duration of lactation with lumbar BMD. The 
regression of AP and duration of lactation with trabecular BMD and cortical BMD was 
independent of each other (Table 4 models 2 and 3) as well as of the variables that weren't 
significant determinants in the simple regressions. The third regression model from Table 4 
could only account for 17 % of the variability of trabecular BMD (R2) and II % of the variability 
of the cortical BMD (R2). Comparing the predicted values of BMD with the obser ved, it was 
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Table 2 Trabecular and Cortical BMDa (mean ± SD) of the lumbar spine according to: 
use of OAC, parity and duration of lactation; in 94 women 1-3 yrs after 
spontaneous menopause. 
All subjects 
UseofOAC: 
subject 
number 
94 
non-users 21 
users 73 
P-value 
Parity: 
nullipara 9 
multipara 85 
?-value 
Duration of lactation (wks): 
duration = 0 24 
duration > 2 61 
P-value 
duration = 24 58 
duration > 24 27 
P-value 
amg/cm3• 
trabecular BMD cortical BMD 
124 ±33 290 ±48 
125±32 275 ±48 
122 ± 36 294 ±48 
0.71 0.11 
116±17 270±34 
125 ±34 292 ±49 
0.43 0.20 
122 ±28 301 ±46 
126 ± 36 288 ±50 
0.65 0.30 
119 ±28 289±47 
138±41 299 ±53 
0.02 0.35 
found that only 17% of the women with low trabecular and 10% of the women with low cortical 
BMD were correctly identified by these regression models. 
2.1.4 Discussion 
Early postmenopausal bone mass depends on the amount of peak bone mass and subsequent 
bone loss. Therefore. early postmenopausal bone mass is influenced by many hereditary and 
environmental factors. The present study addresses to a selection of these enviTonmental factors. 
The CA-intake of the subjects in this study was not estimated. Low CA-intake may have an 
independent influence on premenopausal bone mass (Elders et al.., 1989: Hansen et al .. 1991; 
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Table 3 Correlation coefficients between clinical, biochemical characteristics and 
trabecular, cortical BMD in 94 women 1-3 yrs after spontaneous menopause. 
Variables 
Age (yrs) 
Height (m) 
Weight (kg) 
BMI (kg/m2) 
Gynecological parameters: 
Age at Menarche (yrs) 
OAC-use (yrs) 
Pregnancies (Number) 
Parity (Number of births) 
Lactation (weeks) 
(Number of children) 
Months since Menopause 
Biochemical markers: 
OH-index (mmol/mol) 
Ca-index (mmol/mol) 
AP (U/L) 
Ca-corr (mmolm 
* P< 0.05 
** P< 0.01 
LumbarBMD 
Trabecular Cortical 
-0.06 -0.01 
-0.13 -0.16 
-0.14 -0.18 
-0.04 -0.04 
0.10 0.10 
-0.06 0.11 
0.14 0.11 
0.26** 0.22* 
0.29** 0.20 
0.18 0.05 
-0.12 -0.04 
-0.06 -0.02 
-0.08 -0.15 
-0.31 ** -0.30** 
-0.08 -0.15 
Heany. 1991). We assumed that the CA-intake of the study population is representative for the 
Dutch population. ln the Netherlands CA-intake is relatively high compared to other countries 
(i.e. USA)(Heany. 1991). Furthermore. a dutch study (Elders et al., 1989) with a similar study 
population found no relationship between CA-intake and peri- or postmenopausal bone mass. 
BMI or other life-style factors. Therefore we believe that CA-intake has not substantially 
influenced our results. 
Influence of OAC on early postmenopausal bone mass: When non-users of OAC were 
compared with users. no significant difference in trabecular and cortical BMD was found. The 
finding that OAC-use has no effect on early postmenopausal BMD is in agreement with 
observations in premenopausal women (Rodin et al.. 1987: Hreshchyshyn et al.. 1988: Llyod et 
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al., 1989; Stevenson et al., 1989; Mazess et al., 1991; Rodin et al., 1991). Goldsmith and 
Johnston (Goldsmith et al., 1975) found a higher amonnt of peripheral bone mass, measnred by 
single photon absortiometry (SPA) of the disral radius, only in women using high dosages (> 100 
!lg) of mestranol. Stevenson and colleagues (Stevenson et al., 1989) found a positive effect of 
OAC on postmenopausal lumbar BJVID, using DPA. However. the age of postmenopausal 
women in this smdy ranged from 28 to 69. Lindsay (Lindsay et al .. 1986) suggested that the 
positive effect of OAC on premenopausal bone mass, measnred by DP A was still present in 
postmenopausal women within two years following their last menstruation. This suggestion 
could not be confirmed by the present observations. 
Influence of parity and lactation on early postmenopausal bone mass: There was no 
significant difference in BJVID when nulliparous women were compared with parous women. 
Parity had a weak but significant positive correlation with trabecular and cortical BMD. 
However. this association disappeared when duration of lactation was taken into account (Table 
4, model2). Total duration of breast-feeding rather then number of chiJdren that had been breast-
fed showed a positive association with early postmenopausal trabecular BMD (r=0.29, P=0.002). 
Furthermore, trabecular S:MD in women who lactated more than 24 weeks was significantly 
higher compared with parous women who lactated 24 weeks or less. Although the number of 
nulliparous women in the present study was small (n=9), this suggests that parity per se has no 
influence on postmenopausal lumbar BMD. This is in agreement with most (Lindquist et al., 
1981; Aloia et al .. 1983: Hreshchyshyn et al., 1988: Lissner et al., 1991: Hansen et al., 1991), 
but not all previous studies (Stevenson et al., 1989; Goldsmith et al., 1975; Rodin et al., 1987). 
When premenopausal bone mass is concerned, previous studies observed a negative (Wardlaw et 
aL 1986: Lissner et al., 1991), or no (Stevenson et al., 1989; Goldsmith et aL 1975; Koetting et 
al., 1988) association with dnration of lactation. Recently, longitudinal studies observed a 
decrease in BMD dnring lactation (Lamke et al.. !977: Hayslip et al., 1989; Kent et aL 1990: 
Drinkwater et al., 1991 ). The initial deficit of BMD due to lactation may disappear within 6 
months after weaning (Lamke et al.. !977; Kent et al., 1990). According to literature, the effect 
of lactation on postmenopausal bone mass is negative (Goldsmith et al.. 1975: Caraceni et a! .. 
!987; Lissner et al.. 1991), absent (Wasnich et al.. 1983) or positive (Aloia et aL 1983; 
Hreshchyshyn et al., 1988; Hansen et al .. 1991). Studies focusing on fracture risk (Kreiger et aL 
!982; Aloia et al,, 1983) showed that osteoporotic women breast-fed less often then their aged 
matched controls. 
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Table 4 Interrelationships between determinants of Lumbar BMD in 94 women 1 ~3 yrs after 
spontaneous menopause: selected regression models (1-3), with partial coefficients (and 
significance level below). 
Model AP" 
·32.6 
(0.005) 
2 ·35.8 
(0.002) 
3 ·37.1 
(0.001) 
'Log UA. 
bNumber of births. 
cDuration in weeks. 
Trabecular BMO 
Parity' 
6.2 N.A'. 
(0.06) 
2.3 0.36 
(0.52) (0.01) 
N.A. 0.40 
(0.002) 
Cortical BMD 
AP Parity Lactation 
0.11 -46.4 7.3 N.A. 
(0.008) (0.14) 
0.16 ·49.8 3.6 0.35 
(0.005) (0.52) (0.12) 
0.17 ·51.7 N.A. 0.41 
(0.003) (0.04) 
dN.A.: Variables that are not applicable because excluded from that particular model. 
R' 
0.09 
0.10 
0.11 
Little is known about the possible mechanisms responsible for the positive influence of 
lactation on postmenopausal BMD. Experiments in beagles (Miller et al .. 1989) have shown 
some evidence for a "reversible mineral deficit" hypothesis. Based on these observations it may 
be postulated that increased Ca mobilisation is followed by an increased formation of a larger 
volume of osteoid, which may result in an increased B:MD after weaning, when the osteoid is 
calcified. Furthermore, in humans there is evidence of an increased bone turnover and 
augmented renal Ca conservation during lactation (Kent et al.. 1990). Even after recovery of 
BMD within 6 months. elevated Parathyroid Hormone (PTH) and 1.25 hydroxy vitamin D levels 
as well as enhanced renal conservation of CA persists (Kent et al.. 1990: Specker et al.. 199l).ln 
addition. PTH may induce bone formation through lnsulin-like Grow1h Factor 1 (Canalis et al.. 
1989). Therefore we speculate that a "rebound effect" after lactation may be a mechanism that 
could explain the association between duration of lactation and trabecular BMD seen in the 
present smdy. 
Prediction of early postmenopausal bone mass: ln the present study an attempt was made to 
select predictors for spinal bone mass in healthy early postmenopausal women without any 
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obvious risk factors for osteoporosis. Like in clinical practice, possible determinants were used 
which could be easily obtained by interview. physical examination and laboratory measurements. 
With the exception of the influence of lactation, ouly AP showed a clear negative correlation 
with early pos1lnenopausal BMD. Interpretation of this finding in the present cross-sectional 
study is difficult. However, a high turnover seems unlikely because OH-index tended to be lower 
in our group of low B:rv.ID. Furthermore AP showed a significant negative correlation with Ca-
index. Since the accelerated phase of bone loss after menopause (Block et al.. 1989) in this study 
is relatively short (1-3 years). peak bone mass is more likely to be the main determinant of early 
pos1lnenopausal bone mass. This may explain why the OH-index and CA-index did not correlate 
with lumbar BMD in this study. There is evidence that after menopause OH-index and Ca-index 
in combination with AP may be useful in discriminating "fast-losers" of bone from "slow-losers" 
(Christiansen et al.. 1987; Hansen et al .. 1991). The meaning of these markers in respect to the 
subsequent rate of bone loss in the lumbar spine is now subject of further investigation in a 
longitudinal study. 
Present observations show that lumbar trabecular and cortical BMD cannot be predicted by 
assessment of reproductive history. BJ\.1I and measurements of routine markers of bone 
metabolism. This is in agreement with data obtained by others (Citron et al.. 1987; Slemenda et 
al.. 1990). In a similar study (Slemenda et al.. 1990). the linear model for prediction of lnmbar 
spine bone mass. measured with dual photon absorptiometry (DPA). correctly predicted 61% of 
the perimenopausal women with low BMD. compared with only 17% in our study. Reason for 
this may be the fact that the study population in this study was more homogeneous. All women 
were early postmenopausal with a BNil in the normal range and none of them smoked. which 
suggests that prediction of lumbar trabecular Bl\1D in this selected group of women is even more 
difficult. Furthermore. in this study seQCT was used which is capable of measuring trabecular 
B11D exclusively. Previously, it has been suggested that the bone mineral determination in the 
cortical envelope of the vertebral body with seQCT could potentially give additional diagnostic 
information (Sandor et al., 1989). In this study a correlation of r=0.77 was found between the 
trabecular and cortical measurements. The prediction of the BMD in both compar1lnents using 
the clinical data was equally disappointing. The meaning of B:MD of the cortical envelope in 
fracture risk prediction is at present unlmown. Long-term follow-up studies are necessary to 
resolve this issue. The meaning of the present finding is clear: the assessment of clinical risk 
factors is unsuccessful in distinguishing women with low bone mass at a time when. most likely. 
a decision about hormone replacement therapy should be made. The present study addresses only 
low bone mass. not fracture risk. Therefore. the possibility that risk factors provide an additional 
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(independent of low bone mass) contribution to the prediction of fracture risk cannot be 
excluded. Further research is needed to clarify this matter. 
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2.2 EFFECTS OF TWO DOSES OF TIBOLONE ON TRABECULAR AND 
CORTICAL BONE LOSS IN EARLY POSTMENOPAUSAL WOMEN: A 
TWO-YEAR RANDOMIZED, PLACEBO-CONTROLLED STUDY. 
2.2.1 Introduction 
It is well documented that oestrogens alone or in combination with progestagens are effective in 
preventing early postmenopausal bone loss (Ettinger et al .. 1987: Riis et al .• 1987: Munk-Jensen 
et al.. 1988: Ribot et al., 1990: Stevenson et al.. 1990: Marslew et al., 1992). Effects of 
progestagens alone are less clear. Some observations suggest that Medroxy Progesterone Acetate 
could reduce cortical but not trabecular bone loss (DeCbemey et al., 1993), whereas 
Norethisterone has been shown to prevent early postmenopausal cortical bone loss (Abadalla et 
a! .. 1985). 
Tibolone is a synthetic C-19 steroid with weak oestrogenic, progestagenic and androgenic 
properties (Visser et al., 1984). It has been demonstrated that tibolone at a daily dose of 2.5 mg 
effectively alleviates vasomotor climacteric symptoms (Tax et al., 1987). Preliminary data in 
early postmenopausal women suggest that this dose may also be capable of preventing 
metacarpal and spinal bone loss (Lindsay et al.. 1980: Rymer et al.. 1994) by suppressing 
skeletal metabolism (Fogelman et al .• 1981). 1n addition. tibolone prevented bone loss in 
premenopausal women treated with gonadotrophin-releasing hormone agonist medication 
(Lindsay et al., 1996), as well as after oophorectomy (Lyritis et a!., 1995). The present 
randomised double-blind placebo-controlled study is the first to evaluate the effect of two doses 
of tibolone (1.25 and 2.5 mg daily) on trabecular and phalangeal bone density in early 
postmenopausal women. Single energy quantitative computed tomography was used to measure 
exclusively trabecular bone density in the lumbar spine (Sandor et al .. 1985), whereas micro 
densitometry of the mid phalangeal shaft. which consists of 80% cortical bone (Trouerbach eta! .. 
1988), was used for estimation of cortical bone density. 
2.2.2 Materials and Methods 
Suhjects: Approximately 500 women responded after the study was announced in local media. 
After information was collected by telephone about race. height, weight, earlier gynaecological 
history, smoking habits and drug intake, 120 were invited for an interview. In this interview 
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medical history was taken and thorough information about the trial was given. Ninety six women 
gave vvritten consent to participate. After a general and gynaecological examination 94 women 
entered the trial. All were white non-smoking women. 1 to 3 years following spontaneous 
menopause. with an Body Mass Index (weight divided by square of height) :> 27 kg/m2• free of 
past or present diseases or medication known to influence calcium metabolism or contra-indicate 
the trial medication. 
Stndy protocol: The study protocol was approved by the Ethics Review Committee of the 
Dijkzigt Hospital!Erasmus University. The 94 participants were allocated by random medication 
numbers to a placebo group (n=23). tibolone (Org OD 14. Livia!R. NV Organon. Oss. The 
Netherlands) 1.25 mg/d treatment group (n=36) or tibolone 2.5 mg/d treatment group (n=35) 
according to a 2:3:3 ratio. This was done to increase the power of the study in respect to the 
comparison between treatment groups. Medication was provided as identical looking tablets and 
the daily dose was one tablet Patients were seen at three-month interval for two years (9 visits 
total). Blood and urine sampling was performed at each assessment Trabecular and phalangeal 
bone density was assessed at six-month intervals (five total). Medical examination was repeated 
after one year and at the end of the trial. 
Bone measnrements: Single energy quantitative computed tomography (Somatom Plus. 
Siemens AG. Erlangen. Germany) was used for estimation of trabecular bone density of the 
lumbar vertebral bodies (Ll-L3) as described previously (Berning et aL. !993). Midvertebral 
slices were determined using an automated procedure as described previously. For measurement 
within the vertebrae a computerised selection of the trabecular area was used (Sandor et al.. 
1985). Trabecular bone density was expressed as milligram calcium hydroxyapatite per cm3• 
using a standard reference device. Scanning parameters were: 80 kVp 125 mAs with 10 mm slice 
thickness. Coefficient of variation was less than I percent. as measured with COMAC-BME 
phantom (Kalender et al., 1995). The in vivo precision is reported to be less than 2%. 
Bone density of the phalanx was measured by radiographic absorption densitometry. as 
described previously (Trouerbach et aL. 1988). In short: using a standard radiographic technique 
(50 kV. 20 mS; 3M GT X-ray films and 3M Trimax alpha2 intensifying screens) radiographs of 
the right hand were exposed together with a linear Aluminium wedge. Radiographic absorption 
densitometry was performed of the mid-phalanx of the index finger at mid-length. The 
coefficient of variation was found to be less than 2% (Trouerbach et aL. 1988). Results were 
expressed as Aluminium equivalents/mm3 (Al eq!mm'). 
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Laboratory measurements: Venous blood samples were taken between 12:00 and 16:00 brs at 
3-month intervals. For biochemical estimation of bone metabolism the following markers were 
used. Alkaline Phosphatase. Phosphorus and serum Calcium were measured with a Bayer 
Tecbnicon Chem-1 system according to the manufacturers instructions. After overnight fasting, 
urine samples of second morning voids were collected 2 hours after drinking 300 mJ. of water. 
Measurement of urinary Hydroxyproline. Calcium and Creatinine were determined by standard 
procedures in our laboratory, as has described previously (Berning et al.. 1993). Urinary ratios of 
hydroxyproline/creatinine and calcium/creatinine were calculated in mmol per mol. 
Statistical analysis: For trabecular and phalangeal bone density of the spine, analysis of 
covariance was applied on the percentage change from baseline (with the baseline bone density 
as covatiate). This adjusted analysis was required due to differences between the 3 groups with 
regard to the baseline values. For biochemical parameters of bone metabolism analysis of 
valiance was applied. Results are expressed as the P-value of the overall F-test and the 3 paired 
group compatisons in P-values and 95%-confidence intervals (CI). The analysis was performed 
on all subjects who participated in this trial and had at least one post-baseline assessment of bone 
density. 
2.23 Results 
Baseline data and drop-onts: Clinical and biochemical data and bone density at baseline are 
shown in Table 5. In respect to patity or oral contraceptive use the 3 groups were comparable. 
Initial bone density of the two treatment groups were similar. However. women in the placebo 
group had a significantly higher trabecular bone density (P=0.03) compared to the tibolone 1.25 
mggroup. 
Of the 94 women 84 (89%) completed the two-year study. Four women of the placebo group 
discontinued prematurely due to intercurrent illness (two after 12 months and two after 18 
months). There were three drop-outs in each treatment group. In the tibolone 1.25 mg group, one 
woman started oestrogens without consulting the investigator and two women discontinued due 
to adverse experiences (i.e. vaginal bleeding. allergic skin reaction). In the tibolone 2,5 mg 
group, one woman had hypercholesterolaemia. one participant experienced a for her 
unacceptable weight gain of 3 kg. the other had enlargement of myoma uteri. Two women of 
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Table 5 Clinical, biochemical data and bone mineral mass (mean ± SO) at baseline of 
the placebo group and the two treatment groups. 
mg!d 
Variables 
Age (yrs) 
Body mass index {kg!m2) 
Gynaecological parameters: 
Age at menarche (yrs) 
Age at menopause (yrs) 
Months since menopause 
Biochemical markers: 
urinary Hydroxyproline/ 
creatinine ratiosa 
urinary Calcium/ 
creatinine ratiosa 
Alkaline 
Phosphatase {IU/1) 
Calcium (mmoVI) 
Phosphorus (mmol/1) 
Bone density: 
Trabecular (mg!cm3) 
Phalangeal (AI eq/mm3) 
(mmollmmol) 
placebo 
(n=23) 
51.9 ±2.5 
24.5 ±2.2 
14±1.7 
50.5 ±2.4 
19 ±7 
0.031±0.008 
0.326±0.201 
58±20 
2.44±0.07 
1.24 ± 0.16 
138±40b 
0.530±0.035 
tibolone1 ,25 mg!d 
(n=36) 
52.9 ±3.1 
23.8 ±2.3 
14 ± 1.9 
51.1 ±2.8 
23±7 
0.028±0.008 
0.411 ±0.242 
57±20 
2.42 ± 0.11 
1.23 ± 0.14 
118 ± 28 
0.513±0.046 
bp < 0.05 compared to tibolone 1 ,25 mg!d group 
tibolone2,5 
(n=35) 
51.6 ±2.9 
23.6 ±2.4 
13 ± 1.5 
49.9 ±2.8 
23±8 
0.029±0.01 
0.349±0.175 
58±17 
2.44 ± 0.12 
1.25 ± 0.16 
121 ± 29 
0.514±0.036 
each treatment group were excluded from the analysis because there was no post-baseline 
assessment of bone density. Hence. the fmal statistical analysis was performed on 90 women. 
The remaining drop-out in each treatment group discontinued after 18 months. None of the 
subjects missed more than 10 % of the tablets over the 2 year treatment period. as detennined 
by the record of dispensed and returned tablets. 
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• placebo (n=23) 
A 1,25 mgtlbolone (n=34) 
Ill 2,5 mg tibolone (n=33) 
6 --------------------J?:~---r....:::::.:::. 
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Figure 1 
Unadjusted percent change In trabecular bone density of the lumbar spine (mean percentage initial value with 
standard error of the estimate) in 90 healthy postmenopausal women, using placebo, 1.25 or 2.5 mglday tlbolone. 
Trabecular bone density: The results on trabecular bone density are illustrated in Figure I. In 
the 1.25 mg tibolone group 24 of the 32 women had a higher trabecular bone density at the end 
of the trial compared to baseline, whereas 8 women exhibited a lower trabecular bone density. 
Analysis of the trend in the second year showed no significant change for either 2.5 mg or the 
!25 mg tibolone groups. The baseline trabecular bone density was significantly negatively 
related to the response expressed as percent change from baseline. An adjusted analysis was 
required to give unbiased estimates for comparisons between the placebo and the treatment 
groups (Table 6). When compared to the placebo group both treatment groups showed a 
significantly positive response at 12 and 24 months. Funhermore, the response to 25 mg 
tibolone was significantly greater compared to the response to 1,25 mg tibolone at 12 and 24 
months (Table 6). 
Phalangeal bone density: Results on phalangeal bone density are illustrated in Figure 2. 
Phalangeal bone density of the placebo group did not show a significant decrease over the study 
period (mean -1.7%, 95% CI [-6.7%- +4.0%)). Both treatment groups showed a linear increase 
8 --------------------------------------------------------------------------------
• placebo (n=23) 
A 1,25 mgtibolone (n=34) 
II 2,5 mg t[bolone (n=33) 
-1.7% 
-sL-------------~------~---------------------
0 6 12 18 24 
Months of medication 
Figure 2 
Unadjusted percent change in cortical bone density of the phalanx spine (mean percentage initial value with standard 
error of the estimate) in 90 healthy postmenopausal women, using placebo, 1.25 or 2.5 mg/day tlbolone. 
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in phalangeal bone density. starting 6 months after initiation.. continuing throughout the study 
period (Figure 2). Although this increase seems higher in the 2~5 mg tibolone group as compared 
to the 1.25 mg this difference did not reach statistical significance. The baseline phalangeal bone 
density was significantly negatively related to the response expressed as percent change from 
baseline. An adjusted analysis was required to give unbiased estimates for comparisons between 
the placebo and the treatment groups (Table 6). Both tibolone treatment groups had a 
significantly higher phalangeal bone density compared to the placebo group at 12 and 24 months 
(Table 6). 
Body weight and biochemical parameters of bone metabolism: There was a significant 
weight gain in the placebo group as well as in the L25mg/d and 2.5 mg/d tibolone treatment 
group (2.6 kg. 2,4 kg and 2.8 kg. respectively). Group comparison showed no significant 
differences. 
Results of serum and urinary parameters of bone metabolism are summarized in Table 7. Both 
treatment groups showed a significant reduction of alkaline phosphatase and phosphorus 
Table 6 Group comparison of percental change from baseline to 12 or 24 months and from 12 to 24 months for trabecular 
and phalangeal bone density, expressed as mean and 95% confidential interval (95% Cl). 
Trabecular bone densi!Y__ Phalangeal bone densil~ 
Period Group comparison mean I [95% Cl] I P' mean I [95% Cl] I P' 
0-12 months 2,5 mgb vs. placebo 9.5 [ 7.0- 12.0] <0.001 3.3 [1.2 - 5.3] 0.002 
1 ,25 mgb vs. placebo 6.0 [ 3.5 - 8.5] <0.001 2.3 [0.3 - 4.3] 0.026 
2,5 mg vs. 1 ,25 mg 3.5 [ 1.3 - 5. 7] 0.003 1.0 [-0.8- 2.8] 0.28 
0-24 months 2,5 mg vs. placebo 14.7 [11.8- 17.5]<0.001 6.8 [3.8- 9.8] <0.001 
1 ,25 mg vs. placebo 9.4 [ 6.6- 12.2] <0.001 4.4 [1.5 -7.4] 0.004 
2,5 mg vs. 1,25 mg 5.3 [ 2.9- 7.6] <0.001 2.3 [-0.1 - 4.8] 0.064 
12-24 months 2,5 mg vs. placebo 6.0 [ 3.3- 8.8] <0.001 2.5 [-0.6- 5.5] 0.11 
1 ,25 mg vs. placebo 4.2 [ 1 A - 6.9] 0.003 0.7 [-2.3- 3.7] 0.63 
2,5 mg vs. 1,25 mg 1.9 [-0.5- 4.2] 0.12 1.8 [-0.8- 4.4] 0.18 
'ANCOVA, 
b daily dosage of tibolone. 
53 
compared to the placebo group. There was no significant difference bet\Veen tibolone treatment 
groups. Although there were a dose-related decreases in urinary calcium/creatinine ratios and 
hydroxyproline/creatinine ratios in both treannent groups. these decreases were statistically only 
in the 2,5 mg tibolone group. 
2.2.4 Discussion 
Posnnenopausal bone mass- which is the best predictor of fracture risk at present (Gardsel et al.. 
1991) - depends on the amount of peak bone mass and subsequent loss. From the onset of 
perirnenopause and in the initial years following menopause, an increase in bone remodelling 
(Recker et al.. 1988) and an imbalance between bone resorption and formation is observed 
(Nordin et al.. 1985). This results in an accelerated loss of primarily trabecular bone (Riggs et 
al.. 1986). Oestrogen deficiency plays a crucial role in this accelerated bone loss. Several studies 
have shown that oestrogen replacement therapy can effectively prevent trabecular as well as 
cortical bone loss by reducing bone resorption. 
The present study. focusing on early postmenopausal bone mass during 2 years of tibolone 
medication. included measurements of both phalangeal (which comprises mainly cortical bone) 
and trabecular bone density at 6-month intervals. Measurement of trabecular bone density of the 
lumbar spine by quantitative computed tomography may be less precise than Dual X-ray 
Absorptiometry (Reinbold et al.. 1986). However. this technique allows earlier detection of 
changes in response to treannent. since trabecular bone (which is measured exclusively) has a 
much faster turnover rate. Moreover. trabecular bone is much more responsive to hormonal as 
well pharmacological intervention as compared to cortical bone (Genant et al.. 1982; Nilas et al.. 
1985). This is in agreement with observations in the present study. Loss of trabecular bone in the 
placebo group was -6.4 %, whereas cortical bone showed no significant loss during the study 
period. Furthermore in the treatment groups a more pronounced dose-related increase was 
observed in trabecular bone density as compared to phalangeal bone density. In both treatment 
groups trabecular bone density showed an increase in the first year with a plateau phase in the 
second year. Cortical bone density increased after 6 months and showed a linear pattern. 
Comparison with similar trials using oestrogens is hampered by differences in treatment 
regimens (combination with progestagens and/or calcium supplements), types of oestrogens 
used. routes of administration and applied methods for bone mass measurement. Earlier studies 
using quantitative computed tomography showed conservation of trabecular bone density with 
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Table 7 Biochemical parameters of bone metabolism. 
treatment 
variable grou~ mean [95% Cl] P-value 
Hydroxyproline/ 2,5 mga -0.006 [-0.012 to -0.0003] 0.041 
creatinine ratios 
(mmol/mmol) 1,25 mga -0.003 [-0.009 to +0.003] 0.4 
Calcium/ 2,5 mg -0.208 [-0.334 to -0.082] 0.002 
creatinine ratios 
(mmol/mmol) 1,25 mg -0.102 [-0.229 to +0.025] 0.12 
Alkaline 2,5 mg -15 [-23 to -7] <0.001 
Phosphatase 
oum 1,25 mg -11 [-19to-4] 0.004 
Calcium 2,5mg -0.03 [-0.11 to +0.04] 0.37 
(mmol~) 
1,25 mg -0.02 [-0.09 to +0.06] 0.67 
Phosphorus 2,5mg -0.20 [-0.29 to -0.1 0] <0.001 
(mmol/1) 
1,25 mg -0.17 [-0.26 to -0.08] <0.001 
aGroup comparison of treatment groups versus placebo group at 24 months, expressed 
as mean difference and 95% confidence interval [95% Cl]. 
bdaily dosage of tibolone. 
0.625 mg conjugated oestrogens after oophorectomy (Genant et a/.,1982) and in osteoporotic 
women (Pacifici et al.. 1998). Early postmenopausal women treated with low dose (0.3 mg) 
conjugated oestrogens combined with calcium supplements showed no significant loss of 
trabecular bone density (Ettinger et al.. 1987). Studies using dual photon absorptiometry or dual 
x-ray absorptiometry for estimation of spinal bone mass in early postmenopausal women using 
various oestrogen replacement regimens showed changes between 0 and 6.4% (Riis et al.. 1987: 
Munk-Jensen et al., 1988: Stevenson et al., 1990: Ribot et al .. 1990: Marslew et al., 1992). A 
recent study in early postmenopausal women treated for 2 years with 2.5 mg/d tibolone showed 
an increase of 2.5% in spinal bone density measured with dual x-ray absorptiometry (Rymer et 
aL. 1994), which is somewhat lower as compared to the 9.1% increase observed with the same 
dose of tibolone in the present study. The most probable explanation for this discrepancy is 
55 
measurement of exclusively trabecular bone density of the spine in the present study. as 
previously mentioned. A study of tibolone 2.5 mg/d in women with established osteoporosis 
(Geussens et al.. 1991) showed an increase of spinal bone mass (measured with dual photon 
absorptiometry) of 8%. which is similar to the increase induced by fluoride (Hansson et al .. 
1987) or biphosphonates (Storm et al.. 1990). 
Biochemical parameters showed a doses-related response following tibolone medication. 
indicating a decrease in bone resorption and turnover rate. 
In summary the present study shows that tibolone induces a dose-related increase in early 
postmenopausal trabecular and cortical bone mass. We therefore conclude that 2,5 mg tibolone 
effectively prevents early postmenopausal bone loss. The 1.25 mg dose can prevent bone loss in 
the majority of early postmenopausal women. 
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2.3 INCREASED LOSS OF TRABECULAR BUT NOT CORTICAL BONE 
DENSITY, 1 YEAR AFTER DISCONTINUATION OF 2 YEAR HORMONE 
REPLACEMENT THERAPY WITH TlBOLONE. 
2.3.1 Introduction 
Several studies have documented that hormone replacement therapy (HRT) with estrogens 
alone, or in combination with progestagens are effective in preventing early postmenopausal 
bone loss (Ettinger et al., 1987; Riis et al., 1987: Stevenson et al.. 1990; Marslew et al.. 
1992). Effects of cessation of HRT on bone metabolism and bone loss are less clear. Some 
(Lindsay et al.. 1978; Horsman et al .. 1979: Fogelman et al., 1980) but not all (Christiansen et 
al.. 1981; Thomsen et al., 1987) studies in women after oophorectomy or following natural 
menopause suggested a rebound phenomenon on markers of bone metabolism or accelerated 
bone loss following cessation of HRT. Further doubts regarding long-term beneficial effect of 
temporary HRT used in early postmenopause on eventual bone mass at advanced age have 
arisen from data of The Framingham Osteoporosis Study (Felson et aL 1993) and The 
Rancho Bernardo Study (Schneider et al., 1997). 
Tibolone is a synthetic C-19 steroid with weak estrogenic, progestagenic and androgenic 
properties (Visser de et al., 1984). It has been previously documented that tibolone is capable 
of preventing metacarpal and spinal bone loss (Lindsay et al., 1980: Rymer et al.. 1994: 
Berning et al., 1996: Bjarnason et al., 1996) in postmenopausal women by suppressing 
skeletal metabolism (Fogelman et al., 1981). In addition. tibolone prevented bone loss in 
premenopausal women treated with gonadotropin-releasing hormone agonist medication 
(Lindsay et al., 1996), as well as after oophorectomy (Lytitis et al., 1995). 
The present study is an extension of an earlier. randomized. double-blind. placebo-
controlled study (Berning et al.. 1996) evaluating the effect of tibolone on early 
postmenopausal bone loss. This study reported, for the first time. a dose dependent increase in 
trabecular and cortical bone density in early postmenopausal women using L25 mg/d or 2.5 
mg!d tibolone during a 2 year study period. The present study reports on trabecular and 
cortical bone density one year after completing this initial study. Single energy quantitative 
computed tomography was used to measure exclusively trabecular bone density in the lumbar 
spine (Sandor et al.. 1985), whereas micro densitometry of the mid phalangeal shaft (which 
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consists of 80% cortical bone) (Trouerbach et al.. 1988), was used for the estimation of 
cortical bone density. (Benting et al.. 1996). 
2.3.2 Materials and Methods 
Subjects: Sixty-four out of 84 subjects who completed a 2 year randomised placebo 
controlled study regarding the effects of two doses of tibolone (NV Organon. Oss, The 
Netherlands) on early postmenopausal bone loss entered the present study. Selection of 
subjects and inclusion criteria for the initial study have been described earlier (Berning et al.. 
1996). In brief; 94 healthy Caucasian non-smoking women, 1-3 years following spontaneous 
menopause. with a body mass index (BMI: weight divided by square length) < 27 kg/m2, free 
of diseases or medication known to influence calcium metabolism or contraindicate the trial 
medication entered the initial trial. Subjects were allocated by random medication number. 
according to a 2:3:3 ratio, to a placebo (n;23). a tibolone 1.25 mgld (n;36) or a tibolone 2.5 
mg!d (n;35) treatment group. Ten subjects dropped out of the initial trial due to adverse 
experiences or intercurrent illness. As described earlier, they were distributed equally among 
the 3 groups (Berning et al., 1996). Of the remaining 84 subjects. 4 wanted to continue the 
use of HRT for relieve of climacteric symptoms. Five subjects refused to participate further 
for no particular medical reason. Fifteen subjects of the original group of 84 participants had a 
trabecular bone mineral density below 1 standard deviation (SD) of the mean value of the 
study group at baseline. Eleven of these women started or continued HRT afrer the initial trial 
and were therefore excluded from study. They were distributed equally among the three 
groups (placebo: 2, tibolone 125 mg: 4 and tibolone 2.5 mg: 5 ). The remaining four women 
did not use HRT in the 1 year follow-up, one was a drop out in the initial study and 3 enrolled 
in the present study. Subjects who did not participate regardless the reason. were also 
distributed equally among the three groups, 7 in the placebo group. 11 in the 1.25 mg tibolone 
group and 12 in the 2.5 mg tibolone group. regarding the 2:3:3 ratio of randomisation. 
Therefore. sixty-four subjects who were free of disease or medication known to influence 
calcium metabolism were included in this 1 year follow-up period. 
Study protocol: The study protocol was approved by the Ethics Review committee of the 
Dijkzigt Hospiral!Erasmus University. Sixty-four participants were assessed 1 year afrer 
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completing the initial 2 year medication period. Blood and urine sampling was performed as 
well as measurement of trabecular and phalangeal bone density. 
Bone measurements: Single energy Quantitative Computed Tomography (QCT) (Somatom 
plus. Siemens AG, Erlangen. Germany) was used for estimation of trabecular bone density of 
the lumbar vertebral bodies (Ll-L3). Trabecular bone density was expressed as milligram 
hydroxyapatite per cm3. using a standard reference device. Bone density of the mid-phalanx 
of the index fmger was measured by radiographic absorption densitometry. Results were 
expressed as aluminium equivalents per mm3 (AI eq/mm3). Both techniques have been 
described in detail previously (Berninger al.. 1993). 
Laboratory measurements: For biochemical estimation of bone metabolism the following 
markers were used. Alkaline Phosphatase. Phosphorus and serum Calcium were measured 
with a Bayer Technicon Chern-! system ( Bayer AG. Leverb:usen, Germany) according to the 
manufacturers instructions. After overnight fasting, urine samples of second morning voids 
were collected 2 hours after drinking 300 ml of water. Measurement of urinary 
Hydroxyproline. Calcium and Creatinine were determined by standard procedures in our 
laboratory. as has been described previously (Berning er al.. 1993). Urinary ratios of 
hydroxyproline/creatinine and calcium/creatinine were calculated in rnmol per rnmol. 
Statistical analysis: For trabecular and phalangeal bone density. analysis was applied 
regarding changes expressed as percentage from baseline. For parameters of bone metabolism 
comparison of means was performed within the study group as well as between groups. All 
variables were tested for normal distribution. Ouly for normally distributed variables student t 
test for independent sample, was used for group comparison. For comparison within groups 
the t-test for paired samples was applied. For all others variables the Mann-Whitney test was 
used for group comparison, and for comparison within groups the Wilcoxon Rank Sum W 
Test was used. The upper limit for statistical significance was 0.05. All p-values are two-
tailed. A difference between treatment groups of 5,5% in trabecular bone density could be 
detected with a power of 80% with the conventional 0,05 level for alpha. Statistical 
calculations were performed in SPSS for windows. release 6.1. 
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2.3.3 Results 
Study group: Initial clinical and biochemical characteristics and bone density of the 64 
participants are shown in Table 8. There were no significant differences. With respect to 
parity or oral contraceptive pill use the 3 groups were also comparable (data not shown). 
Trabecular bone density: Results in relative changes of trabecular bone density are depicted 
in Figure 3. During the 2 year medication period trabecular bone density increased 
significantly in both treatment groups as compared to baseline, whereas during the same time 
period a significant loss was observed in the placebo group. During the 1 year follow-up 
period a significant loss of bone mass occurred in both treatment groups. whereas the placebo 
group showed a further loss of 1.4%. Compared to baseline. at 36 months trabecular bone 
density was significantly lower in the placebo and 1.25 mg tibolone group. whereas the 
reduction of 2% trabecular bone density in the 2.5 mg tibolone group reached borderline 
significance (P=0.05). Group comparison of the percent change during the 2 year medication 
period and I year follow-up period are presented in Table 9. When compared to the placebo 
group both treatment groups showed a significantly greater decrease in trabecular bone 
density (P<0.03 and P<O.OOI) during the one year follow-up period. The decrease in 
trabecular bone density in both treatment groups during the 1 year follow-up period was not 
significantly different. 
Phalangeal bone density: Results of relative changes in phalangeal bone density are also 
depicted in Figure 3. During the 2 year medication period phalangeal bone density increased 
significantly in both treatment groups as compared to baseline. A continuous decrease in 
phalangeal bone density was observed in the placebo group during 3 years of monitoring. 
Compared to baseline. at 36 months phalangeal bone density was significantly higher in the 
2.5 mg treatment group. In contrast there was a significantly lower phalangeal bone density in 
the placebo group at 36 months compared to baseline, whereas phalangeal bone density at 36 
months in the 1.25 mg treatment group did not differ significantly from baseline. Group 
comparison of the percent change during the 2 year medication period and 1 year follow-up 
period are presented in Table 9. When compared to the placebo group both treatment groups 
showed no significantly different change in phalangeal bone density during the 1 year follow-
up period. 
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Table 8 Clinical, biochemical data and bone mineral mass (mean ± SO) of the 64 
postmenopausal women at baseline of the initial study divided in placebo 
group and the two treatment groups. 
placebo (n=16) tibolone tibolone 
1,25 mg/d 2,5 mg/d 
(n=25) (n=23) 
Variables 
Age (yrs) 52.9 ±2.6 53.6 ±3.3 52.3 ± 3.0 
Body mass index (kglm2) 24.3 ± 2.4 23.6±2.5 23.4 ±2.7 
Gynaecological parameters: 
Age at menarche (yrs) 13±1.9 14±1.7 13±1.4 
Age at menopause (yrs) 50.9±2.5 51.2 ±3.0 52.2 ± 3.1 
Months since menopause 20 ±7 24±8 23±8 
Biochemical markers: 
urinary Hydroxyproline/creatinine ratlosa 0.030 ± 0.008 0.030 ± 0.009 0.030 ± 0.01 
urinary Calcium/creatinine ratiosa 0.331 ± 0.217 0.457 ± 0.248 0.367±0.189 
Alkaline Phosphatase (IU/1) 53± 14 52±13 57±14 
Calcium (mmoVI} 2.42 ± 0.07 2.42±0.11 2.47 ± 0.11 
Phosphorus (mmol/1) 1.23±0.17 1.23±0.12 1.26±0.17 
Bone density: 
Trabecular (mg/cm') 148±39 127±26 129 ± 26 
Phalangeal (AI eq/mm1 0.539 ± 0.035 0.519 ± 0.042 0.511 ± 0.0354 
a(mmoVmmol) 
Biochemical parameters of bone metabolism: There was no change in serum calcium 
throughout the 2 year medication period as well as in the I year follow-up. Changes in 
alkaline phosphatase, phosphate. urinary calcium/creatinine ratio and urinary 
hydroxyproline/creatinine ratio are illustrated in Figure 4. For alkaline phosphatase, 
phosphorus and urinary calcium/creatinine ratio a significant decrease during the 2 year 
medication period was observed in both treatment groups. resulting in significantly lower 
values in the group comparison at the end of the 2 year period. During the 1 year follow-up 
these values increased to pre-treatment levels. Therefore, group comparison for these 
parameters after 1 year of follow up showed no significant differences. A significant 
reduction in urinary hydroxyproline/creatinine ratio during the 3 years of monitoring was 
observed in all groups. Group comparison after 1 year follow-up showed no significant 
differences. 
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Percent change as compared to baseline in trabecular bone density of the lumbar spine (mean 
and 95% confidence interval) (upper panel) and phalangeal bone density (mean and 95% 
confidence interval) (lower panel) in 64 healthy early postmenopausal women having used 
placebo, 1.25 or 2.5 mg/day tibolone for 2 years (24 months), followed for 1 additional year 
after discontinuation of medication (36 months). 
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2.3.4 Discussion 
The skeleton consists of two different types of bone. Cortical bone forms the shafts of long 
bones and most effectively resists bending forces. The internal structnre of metaphyses of 
long bones and vertebral bodies consists of trabecular bone and is best designed to resist 
compressive stress (Dempster. 1992). Trabecular bone has a much higher surface to volume 
ratio. Since the processes of bone remodelling are primarily surface phenomena (Parfitt 
1979) trabecular bone is considerably more metabolically active as compared to cortical bone. 
Therefore. trabecular bone is much more responsive to hormonal and pharmacological 
intervention as compared to cortical bone (Genant et al., 1982; Nilas et al.. 1985). From the 
onset of perimenopause and during initial years after menopause an accelerated loss of 
primarily trabecular bone takes place due to decremental estrogen production. 
It has been clearly documented in the literatnre that HRT can effectively prevent trabecular 
as well as cortical bone loss. In contrast. there are few data on bone loss after cessation of 
HRT. Histomorphometry in oophorectomised rats showed an accelerated bone tnrnover after 
discontinuation of estrogen therapy (Wornski et al.. 1993; Takahashi et al.. 1994). Studies in 
oophorectomised (Lindsay et al.. 1978) and postmenopausal women (Horsman et al.. 1979; 
Davis et al., !995) showed an accelerated bone loss after withdrawal of HRT. Lindsay and 
colleagnes, (Lindsay et al., 1978) who used single photon absorptiometry (SPA) at the mid-
point third metacarpal of the rigbt hand for determination of bone density. found no benefit of 
4 years of treatment with estrogens 4 years after discontinuation of treatment. A population 
based study showed that women who stopped HRT had a greater than average loss of bone 
mass in the calcaneus. distal and proximal radius using SPA (Davis et al.. 1995). One study 
(Christiansen et al., 1981) using SPA at the distal forearm in postmenopausal women found 
no accelerated bone loss after withdrawal of HRT. However, women in this study used 
supplementary calcium tablets. which may have influenced their results. When skeletal uptake 
of diphosphonate (a sensitive measure of skeletal metabolism) is measured in postmenopausal 
women, one study suggested a period of accelerated bone turnover (Fogelman et al., 1980), 
whereas Thomsen (Thomsen et al., 1987) found a bone tnrnover similar to the placebo group 
after withdrawal of HRT. 
The present study evaluated for the first rime both trabecular bone density at the lumbar 
spine and mid-phalangeal bone density (which comprises mainly cortical bone), I year after 
cessation of 2 years of HRT with tibolone. Due to ethical considerations the present study 
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Figure 4 
Biochemical parameters of bone metabolism (mean and SE) at baseline, after a 2 year period of tibolone medication or 
placebo (24 months) and 1 additional year after discontinuation (36 months) in 64 healthy early postmenopausal women, 
having used placebo (n=16) (II), 1.25 mg/day (n=25) (A), 2.5 mg/day (n=23) (Ill) tibolone. 
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population did not include 11 out of 15 subjects with low bone mass at baseline of the initial 
study since these patients started or continued to use HRT during the 1 year follow-up period. 
However, these subjects where distributed equally among the three groups. Hence, most likely 
group comparison is not affected. Furthermore, in the initial study bone density at baseline 
was negatively related to the response during the 2 year medication period. This means that 
low initial bone mass was associated with a greater increase in both treatment groups and a 
smaller decrease in the placebo group. Since there is a strong negative correlation between 
changes during the 2 year medication period and in the I year follow-up period, it is unlikely 
that any selection avoiding low bone mass would have lead to the observations in this study. 
The present observations show a significantly greater decrease in trabecular bone density in 
both tibolone regimens as compared to the placebo group. The decrease in trabecular bone 
density during the I year follow-up period in both treatment groups (7-11%) is comparable 
with the decrease in trabecular bone density (also measured with QCT) seen after bilateral 
oophorectomy (7-9%) (Genant et aL 1982) but is substantially greater than the annual 
decrease of 3.2% seen after spontaneous menopause (Berning et aL !996). In the placebo 
group the decrease in trabecuar bone density during the 1 year follow-up period is 
approximately half the rate during the two year study period. The exact reason is not known 
but it could be hypothesised that the increased loss of trabecular bone density in the years 
immediately after menopause decreases in the fourth to sixth year since menopause. In 
contrast to trabecular bone density. the decrease in phalangeal bone density during the 1 year 
follow-up, in both tibolone regimens did not differ from the placebo group. After I year 
follow-up following 2 years of tibolone medication, phalangeal bone density was still 
significantly greater compared to the placebo group. However. since cortical bone may react 
slower than trabecular bone. the decreasing trend seen in cortical bone density during the frrst 
year after HRT is likely to continue. The decrease of phalangeal bone density during the 1 
year follow-up is greater than during the two year study period. the reason for this is not 
known. Only long-term follow-up of healthy early postmenopausal women gives insight in 
the annual rate of phalangeal bone density during the years following menopause. Reduction 
in serum Alkaline Phosphatase. Phosphorus as well as decrease in urinary excretion of 
calcium and hydroxyproline indicated a reduction in bone resorption during tibolone 
medication with a return to pre treatment values 1 year after discontinuation of tibolone. 
Unfortunately biochemical markers of bone metabolism were not assessed immediately after 
the wash-out period of the tibolone medication. therefore 
Table 9 Group comparison of percent change from baseline to end of study (24 months) and in post study year (24-36 months) for 
trabecular and phalangeal bone density, expressed as mean difference and 95% confidence interval (CI). 
Period 
study period: 
0-24 months 
post study year: 
24-36 months. 
a :Daily dosage of tibo!one 
Trabecular bone density Phalangeal bone density 
Group comparison Mean (95°/o Cl) P Mean (95% Cl) 
2.5 mga vs. placebo 15,6 (12,5. 18,7) <0,001 6,9 (3,6. 10,2) 
1,25 mga vs. Placebo 9,5 (6,8. 12,2) <0,001 5,8 (2,5. 9,2) 
2,5 mg vs. 1,25 mg 6,1 (3,0. 9,2) <0,001 1,0 (·1,9. 4,0) 
2.5 mg vs. placebo -10,0 (-12,9- -6,9) 0,001 -0,3 (-4,5- 4,0) 
1 ,25 mg vs. Placebo -6,0 (-8,4 - -3,5) 0,03 0,02 (-3,5- 3,5) 
2,5 mg vs. 1,25 mg -3,9 (-6,7- 1,1) 0,12 -0,3 (-4,2- 3,6) 
p 
<0,001 
0,001 
0,47 
0,9 
1,0 
0,9 
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a rebound phenomenon normalising within one year can not be excluded. At the end of the 
follow-up year these markers did not indicate an increased bone resorption compared to the 
placebo group or to baseline values of the initial study. 
Observations from the present study suggest that there is an accelerated loss of more 
metabolically active trabecular bone, but not of cortical bone following cessation of 2 year 
tibolone intake. It should be realised, however. that techniques of bone mass measurements 
used in the present study as well as skeletal sites measured may have influenced results, and 
may attribute to the present controversy in the literature. Although our follow-up period is 
short, it seems that HRT with tibolone like with estrogens should be continued into late life in 
order to maintain high bone density. Data concerning early HRT use and bone density later in 
live are available from the Framingham Study (Felson et a!.. !993). Only early HRT longer 
than 7 years resulted in a higher bone density up to 75 years of age. Even this duration of 
HR.T in early postmenopause may have little residual effect on bone density among women 
older than 75 years of age, who are at the higbest risk for hip fractures. Data from Scbneider 
and colleagues (Schneider et al., 1997) also suggests that past estrogen use provides little or 
no long-term benefit for preservation of bone density. Therefore, the possibility of an 
alternative strategy to start HRT many years after menopause and to continue treatment for 
the rest of a women lifetime, in order to prevent osteoporotic fractures, has been proposed 
(Ettinger et ol .. 1996; Scbneider et al.. 1997). Since a daily dose of 1.25 mg or 2.5 mg 
tibolone has been shown to prevent bone loss in late menopause in a similar way (Bjarnason 
et al., 1996). this medication may represent an alternative strategy for the prevention of 
postmenopausal osteoporosis in late postmenopausal women (Riggs. 1996). 
In summary, the present study suggests that in contrast to cortical bone density there is an 
increased loss of trabecular bone density in the first year after discontinuation of treatment 
with tibolone. 
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2.4 ABSENT CORRELATION BETWEEN VAGINAL BLEEDING AND 
OESTRADIOL LEVELS OR ENDOMETRIAL MORPHOLOGY DURING 
TffiOLONE USE IN EARLY POSTMENOPAUSAL WOMEN. 
2.4.1 Introduction: 
Despite the well documented beneficial long-term effects of hormone replacement therapy 
(HRT) on postmenopausal osteoporosis and cardiovascular disease. compliance of HRT is 
poor. In the Netherlands. more than 60% of women withdraw from HRT within 6 months and 
only 8% of the women remained on HRT for more than 2 years (Groeneveld et al.. 1998). The 
two most common reasons for stopping oestrogen's or failing to initiate HRT in 
postmenopausal women are fear for cancer and the withdrawal bleeding induced by cyclical 
progesterone given to prevent endometrial hyperplasia and subsequent cancer. 
Tibolone is a synthetic steroid with an unique pharmacological profile. Studies in animals 
showed oestrogenic. progestagenic and weak androgenic properties (Visser de et a!., 1987). 
Tibolone relieves vasomotor symptoms (Trevoux et al.. 1983; Tax et al.. 1987) and maintains 
skeletal integrity in early (Berning et al.. 1996) and late (Bjarnason et al.. 1996) 
postmenopausal women comparable to estrogens. Several clinical studies established that 
tibolone 2.5 mg/d does not stimulate the endometrium (Genazzani et al.. 1991; Rymer et al.. 
1994; Ginsburg et al .• 1995. Habiba et al.. 1996) thus eliminating the need for women to have 
a progesterone induced withdrawal bleed. However. some postmenopausal women do bleed 
while taking tibolone (Lindsay et al.. 1980; Trevoux et al.. 1983: Genazzani et al.. 1991; 
Rymer et al., 1994: Ginsburg et al.. 1995. Habiba et al.. 1996). In the present study we 
compare baseline characteristics and serum levels of oestradiol (E2) in women who bled and 
those who did not. in an attempt to determine factors that are associated with bleeding in early 
postmenopausal women using two doses (1.25 mg/d and 2.5 mg/d) of tibolone in a two year 
randontised. placebo-controlled study. Furthermore. endometrial histology is studied in 
women with vaginal bleeding. 
2.4.2 Subjects and Methods: 
Subjects: Ninety four healthy women were recruited for a 2 year randontised placebo-
controlled study evaluating two doses of tibolone (Liviai®.NV Organon. Oss. The 
Netherlands) on early postmenopausal bone loss. Selection of subjects and inclusion criteria 
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for the initial study have been described earlier (Benting et al .. 1996). In brief; 94 healthy 
Caucasian non-smoking women~ 1-3 years following spontaneous menopause, with a body 
mass index (BMI; weight divided by square length)< 27 kg/m2• free of diseases or medication 
known to influence calcium metabolism or contraindicate the trial medication. At the initial 
visit information was collected regarding medical history, gynaecological history and drug 
intake. Detailed description of baseline characteristics has been published earlier (Berning et 
al.. 1993). 
Study protocol: The study protocol was approved by the Ethics Review committee of the 
Dijkzigt Hospital/Erasmus University. Following thorough information 96 women gave 
written consent to participate. After a general and gynaecological examination 94 women 
entered the study. Subjects were allocated by random medication number, according to a 2:3:3 
ratio. to a placebo. tibolone 1.25 mg/d or a tibolone 2.5 mg/d treattnent group. Medication 
was provided as identically looking tablets. The daily dose was one tablet. Patients were 
asked to make a note of any vaginal bleeding or other side effect. Patients were seen at three-
months intervals for 2 years (9 visits total) at which they were asked about vaginal bleeding or 
any other side effect. In case of vaginal bleeding women underwent a Vabra curettage 
(Alberico et al .• 1986). Assessment of BMI was performed at each visit. 
Laboratory measurements: The serum concentrations of E2 and Follicle-Stimulating 
Hormone (FSH) were measured at each assessment (i.e. every 3 months) by a commercially 
available fluoro-immunoassay (Delfia®. Wallac Oy. Turk-u. Finland). For E2 the assay 
sensitivity was 50 pmo!JL The intra- and inter-assay variability was 4.5-7.8% and 6.3-10.3% 
for E2 and FSH. respectively. 
Statistical analysis: Baseline characteristics of normally distributed variables were expressed 
as mean and standard deviation (SD). For not normally distributed variables median and range 
was used. Baseline characteristics of women who bled were compared to those who did not 
within each group as well as both treatment groups together. The Student t test for 
independent samples was used for comparison of means of normally distributed variables. For 
comparison of medians of not normally distributed variables the Mann-Whitney U test was 
used. The number of women who bled as well as the number bleeding episodes in each group 
were compared using the x2 test. To determine whether the E2 serum level prior to bleeding 
was higher than the overall E2 serum level of women who did not bleed in each group. the 
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median E2 serum concentration prior to the bleeding episode was compared to the median of 
the median of the 9 E2 levels measured during the entire study period of women who did not 
bleed. Since E2 levels were not normally distributed the Mann-Whitney U test was used. 
Furthermore. the number of women who had E2 serum levels > 70 pmol/1 at any occasion 
during the study period were also compared using the x2 test. The analysis included all 
women randomised to the study (i.e. intent to treat subjects) to rule out bias as a result of 
selection caused by leaving out patients who did not complete the srudy. 
2.4.3 Results: 
During a 18 months recruitment period 94 women were allocated (according to the 2:3:3 
ratio) to a placebo (n=23). a 1.25 mg (n=36) and a 2.5 mg tibolone treatment group (n=35). 
Their mean age was 52.7 ± 2.9 years. the median time since menopause was 20 months 
(range: 12-36). The mean age at menopause was 505 ± 2.8 years. The median BMI at 
baseline was 24.3 kg/m2 (range 18.2-27.0) The median serum E2 level and the mean 
concentration FSH at baseline was 54 pmolfl (range: 50-447 pmolfl) and 69 ± 26 IU/l. 
respectively. 
Eighty-four (89%) women completed the 2 year study. In the placebo group there were 4 
drop-outs due to intercurrent illness. In the 1.25 mg tibolone group one women started 
estrogen use without consulting the investigator. Two women discontinued due to adverse 
experiences (i.e. vaginal bleeding, allergic skin reaction). In the 2.5 mg tibolone group one 
woman had hypercholesterolemia. one participant experienced an unacceptable weight gain of 
3 kg, and the other had enlargement of uterine fibroids. 
As shown in Table 10. the number of bleeders in the 2.5 mg tibolone group were significantly 
higher compared to placebo. Also in the 1,25 mg tibolone group percentage of women who 
bled was also higher (44% compared to 22% in the placebo group) but this difference failed to 
reach statistical significance. When both treatment groups together were compared to placebo. 
percentages of bleeders was significantly higher 48% versus 22% (X2 test P<0.05). When 
bleeding episodes were expressed in months of usage of trial-medication. in the placebo group 
there were 8 in nearly 500 months. For 1.25 mg tibolone this was 20 in approximately 770 
months of usage. In the 2.5 mg tibolone group there were 42 episodes of bleeding in nearly 
740 months which was significantly more compared to placebo and 1.25 rug tibolone cl test 
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Table 10 Number of women who experienced bleeding, number of bleeding episodes 
and distribution among 94 early postmenopausal women receiving placebo, 
1 ,25 mg/d or 2,5 mg/d tibolone during the two year study period. 
No. of bleeders 
placebo 
(n=23) 
5 (22%) 
No. of bleeding episodes 
0 
1 
2 
3 
4 
5 
8 
18 (79%) 
3 {13%) 
1 (4%) 
1 (4%) 
Total no. of bleeding episodes 8 
a : significantly different from placebo P<0.05 
b : significantly different from placebo P<0.01 
Group 
1 ,25 mg tibolone 
(n=36) 
16 {44%) 
20 (56%) 
13 {36%) 
1 {3%) 
2 (6%) 
20 
c: significantly different from 1,25 mg/d tibolone P<0.05 
P<0.001 and P<0.05, respectively). 
2,5 mg tibolone 
(n=35) 
18(51%)a 
17 (49%) 
12 (34%) 
1 (3%) 
1 (3%) 
1 (3%) 
1 (3%) 
2 (6%) 
Table 11 compares bleeders to non-bleeders with respect to baseline characteristics and 
serum E2 levels during the study period. In the placebo group bleeders were younger. had 
their menopause earlier and months since menopause was less compared to the non-bleeders 
(Table 11). In the 2.5 mg tibolone group. non-bleeders were younger and had their menopause 
at an younger age. In contrast. months since menopause was less for bleeders although this 
failed to be statistical significant (Table 11). In the 1,25 mg tibolone group as well as both 
treatment groups as a whole, baseline characteristics were comparable to non-bleeders (Table 
11). Table 11 also compares bleeders to non-bleeders with respect to serum E2 levels. In the 
placebo group the incidence of E2 levels > 70 pmol/1 during the two year study period were 
comparable. However, when the median E2 level prior to bleeding was compared to the 
overall serum E2 level of non-bleeders during the study period. bleeders had a higher median 
serum E2 level (Table 11). In both treatment groups (separately as well as together). bleeders 
were comparable to non-bleeders with respect to serum E2levels (Table II). 
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Table 11 Comparison of age, age at menopause, months (mths) since menopause and Body Mass 
Index (BMI) at baseline between bleeders and non-bleeders (mean :t SO or median and 
range). Comparison of the median oestradiol (E2) level prior to bleeding to the median of 
the median E2 level of the non-bleeders during the two year study period. Comparison of 
number of women with detectable (E21evel > 70 pmol/1) or premenopausal (E2 levels >100 
pmol/1) E2 levels at any occasion, during the two year study period, between bleeders and 
non-bleeders, for placebo group, 1 ,25 mg tibolone group, 2,5 mg tlbolone group and both 
tibolone groups. 
Bleeders 
Placebo group (n=23) n=5 
Age (yrs) 50.0 ± 3.3 
Age at menopause (yrs) 48.6 ± 3.3 
Mths since menopause (yrs) 13 (12-18 0) 
BMI (kg/m2) 24.3 (23.0-26.8) 
E2 level (pmoVI) 56 (50-285) 
E2 levels> 70 pmoln (n) 4 
E2 levels> 100 pmoVI (n) 3 
1,25 mg tibolone group (n=36) n=16 
Age (yrs) 53.1 ± 3.1 
Age at menopause (yrs) 50.9:!: 3.0 
Mths since menopause (yrs) 23 (12-18) 
BMI (kg/m2) 25.2 (18.2-26.9) 
E2 level (pmoVI) 51 (50-197) 
E2 levels> 70 pmoVI (n) 7 
E2 levels> 100 pmoVI (n) 6 
2,5 mg tibolone group (n=35) n=18 
Age (yrs) 53.2 ± 2.0 
Age at menopause (yrs) 51.2 ± 2.0 
Mths since menopause (yrs) 18 (12-36) 
BMI (kg/m2) 23.4 (19.8-26.9) 
E2 levels (pmol/1) 56 (50-447) 
E2 levels> 70 pmol/1 (n) 6 
E2 levels> 100 pmol/1 (n) 5 
Both tibolone groups (n=71) n=34 
Age (yrs) 53.1 :!: 2.5 
Age at menopause (yrs) 51.1 ± 2.5 
Mths since menopause (yrs) 20 (12-36) 
BMI (kg/m2 ) 24.1 (18.2-26.9) 
E2 level (pmol/1) 55 (50-447) 
E2 levels> 70 pmol/1 (n) 13 
E21evels > 100 pmol/1 (n) 11 
: Student-t test 
... :Mann-Whitney Utest 
Non-bleeders 
n=18 
53.2 ± 1.8 
51.0 ± 1.9 
19 (12-36) 
25.3 (19.1-26.9) 
50 (50-62) 
10 
8 
n=20 
53.6:!: 3.2 
51.2 ± 2.9 
22 (12-36) 
23.7 (20.3-27.0) 
53 (50-69) 
8 
3 
n=17 
51.2 ± 3.2 
48.9 ± 3.3 
24 (12-36) 
23.8 (18.3-26.8) 
51 (50-70) 
5 
2 
n=37 
52.5:!: 3.3 
50.1 ± 3.3 
24 (12-36) 
23.7 (18.3-27) 
51 (50-70) 
13 
5 
p 
<0.01* 
<0.05* 
<0.05"1" 
<0.05"1" 
<0.05* 
<0.05' 
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Figure 5 shows the cumulative percentage of women presenting with a first bleeding 
during the study period. Ninety percent of the first bleeding episodes in the L25 mg and 2.5 
mg tibolone group were within 41 and 36 weeks, respectively. Within 12 weeks about 50% of 
the first bleeding episodes occurred in both treatment groups. 
Table 12 shows the endometrial findings of women who experienced bleeding. No 
hyperplasia was found. One woman. who bled 8 times. had uterine fibroids diagnosed with 
vaginal ultrasound. At hysteroscopy no abnormal findings were seen. All women who bled 
after the endometrial sampling had normal findings at vaginal ultrasound with a regular 
endometrium and a endometrial thickness of less than 4 mm. 
2.4.4 Discussion: 
Tibolone is a synthetic C-19 steroid ((7o:.l7o:)-l7-hydroxy-7-methyl-l9 norpregn-5(10)-en-
20-yn-3-one) which effectively alleviates climacteric vasomotor symptoms (Trevoux et al.. 
1983: Tax et al.. 1987). Furthermore. randomised placebo-controlled trials showed that it is 
capable of preventing bone loss in early (Berning et al.. 1996) and late (Bjarnason et al.. 
1996) postmenopausal women. When tibolone is used for long-term HRT it is important to 
assess its effects on the endometrium as well as on the incidence of vaginal bleeding. 
Tibolone has a mixed hormonal profile. The estrogenic potency of tibolone is about 1150 that 
of ethinyl oestradioL the progestagenic potency is 1/8 that of norethisterone. and the 
androgenic potency is about 113 that of norethisterone (Vies van der et al.. 1987). These 
actions are receptor mediated, as shown by the inhibition of anti-oestrogens and anti-
progestins (Markiewicz et al.. 1994). Tibolone is extensively metabolised in 3o: hydroxy 
tibolone. 3~ hydroxy tibolone and its A4 isomer (Sandker et al.. 1994). These metabolites 
exhibit different oestrogenic and progestagenic capabilities in vitro. Furthermore. 
concentrations of metabolites differ depending on the target tissue. For instance. in the human 
endometrium tibo1one is predominately metabolised to its ~4 isomer. which has more 
progestagenic activity (Tang et al.. 1993). This finding suggests a metabolic regulation of 
hormonal activity oftibolone at the target tissue level (Markiewicz et al.. 1990). 
Several clinical trials showed that tibolone does not stimulate the endometrium (Genazzani 
et al.. 1991; Rymer et al.. 1994; Habiba et al., 1996: Ginsburg et al .• 1996). Even dnring long-
term use up to 5 years no stimulatory effects on the endometrium could be found (Genazzani 
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Table 12 Endometrial histological findings after Vabra curettage in 39 women who 
experienced first vaginal bleeding during the 2 year study period (number 
of subjects). 
Histological finding placebo 1,25 mg tibolone 2,5 mg tibolone total. 
Missing/not performed 0 2 1 3 
Insufficient amount of material 3 8 9 20 
Atrophic/inactive 0 4 8 12 
Proliferative 2 2 0 4 
et al.. 1991; Ginsburg et al.. 1996). Earlier studies state that vaginal bleeding does occur in 
women taking 2.5 mgld tibolone. but no incidence was given (Genazzani et al.. !991; Lindsay 
et al.. 1980). In 1994 Rymer et al. (Rymer et al., 1994) reported for the first time the 
incidence of bleeding during a 2 year non-randomised study in one hundred early 
postmenopausal women. They found a 20% incidence in the tibolone group compared to 
9.4% in the group which did not receive medication. Furthermore women who bled in the 
tibolone group were younger at menopause. were recently menopausal and may have 
remaining endogenous oestrogen production. Ginsburg et al. (Ginsburg et al.. 1995) published 
their experience with long-term use of tibolone and calculated an incidence of vaginal 
bleeding of 12.6%. The majority of women in this report were 5 years or more after 
menopause. suggesting that the incidence of vaginal bleeding may be less in late 
postmenopausal women. 
The present randomised placebo-controlled study is the first reporting on the incidence of 
bleeding using two doses of tibolone in early postmenopausal women. Vaginal bleeding 
occurred in 22% of the placebo group. and in 44% (1,25 mg/d) and 51% (2.5 mg/d) in 
tibolone users which is substantially higher than the incidence reported by Rymer (Rymer et 
a!.. 1994) involving a similar population of early postmenopausal women. Taking the 
incidence of the placebo-group into account. like Rymer, we found that the percentage of 
bleeding is about twice as high in tibolone group. We found that women who bled in the 
placebo group were younger, had their menopause at an younger age and may had 
endogenous oestrogen production. In contrast to Rymer (Rymer et al., 1994), in the tibolone 
group we could not detennine factors that are associated with bleeding. With respect to the 
incidence of bleeders. the L25 mgld tibolone group was comparable to 2,5 mgld tibolone 
group. However, looking at bleeding episodes. recurrence of bleeding was significantly less in 
the 1,25 mg tibolone group compared to the 2.5 mgld tibolone group. The use of L25 mgld 
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Figure 5 
Cumulative percentage of first bleeding episode in early postmenopausal women during the 2 year 
study period, using placebo, 1 .25 mg/d or 2.5 mgiday tibolone. 
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and 2.5 mg/d tibolone in women who had their menopause at least 10 years ago (Bjarnason et 
al.. 1996), resulted in an incidence of bleeding of. 11% and 20%, respectively. These findings 
are in agreement with the contention that the incidence of bleeding is less in late 
postmenopausal women. 
Like other clinical trials (Genazzani eta! .. 1991: Rymer et al., 1994. Ginsburg et al .. 1995: 
Bjarnason et al.. 1996: Habiba et al.. 1996) we found no stimulatory effect on the 
endometrium in women who bled during tibolone treatment, using Vabra endometrium 
sampling. This seems in agreement with present observations that no relationship exists 
between E2 levels and the occurrence of bleeding in tibolone users. In the present study one 
woman with recurrent bleeding showed uterine fibroids on vaginal ultrasound. Hysteroscopy 
in this patient showed no abnormalities. All other women with recurrent bleeding had normal 
findings on vaginal ultrasound at the end of the study. Therefore. no further diagnostic 
evaluation was performed. 
Hysteroscopic evaluation was not performed routinely in the present study and therefore 
the possible role of intracavitary anomalies could not be addressed. Recently Ginsburg et a!. 
(Ginsburg et al.. 1996) reported on the cause of vaginal bleeding in 47 out of 434 women 
using 2.5 mg/d tibolone. They found endometrial polyps in 11 cases and uterine fibroids in 7. 
In 3 out of 6 women with an thickened endometrium on vaginal ultrasound no histological 
abnormality could be found. Two women had simple hypei]Jlasia, one had used tamoxifen for 
years. the other consumed large quantities of Chinese vegetables raising the possible role of 
phyto-oestrogens. There were two cases of carcinoma in situ. which is less than the presumed 
occurrence of 2-3 in 300 women (Da!deszen et al.. 1994). Despite full investigation. no 
mOI]Jhologica! abnormality was found in over half the women who bled dnring tibolone. 
Habiba et a!. found in 17 women (39%) benign intracavitary abnormalities and one case of 
simple hypei]Jlasia. fu addition. immunohistochentica! makers for proliferation and for 
oestrogenic effect did not demonstrate any differences with a matched control group of 
women who did not bleed during tibolone treatment. 
fu conclusion. in the present study occasional bleeding in the first 9 months of treatment 
with tibolone in early postmenopausal women is approximately 2-2,5 times as likely as 
compared to placebo. The majority of the first bleedings occurred within 9 months of 
treatment. No correlation with E2 serum levels or stimulatory effect of tibolone on the 
endometrium was seen. 

3 
Tibolone and its effects on bone, a review. 
3.1 Introduction 
Osteoporosis is defmed as a systemic skeletal disease characterised by low bone mass and 
microarcbitectural deterioration of bone tissue, leading to an increase in bone fragility with 
susceptibility to fracture (anonymous Am J Med; 1993). In contrast with earlier consensus 
definitions this definition does no longer state the presence of a non-traumatic fracture 
necessary for the diagnosis of osteoporosis. 
The skeleton consists of two different types of bone. Cortical bone forms the shaft of long 
bones and most effectively resists bending forces. The internal structure of metaphyses of 
long bones and vertebral bodies consists of trabecular bone and is best designed to resist 
compressive stress (Dempster. 1992). Over their lifetimes. women lose about 35 percent of 
their cortical bone and 50 percent of their trabecular bone (Riggs et al., 1981; Mazess, 1982). 
Trabecular bone. with its greater surface area. is metabolically much more active than cortical 
bone and thus more responsive to changes in mineral homeostasis (Parfitt, 1979: Genant et 
al.. 1982; Ntlas et al., 1985). From the onset of perimenopause and during initial years after 
menopause decremental estrogen production leads to increased bone resorption which 
exceeds bone formation, resulting in an accelerated loss of primarily trabecular bone. These 
differences in the rate and timing of cortical bone and trabecular bone loss determine the age 
at which specific osteoporotic fractures occur. The incidence of fracture of trabecular bone 
dominant sites (such as the distal radius, or vertebral bodies) starts to increase within a few 
years after menopause, while at sites predominantly consisting of cortical bone (for example 
the hip) the incidence of fractures increases after the age of 70 (Riggs et al.. 1986). It should 
be mentioned that 90% of the hip fracture are the result of a fa!J (Sattin et al., 1990). 
Furthermore, several risk factors for falling have been identified (Grisso et al.. 1991). 
Prevention of falling may considerably reduce the risk for fracture in osteoporotic elderly. As 
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yet no. specific intervention which has been proved to be widely effective exists. Therefore, 
the first goal for therapy of osteoporosis should be the restoration of bone turnover to 
premenopausal levels. 
Hormone replacement therapy (HRT) of traditional dose regimens has been shown to 
maintain or increase bone mass in healthy as well as in osteoporotic postmenopausal women 
(Ettinger et aL 1987; Munk-Jensen et al., 1988; Christiansen et al., 1990; Stevenson et al .. 
1990). Subsequently, numerous epidemiological and observational studies of traditional HRT 
dose regimens (Weiss et al.. 1980; Krieger et al., 1982; Ettinger et al .• 1985; Kiel et al., 1987; 
Naessen et al., 1990; Kanis et aL 1992; Cauley et al., 1995) and three randomized 
prospective trials (Lufkin et al., 1992; Komulainen et al., 1998; Mosekilde et aL 2000) 
showed a reduction in fracture risk. To maximize the preventive effect on osteoporosis. HRT 
should preferably be started soon after menopause and be continued for at least 7 years. but 
probably for life (Felson et al .. 1993; Schneider et al., 1997). Current use of HRT in various 
countries ranges from 3% in Southeast Asia (Boulet et al.. 1994) to 34% in the United States 
of America (Utian et al.. 1994) and France (Limouzin-Lamothe. 1996). In addition. despite 
well-known advantages of long-term HRT, at present continuation of treatment is poor. In the 
Netherlands, the mean duration of use is only 7 months. Only 8% of women on HRT continue 
beyond 2 years (Groeneveld et al.. 1998). Other studies show similar results (Barlow et al.. 
1991; Speroff et al.. 1991) Fear of breast cancer. and return of vaginal bleedings with the 
addition of progestins to protect the endometrium, are important factors in refusal or 
discontinuation of HRT. Therefore. avoiding or reducing bleedings could improve 
continuation with long-term HRT. 
This review examines the evidence for the effects of tibolone (Org Od 14, Livia!®) on 
bone. Therefore a sensitive search for published information used Medline and the words 
Livia!, tibolone and Org Od 14. The date of the last search was January 2000. The intention 
was to use full journal publications or abstracts not yet published in full. Furthermore. data 
from a formal meta-analysis performed by Organon International (The Netherlands) on the 
efficacy of tibolone in prevention and treatment of osteoporosis are presented in this review. 
Tibolone was first introduced in the Netherlands in 1988 as treatment for vasomotor 
symptoms without the need for scheduled withdrawal bleedings (Kicovic et al .. 1982). 
Tibolone is a Cl9 synthetic steroid with a mixed hormonal profile. showing estrogenic, 
progestagenic, and weak androgenic properties 0fies et al., 1987). Although vaginal bleeding 
may occur in the first months of tibolone use. the incidence of bleeding or spotting episodes 
during the first 6 months is lower compared to a continuous combined regimen (Hammar et 
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al.. 1998). The standard available dose is 2.5 mg daily. Although lower doses (1.25 mg. 0.625 
mg and 0.03 mg) are not yet clinically available. data on their effects on bone will be also 
discussed in the present review. 
3.2 Mixed hormonal profile of tibolone 
In classical in vivo bioassays the estrogenic potency of tibolone is about one-tenth that of 
ethinyl oestradiol, a progestagenic potency less than one-eighth that of norethisterone, and the 
androgenic potency is about one-fiftieth that of 17 a-methyltestosterone (Visser et al.. 1984). 
Endocrine studies in rats and rabbits also showed that tibolone had weak progestagenic 
estrogenic and very weak androgenic effects (Vies eta!., 1987). These actions are receptor 
mediated. as evidenced by the inhibitory effects of anti-estrogens and anti-progestogens. The 
effects of tibolone at the receptor level is complex. since progestogens reduce estrogen 
receptor levels. while estrogens increase progesterone receptor concentrations (Markiewicz et 
al., 1994). 
The complexity is increased by the fact that tibolone is rapidly converted after 
administration into three metabolites: a 3a(OH)-. 3~(0H) metabolite and a L'i4 isomer 
metabolite. These three metabolites of tibolone show different estrogenic and progestogenic 
properties. In vitro, these metabolites were found to exhibit different relative binding affinities 
to human progesterone, estrogen and androgen receptors. Tibolone bound weakly to all these 
receptors: progesterone receptor 1.1% (pure progestagenic agonist: Org 2058 = 100%), 
estrogen receptor 0.5% (estrogen = 100%), androgen receptor 2.4% (dihydrotestosterone = 
100%). The L'i4 isomer only bound to the progesterone (10.4%) and the androgen receptor 
(29.1% ). The 3a(OH) metabolite and 3~(0H) metabolite bound only to the estrogen receptor 
(2.5% and 1.9% respectively). Sintilar results were seen in Chinese hamster ovary cells 
containing progesterone. estrogen and androgen receptors (Kloosterboer, 1997). 
Furthermore, the concentrations of metabolites differ depending on the metabolism of the 
target tissue. It is therefore likely that the estrogenic or progestagenic properties are different 
depending on the target tissue. For example, tibolone and its ~4 isomer stimulate 17~ 
dehydrogenase activity and glycogen accumulation in proliferative endometrium comparable 
to progesterone. In contrast, the 3a(OH)- and 3~ (OH) metabolite increases prostaglandin 
output in proliferative endometrium (i.e. estrogenic effect). Furthermore, it was shown that 
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t:ibolone was extensively metabolised to its ~4 isomer in the endometrium by 
3~hydroxylase/isomerase. (Tang et al.. 1993). These findings suggest a complex receptor 
mediated as well as metabolic regulation of the activity of tibolone at the target tissue leveL 
which probably accounts for tissue specificity in relative estrogenic/progestagenic activities of 
tibolone (Markiewicz et al.. 1990). To what extent tibolone is metabolised in other tissues is 
unknown. However, clinical effects clearly demonstrate estrogenic. progestogenic and 
androgenic properties in different tissues. For instance. tibolone has estrogenic effects on 
bone and in the brain judged by its effects on bone ntineral density (BMD) and vasomotor 
symptoms. In contrast. the progestogenic effect predominates in the endometrium. As far as 
the breast is concerned, all preclinical data suggest that tibolone exhibits no estrogenicity in 
breast tissue (Kloosterboer et al.. 1994; Pasqualini et al., 1997; Chetrite et al.. 1997; Gompel 
et al.. 1997). which is clinically confirmed by lack of effect on breast density assessed by 
mammography (Ere! et al.. 1998) as well as the significantly lower incidence of mastalgia in 
postmenopausal women using tibolone compared to conventional HRT (Mol-Arts et al .. 
1999). 
3.3 Studies in animals 
The effects of tibolone on bone mass. bone metabolism and bone quality have been studied 
extensively in rats. Recently, the effect of varying doses of tibolone administrated once or in 
two portions on trabecular BMD and biochemical markers of bone metabolism in 3-months-
old ovatiectontised rats were compared to varying doses of EE (Ederveen et al.. 1999). 
Trabecular BMD of the distal metaphysis of the femur was measured with peripheral 
Quantitative Computed Tomography or by quantitative x-ray densitometry on defatted bone. 
It was concluded that all doses of tibolone and EE significantly prevent trabecular bone loss. 
In contrast to EE. the effect of tibolone was independent from the frequency of dosing. This 
may be due to differences in plasma half-life of tibolone versus EE. Both tibolone and EE 
showed inhibition of bone resorption judged by the reduction of urinary 
deoxypyridinoline/creatinine excretion. Osteocalcin was dose dependently reduced by 
tibolone as well as EE. There was a significant increase in serum alkaline phosphatase in the 
tibolone treatment group. indicating that tibolone may reduce bone resorption more than bone 
formation. However. since the source of alkaline phosphatase is unknown (bone. liver or 
intestinal isoenzyme) no firm conclusions could be drawn from this observation. Unlike 
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androgens, tibolone significantly reduced length growth of the femur, equalling the effect of 
EE. Furthermore, they found that in the rat, tibolone and EE decreased body weight, which 
indicates that tibolone behaves also in this respect as an estrogenic compound, since 
androgens increase body weight. In addition, a dose dependent prevention of ovariectomy-
induced bone loss of the appendicular as well as axial skeleton was seen in 3-months-old 
ovariectomized rats. treated with varying doses of tibolone. This was comparable with the 
effect seen in rats treated with 0.024 mg of EE (Ederveen et al., 1996). 
Since rats of 3 months of age show skeletal growth in addition to remodelling, the effect of 
ovariectomy-induced bone loss was also tested in 20 months old rats treated for 16 weeks. As 
in young rats, tibolone prevented bone loss in the axial and peripheral skeleton of these 
senescent. skeletal mature ovariectomized rats (Ederveen et al., 1993). 
Bending strength of the femoral diaphysis and compression strength of the vertebral body 
was tested in this rat model to evaluate the effect upon bone quality upon 16 months treatment 
(Ederveen et al.. 1996). Tibolone 1 mg and EE 0,024 mg resulted in a 10% increase in 
bending strength of the femoral diaphysis compared to placebo-treated ovariectomized rats. 
Compression strength of the vertebral body was increased by 60% and 23% for tibolone 
(0.5mgid) and EE (0.024 mg/d), respectively. These data indicate that tibolone is as effective 
as EE in maintaining strength of the cortical bone. Furthermore tibolone was significantly 
more effective in maintaining trabecular bone strength. In mature ovariectomized rats on low 
calcium diet treated with tibolone similar results were seen in respect to femoral and vertebral 
BMD. as well as compression strength of the lumbar vertebra (Kasugai et al., 1998). In 
mature ovariectomized rats on low calcium diet with established osteopenia. tibolone, EE and 
1 alpha(OH) D3 showed increase in trabecular as well as cortical BMD. resulting in an 
increased compressive strength of the vertebral body in the treated group compared to the 
control group. In contrast to lalpha(OH)D3, the effect of tibolone was similar to EE, showing 
a decrease in bone turnover as apparent from biochemical makers of bone metabolism 
( osteocalcin. bone specific alkaline phosphatase. urinary levels of deoxypyridinoline and 
pyridinoline). Accordingly bistomorphometric indices like mineralising surface. bone 
formation rate, osteoclast surface and osteoclast numbers were decreased by tibolone and EE 
(Yoshitake et al.. 1999). 
Interestingly. the protective effects of tibolone and 17~ estradiol on BMD and bone 
metabolism in ovariectomized rats were blocked by a pure anti estrogen (ICI 164.384). The 
anti-androgen (flutamide) however could not block the protective effects of tibolone treatment 
on BMD and markers of bone metabolism. The fact that the anti-estrogen blocks the 
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protective effects of tibolone (and 17~ estradiol) on bone confirms an action through the 
estrogen receptor (Ederveen et al., 1997). 
In sununary, tibolone has been tested exclusively in the rat model. It has been shown that 
t:ibolone can prevent axial and appendicular bone loss induced by ovariectomy and/or low 
calcium diet in young and mature rats. In addition. tibolone increases trabecular and cortical 
BMD in rats with established osteopenia. Similar to estrogens this effect is due to reduction in 
bone turnover and tibolone seems to be as effective as estrogens. The protective effect on 
bone can be blocked by anti-estrogens indicating that the effect is estrogen-receptor mediated. 
Furthermore, tibolone acts as an estrogen rather than androgen in the rat model. Studies on 
bone quality show that the positive effect of tibolone is comparable to that of estrogens. In 
respect to compressive strength of the vertebra tibolone even may be more effective. 
3.4 Studies in postmenopausal women 
At present. the best available secondary endpoint to estimate fracture risk the assessment of 
bone mass (Wasnich et al., 1985: Gardsell et aL 1993:Cummings et al., 1995). Therefore, 
most clinical studies evaluating the efficacy of medications for prevention or treatment of 
osteoporosis have focused on bone mass. 
Various techniques have been developed for the assessment of bone mass. At first single 
photon absorptiometry and X-ray micro-densitometry were used to determine BMD of the 
appendicular skeleton (radius, metacarpal and phalanx). Later dual photon absorptiometry 
made it possible to determioe BMD of the axial skeleton (lumber spine and hip). Dual energy 
X-ray absorptiometry (DEXA) is the modem upgraded version of dual photon 
absorptiometry, it is the current "'gold standard'" method for assessment of BMD (Bracker et 
aL 1998). None of these measurement techniques can differentiate between cortical and 
trabecular bone. Single energy Computed Tomography is the only method that can estimate 
BMD separately in the trabecular and cortical compartment (Sandor et aL, 1985), which, as 
mentioned above, differ in metabolic activity (Parfitt 1979). Correlation between different 
techniques is modest (between 0.6-0.7). This is due to technical differences between 
techniques and to differences in measurement sites. with different compositions (ratio 
cortical/trabecular bone). However, all of the above mentioned techniques have predictive 
power for future osteoporotic fractures (Kuijk et al., 1994). Results ofBMD measurement can 
be expressed as T-scores, defined as the difference of the individual bone mass. compared to 
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the mean peak bone mass of a young reference population expressed in standard deviations. 
For each standard deviation reduction in BlviD there is about a tv.ro-fold increased risk of 
fracture (Marshall et al., 1996). For clinical trials it is advised to measure BMD at least at two 
different sites. In addition. priority should be given to those sites of biological relevance (such 
as spine and hip) (Kuijk et al.. 1994). 
Estimation of bone turnover is another accepted means for evaluation of medications for 
prevention or treatment of osteoporosis. Biochemical markers of bone turnover can be divided 
in markers of bone formation (serum osteocalcin or serum (bone specific) alkaline 
phosphatase) and markers of bone resorption (urinary hydroxyproline. urinary calcium 
corrected for urinary creatinine and Cross Laps ™). 
In 1980 Lindsay and col!egues (Lindsay et al.. 1980) were the first to report the effects of 
tibolone 2.5 mg on postmenopausal BMD of the appendicular skeleton. This randontised, 
double-blind placebo-controlled study showed that tibolone 2.5 mg/d prevented 
postmenopausal metacarpal bone loss. whereas the placebo-group lost 3.6% annually (Table 
1). Twenty-four of these patients (ten oophorectontized and 14 non-oophorectontized) who 
used tibolone. received Tc99m hydroxyethylidene diphosphonate. The 24-hrs whole body 
retention of Tc99m hydroxyethylidene diphosphonate ( a sensitive measure of skeletal 
metabolism), was compared to 23 women receiving a placebo. Tibolone was found to have a 
powerful suppressive effect on skeletal metabolism in both oophorectomized and non-
oophorectomized women when compared with control subjects (Fogelman et al..l981). The 
degree of suppression was similar to that found with estrogen therapy (Fogelman et al., 1980). 
The first report on the effects of tibolone on the lumbar spine was published in 1994 by 
Rymer and colleagues (Rymer et al., 1994). This open controlled study versus none use of 
HRT showed increase of spinal and femoral BMD in postmenopausal women who used 
tibolone 2.5 mg/d for 2 yrs of 2.5% and 3.5%. respectively. In the group of women who did 
not use HRT there was a decrease of 2.9% in spinal and 3.7% in femoral BMD during the 
study period (Table 1). Biochentical markers of bone turnover (serum alkaline phosphatase, 
osteocalcin, and urinary OH proline and Calcium excretion) indicated a suppression of bone 
turnover (Table 2). These data suggest that tibolone behaves similarly to estrogen with regard 
to its effect on biochemistry and bone density measurements. Lyritis co-workers (Lyritis et 
al .. 1995) studied the effect of 25mg tibolone on appendicular BMD. in women immediately 
after a hysterectomy and bilateral oophorectomy because of uterine fibroids and uterine 
bleeding (Table 1). In this open randontized trial 15 women were treated with tibolone 2.5 mg 
Table 1 Effects of libo!one on bone mineral density in studies for prevention of postmenopausal osteoporosis. 
'""""' 
~-c~-~""_"_ '""'- - - ---~~"-~"CUUN'N 
- - ~--~"-~-·----""-~'"'"' --
subject yrs since 
Reference medication subjects number* meno~ause design duration technigue site thera~i placebo 
Lindsay 2,5mg pmp 33/30 0,5-3 db-bl-pc 2 yrs SPA metacarpal no change# -3.6% 
etal., 1980 ovx 
Rymer 2,5mg pmp 46/45 0,5-3 controlled 2 yrs DPA hlp +3.5% -3.7% 
et al., 1994 spine l2-4 +2.5% -2.9% 
Lyrilis 2,5mg ovx 15/10 randomized 1 yr SPA distal radius no change -12.4% 
et al., 1995 1g Ca all controlled proximal radius no change -15.2% 
Berning 2,5mg pmp 35/23 1-3 db-bl-pc 2yrs MOM phalanx +5.5% no change 
eta!., 1996 seOCT spine l2-4 +9.1% -6.4% 
1,25mg 36/23 phalanx +3.1% 
spine l2·4 +4.0°/o 
Bjarnason 2,5mg pmp 28/13 >10 db-bl-pc 2 yrs SPA distal radius +1.9% -2.1% 
etal., 1996 DEXA spine l2-4 +5.1% no change 
1,25mg 29/13 distal radius +2.2% 
spine L2-4 +5.9% 
Gallagher 2,5mg pmp total of 770 ? db-bl-pc 2yrs DEXA spine study 11111 2.6%3/2.6%3 -1.6%/-3.0% 
eta!., 1999 500rng ca all mean age 52 hip study !Ill 0.7%3/1.3%3 -2.0%/-3.2% 
1,25mg spine study 1111 2.1%3/1.8%3 
500mg Ca all hip study !Ill 0.4%2/0.6%3 
0,625mg spine study 1/11 0.7%2/1.5%3 
500mg Ca all hip study 1111 0.8%3/-1.4% 
0,3mg spine study 1111 -0.6%/-0.2%3 
500mg Ca all hlp study 1111 0.5%2/-1.0%1 
Breadsworth 2,5mg pmp 22/20 1-? randomized 2 yrs DEXA hlp no change -3.9% 
eta!., 1999 controlled spine l2-4 +3.7% no change 
•: treatmenVplacebo; # non-significant change from baseline; 12 identical independent studies; 1P<0.05; 2P<0.01; 3P<0.001, treatment versus placebo. 
Pmp, postmenopausal; ovx, oophorectomy; db-bl-pc, double-blind placebo-controlled; SPA, single Photon AbsorpHometry; DPA, dual Photon 
Absorptiometry; seQCT, single energy Quantitative Computed Tomography; DEXA, Dual Energy X-ray Absorpt!ometry. 
Table 2 Effects of tibolone on bone markers in studies for___e.~~~D!~!!"~:~tE~~~!!lw~~~~~~.~-·~!~22~?!9~,~-~~·~·-·--""--
subject yrs since bone 
Reference medication subjects number• menopause design duration marker therapy placebo 
Lindsay 2,5mg 
el al., 1980 
Rymer 2,5mg 
etal., 1994 
Lyritis 2,5mg 
etal., 1995 1g Caall 
Berning 2,5mg 
et al., 1996 
1,25mg 
Bjarnason 2,5mg 
etal., 1996 
1,25mg 
•: treatmenVplacebo 
pmp 
ovx 
pmp 
ovx 
pmp 
pmp 
33/30 
46/45 
15/10 
35/23 
36/23 
28/13 
29/13 
0,5-3 
0,5-3 
1-3 
>10 
db-bl-pc 
controlled 
randomized 
controlled 
db-bl-pc 
db-bl-pc 
2yrs Ca/Cr 
OH-P/Cr 
Alk Phosph 
2 yrs Ca/Cr 
OH-P/Cr 
A!k Phosph 
Osteocalcln 
1 yr OH-P/Cr 
osteocalcin 
2 yrs Ca/Cr 
OH-P/Cr 
Alk Phosph 
Caler 
OH-P/C 
Alk Phosph 
2 yrs OH-P/Cr. 
Crosslaps 
Osteocalcln 
OH-P/Cr. 
CrossLaps 
Osteocalcln 
t 
t 
no change 
t 
t 
t 
t 
t 
t 
t 
t 
• 
• 
• 
no change 
• 
• 
• 
• t 
no change 
no change 
no change 
no change 
no change 
no change 
t 
t 
t 
• no change 
no change 
t 
no change 
no change 
t 
no change 
t 
t 
no change 
t 
Pmp, postmenopausal; ovx, oophorectomy; db-bl-pc, double-blind placebo-controlled; Ca/Cr, urinary calcium creatinin ratio; OH-P/Cr, urinary 
hydroxyprolonln creatlnln ratio; Alk Phosph, serum alkaline phosphatase. 
J..: significant decrease compared to baseline 
1': significant increase compared to baseline 
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* 
* 
* 
* 
Densitometric measurements at 3-month intervals, expressed as percentages of initial 
values (mean ± SEM), 2,5 mg tibolone; 1 ,25 mg tibolone; placebo. BMD spine• BMD of the 
spine (1..,-LJ); BMD ann• BMD of the distal forearm. 
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and calcium 1 g or calcium alone. Women treated with calcium alone had a decrease of BMD in 
the distal radius (12.4%) and radial shaft (15.2%).1n contrast. BMD of the distal radius and radial 
shaft was unchanged in women treated with tibolone and calcium. Furthermore there was a 
decrease in urinary OH proline/creatinine ratio and serum osteocalcin levels were unchanged in 
the tibolone group indicating a decrease in bone turnover rate (Table 2). 
Recently two randomized double-blind placebo-controlled 2-year studies with very similar 
study design evaluated the effect of two doses (1.25mg/d and 2.5 mg/d) of tibolone on the 
appendicular and axial skeleton in early (Berning et al.. 1996) and late (Bjarnason et al.. 1996) 
postmenopausal women (Table 1). In women 1-3 years after menopause there was a dose related 
increase in spinal trabecular BMD measured with single energy Quantitative Computed 
Tomography as well as cortical phalangeal BMD measured with Micro Densitometry (Berning et 
al.. 1996). As shown in Figure L spinal BMD showed an increase in the first year of the study 
with a plateau phase in the second study year. In contrast. the phalangeal BMD showed. after 
6months. a more linear increase throughout the rest of the study period. In late postmenopausal 
women. who were at least 10 years after their natural menopause, the effect of tibolone 1.25 mg 
and 2.5 mg on BMD in the spine and distal forearm were studied in a randomized. double-blind. 
placebo-controlled study (Bjarnason et al.. 1996). Data from this study are shown in Figure 2. 
Both doses of tibolone showed a similar increase in BJ\.ID of the spine and distal foreann. This 
suggests that in contrast to early postmenopausal women. 1.25 mg tibolone is as effective as 2.5 
mg in late postmenopausal women. The reason for this is unknown. As judged from the clinical 
observation of an increased incidence of estrogenic side-effects (such as breast tenderness) in 
late-postmenopausal women using HRT, it could be speculated that women long-deprived of 
estrogens are more sensitive to its effects. Nevertheless. evaluation of a lower dose could be 
interesting in this age group. In both studies, the effect of tibolone on bone turnover in early and 
late postmenopausal women showed a decrease in markers of bone turnover compared. to the 
placebo-group (Table 2). 
As 1.25 mg tibolone was also effective in preventing postmenopausal bone loss. it is of 
interest to determine the minimum effective dose of tibolone in this regard. Recently, preliminary 
data from two large. identical. multi-center, randomized. placebo-controlled. studies to evaluate 
the efficacy and minimum effective dose of tibolone in the prevention of postmenopausal bone 
loss be came available (Gallagher et al., 1999). A total of770 early postmenopausal women were 
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Percent change as compared to baseline in trabecular bone density of the lumbar spine (mean 
and 95% confidence interval) (upper panel) and phalangeal bone density {mean and 95% 
confidence interval) (lower panel) in 64 healthy early postmenopausal women having used 
placebo, 1.25 or 2.5 mg/day tibolone for 2 years (24 months), followed for 1 additional year 
after discontinuation of medication (36 months). 
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randomized to four tibolone treatment groups (0,3 mg/d. 0.625 mg/d, 1.25 mg/d and 2.5 mg/d) 
and a placebo group. Published data on BMD of both studies are also presented in Table I. All 
doses tested were statistically significantly effective in preventing bone loss compared to placebo. 
However, the 1.25 mg/d and 2.5 mg/d doses gave more consistent results with more positive 
changes (increase of BMD above baseline) at both sites in both studies. The dose of 0.625 mg/d 
appears marginally effective. The preferred dose of tibolone for the indication prevention of 
postmenopausal bone loss seems to be 1.25 mg/d. 
Only one study has evaluated the effect of cessation of 2 years' treatment with tibolone on 
trabecular and cortical BMD (Berning et al., 1999). Sixty-four out of 84 women who completed 
the 2-year treatment period evaluating the effect of two doses of tibolone on early 
postmenopausal bone loss (Berning et al., 1996) took part in this follow-up study. Interestingly. 
there was an increased loss of spinal (trabecular) BMD but not phalangeal (cortical) BMD as 
compared to the placebo group in one year after cessation of a 2 yrs of tibolone treatment (Figure 
3). This observation suggests that metabolically active trabecular bone is lost more rapidly 
compared to the metabolic less active cortical bone. Although this follow-up period is short it 
seems that tibolone like estrogens (Felson et al.. 1993: Schneider et al.. 1997) should be 
continued into late life in order to maintain bone density. 
3.5 Studies in women with established osteoporosis 
In !991. the first report (Geusens et al., 1991) of the effect oftibolone on spinal and radial BMD 
in women with established osteoporosis was published by Geusens and colleagues (Table 3). 
Radial B11D did not change significantly in either group. A non-linear increase of 8% in 2 years 
was seen in spinal B11D. The placebo-group lost 2% annually and, probably due to small 
numbers of patients treated, there was no statistically significant reduction in fracture risk. More 
recently. two double-blind. placebo-controlled studies of women with established osteoporosis 
(Pavlov et al.. 1996; Studd et al .. 1996). with and without fractures, clearly showed significant 
increases of BMD in spine and hip compared to the placebo group (Table 3). These studies did 
not demonstrate the non-linear increase seen by Geusens and colleagues (Geusens et al., 1991) 
and reduction in subsequent fractures was not assessed. 
Table 3 Effects of tibolone on bone mineral density and markers of bone metabolism, in studies for treatment of postmenopausal osteoporosis. 
concurrent subject Fracture 
Reference medicatlon treatment number* duration desi_gn technigue site/t~e lheraQy Jacebo risk 
Geusens 2,5mg 14/17 2 yrs db-bl-pc SPA/DPA distal radius no change no change NS 
el at., 1990 proximalradius no change no change 
spine L2·4/ +8.0% -4.0% 
bone marker Ca!Cr no change no change 
OH-P/Cr no change no change 
Alk Phosph no change no change 
Pavlov 2,5mg 63/43 2 yrs db-bl-pc DEXA hip +7.2% no change not done 
et at., 1996 spine L2-4/ +2.6% no change 
bone marker osteocalcln • no change 
Studd 2,5mg Ca 1g 31/36 2 yrs db-bl-pc DEXA hip +2.7% +1.4% not done 
et al., 1996 spine L2-4/ +6.9% +2.7% 
bone marker Ca!Cr • no change OH-P/Cr • no change Alk Phosph 
• 
no change 
*: treatmenUplacebo 
Db-bl-pc, double blind placebo controlled; Ca, elementary calcium; N.S., not significant; SPA, single Photon Absorptiometry; DPA, dual Photon 
Absorptiometry; DEXA: Dual Energy X-ray Absorptiometry; CaJCr, urinary calcium creatinin ratio; OH-P/Cr, urinary hydroxyprolonin creatlnin ratio; 
Alk Phosph, serum alkaline phosphatase .. 
J,; significant decrease compared to baseline. 
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3.6 Comparative studies between tibolone and conventional HRT regimens 
Comparison of placebo-controlled trials using estrogens is hampered by differences in treatment 
regimens (combination with progestogens and/or calcium supplements). types of estrogens used. 
routes of administration and applied methods for bone mass measurement. Earlier studies using dual 
photon absorptiometry or DEXA for estimation of spinal bone mass in postmenopausal women 
using various HRT regimens showed changes between 0 and +15.9% (Riis et al., 1987; Munk-
Jensen et aL. 1988: Stevenson et aL 1990; Ribot et aL, 1990: Marslew et aL. 1992; Eiken et aL. 
1996: Bush (PEP! trial) et aL, 1996: Hart et al .. 1998: Recker et aL, 1999). Studies with tibolone, 
using the same techniques showed comparable changes (between +2.5 and +8.0%) in spinal BMD 
(Geussens et aL 1990: Rymer et aL, 1994; Bjarnason et aL 1996, Pavlov et aL, 1996: Studd et al.. 
1996: Breadsworth et al., 1999). 
Three open. non-randomized comparative head to head studies between tibolone 2.5 mg/d and 
conventional HRT regimens have been carried out. Stephan and Schreiber (Stephan et al., 1995) 
compared tibolone 2.5 mg/d with transdermal estrogens 50~g/d in 38 women after hysterectomy 
and bilateral oophorectomy. Therapy was started 3 months after surgery; 9 patients were not 
treated. BMD of the lumbar spine was measured with DEXA. Bone loss of the lumbar spine was 
7% in the first year. Women using tibolone showed a significant increase in spinal BMD with a 
return to pre-surgery values after 6 months of treatment, whereas women using transdermal, 
estradiol maintained their spinal BMD. Prelevic and colleagues (Prelevic et al., 1996) compared 
tibolone to conjugated equine estrogens with sequential norgestrel for 12 days and transdermal 
17~ oestradiol in 82 postmenopausal women with an mean age of 64 years. Measurement of 
spinal and femoral BMD was performed using DEXA. Women taking tibolone showed a 
significant increase in spinal BMD of 10.3% over 3 years. In contrast. women using conjugated 
equine estrogens or transdermal estrogen showed a non-significant increase over 3 years in spinal 
BMD of 8.1% and 6.6% respectively. There was no significant change of BMD of the hip over 
the 3 yrs. irrespective of the therapy taken. although there was a tendency towards a progressive 
increase in women using tibolone. 
Lippuner and co-workers (Lippuner et al, 1997) compared tibolone 2.5 mg/d with oral 17~ 
oestradiol 2 mg/d or transdermal 17~ oestradiol 50~g/d in combination with dydrogestron during 
14 days. Measurement of spinal. femoral and whole body BMD was performed using DEXA. Of 
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the 140 early postmenopausal women. 30 chose no treatment. Over the 2 years bone preservation 
in spine and hip was observed in all three treatment groups. compared with controls. without 
significant differences among treatment regimens. 
3.7 Meta-Analysis of clinical studies in postmenopausal women 
To describe the overall efficacy of tibolone in the prevention and treatment of osteoporosis. a 
formal meta-analysis (Organon NV January 1997. unpublished) has been carried out. with respect 
to relative change from baseline in BMD measurements of femoral neck and lumbar spine after 2 
years of treatment with 2.5 mg/d tibolone. Included were all long-term clinical trials using dual 
photon absorptiometry or DEXA. in early postmenopausal (Rymer et al.. 1994: Lippuner et al.. 
1997) and osteoporotic women (Geusens et al.. 1991: Pavlov et al.. 1996: Studd et al.. 1996). The 
meta-analysis results for prevention and treatment of osteoporosis trials and for both parameters 
are graphically displayed in figures 4 and 5. Early postmenopausal women (72 treated subjects 
versus 75 subjects using placebo) had an increase in femoral BMD of 4,6% (95% confidence 
interval: 3.0-6.2%) and an increase in spinal BMD of 5.5% (95% confidence interval: 4,4%-
6,7%). Osteoporotic women (80 treated subjects versus 68 subjects using placebo) had an 
increase of femoral BMD of 3.9% (95% confidence intenral: 2,4-5.5%) and an increase in spinal 
BMD of 6,3% (95% confidence interval: 3.5%-9.0%). Therefore it is concluded that tibolone is 
capable of increasing spinal and femoral BMD in early postmenopausal and osteoporotic women. 
However, prevention of fractures remains to be investigated. 
3.8 Tibolone as add-back therapy 
Long-term treatment with gonadotropin-releasing hormone (GnRH) agonist in case of 
endometriosis or uterine fibroids is complicated by a transient complete cessation of ovarian 
function. The estrogen deficiency results in vasomotor symptoms and increased bone loss. 
GnRH-agonist induced bone loss averages l% per month during a 6-month, course (Pickersgill 
1998). which is much greater than an average loss of 2-3% annually during the first years after 
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Figure 4 
Meta-analysis results of percent change from baseline in bone mineral density of the lumbar spine (upper panel) and 
femoral neck (lower panel) in healthy early postmenopausal women treated with tibolone 2,5 mg/d for 2 years. The 
thickness of the tines is proportional to the weight of that study-centre in the meta-analysis. 
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Meta~analysis results of percent change from baseline in bone mineral density of the 
lumbar spine (upper panel) and femoral neck (lower panel) in osteoporotic women 
treated with tibolone 2,5 mg/d for 2 years. The thickness of the lines is proportional to 
the weight of that study-centre in the meta-analysis. 
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natural menopause (Riggs et al., 1986). This limits the duration for which treatment with a 
GnRH-agonist can be given. However. many of the conditions for which GnRH-agonists are 
indicated are chronic or recurrent in nature. The mixed hormonal profile of tibolone seems 
suitable to counteract these unwanted effects of GnRH-agonist treatment. Such concomitant 
therapy is known as add-back therapy. 
A double-blind, placebo-controlled trial (Lindsay et al.. 1996) carried out in 29 women using 
triptorelin (Decapepty1'") for 6 months showed a decrease in spinal BMD measured with DEXA 
of 5.1% in women using a placebo versus a 1.1% decrease in women using additional tibolone 
2.5 mg/d. Bone loss in the femoral neck was not significantly different from the baseline values 
in both groups, reflecting the higher levels of cortical bone at this skeletal site. Furthermore. 
tibolone 2.5 mg significantly reduced vasomotor symptoms without affecting the efficacy of 
triptorelin on the treatment of endometriosis. Another randomized placebo-controlled trial 
(Taskin et al.. 1997) found. like Lindsay and colleagues, a reduction in urinary calcium/creatinine 
ratios indicating decrease in bone resorption with tibolone during GnRH-agonist treatment. 
Although most studies indicate that bone mass is partially or completely restored after 
cessation of GnRH-agonist therapy it could be argued that adverse changes in cancellous bone 
structure may occur during bone loss. This could lead to permanently reduced bone strength, 
even when the total bone mass has been restored. Histomorphometric studies in cancellous bone 
(Compston et al., 1995) from a subset of patients from the study of Lindsay (Lindsay et al., 
1996), showed reductions in connectivity of cancellous bone structure during GnRH-agonist 
treatment. No such changes were seen when tibolone was used as add back therapy. Since these 
adverse structural changes are probably irreversible. the importance of preventing bone loss 
during GnRH-agonist treatment is emphasised. Histomorphometric studies of cortical bone (Bell 
et aL 1997) showed, like cancellous bone. an increased bone turnover during GnRH-agonist 
treatment, which can be counteracted by tibolone 2.5 mg. 
3.9 Conclusion 
From data in rats it can be concluded that tibolone is as effective as estrogens in preventing 
oophorectomy-induced bone loss of the appendicular and peripheral skeleton. Even in osteopenic 
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rats, an increase in BMD is observed. In the rat. administration of tibolone results in an increased 
femoral bending strength, similar to the effect with estrogens. Importantly. the beneficial effect of 
tibolone on bone metabolism is estrogen-receptor mediated since only anti-estrogens block the 
effect of tibolone on bone. Furthermore. in the rat tibolone acts as an estrogen-agonist rather than 
an androgen-agonist. 
In humans. clinical trials have clearly shown that loss of bone in the spine and proximal hlp 
can be prevented with tibolone 2.5 mg/d in early- and late postmenopausal women. In addition, a 
dose of 1.25 mg/d seems to be effective as welL especially in late-postmenopausal women. In 
two large randomized placebo-controlled. dose-finding. studies 1.25 mg/d of tibolone seems to be 
the preferred dose. In accordance with data from the animal studies. clinical trials indicate that 
the effect of tibolone. based on measurements of makers of bone turnover. is an estrogen-like 
decrease in bone turnover. Furthermore. effects of tibolone, on trabecular dominant sites are 
greater compared to cortical bone dominated sites. In women with established osteoporosis, bone 
density of the axial and appendicular skeleton increases v.rith tibolone. In comparative studies. 
tibolone 2.5mgld seems as effective as conventional HRT regimens. However. it should be noted 
that the effects of tibolone on postmenopausal bone mass have yet not been compared with the 
effects of biphosphanates and raloxifene. Furthermore. studies on the magnitude of reduction in 
fracture risk remain to be conducted. 
In premenopausal women. tibolone seems to be effective in preserving bone density in patients 
treated with Gonadotropin releasing hormone agonist. Histomorphometric studies in humans 
indicate that possible irreversible adverse changes in the structure of trabecular bone can be 
prevented by tibolone 2.5 mgld. The effect of tibolone on osteoporosis resulting from other 
causes than postmenopausal and gonadotropin-releasing hormone agonist induced bone loss. 
have not been investigated. 
Finally. tibolone with its mixed hormonal profile seems to have a generally favorable clinical 
profile. It is capable of preventing bone loss in estrogen-deprived women and, in a dose of 2.5 
mg/d it alleviates postmenopausal complaints. As with other "bleed-free'' HRT regimens. vaginal 
bleeding, especially at the beginning of treatment. does occur. However, data suggests that the 
frequency and severity of vaginal bleeding during tibolone treatment is less. compared v.rith 
continuous combined HRT. Late-onset bleeding during tibolone treatment. as with all "bleed-
free·· HRT regimens, merits investigation. Regarding cardiovascular effects. it is yet unknown 
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whether favourable metabolic changes with tibolone such as increased fibrinolysis, unchanged 
coagulation and lowering of lipoprotein (a) will counterbalance the potentially negative effect of 
the decrease in high-density lipoprotein cholesterol. As far as the breast is concerned, all 
preclinical data suggest that tibolone exhibits no estrogenicity in breast tissue. However, effects 
of long-term use of tibolone on incidence of breast cancer or cardiovascular events are yet 
unknown. 
4 
General Discussion and Conclusions 
First objective of this thesis was to evaluate the effect of tibolone on postmenopausal bone 
loss. We studied this issue during a 2-year placebo-controlled randomised trial in healthy 
women, l-3 yrs after spontaneous menopause. In a group of 94 healthy early postmenopausal 
women, tibolone 2.5 mg/d significantly increased trabecular lumbar bone density measured 
with single energy Computed Tomography. After an increase of 9% in the first year of 
treatment there is a plateau phase in the second year, a pattern comparable with estrogens. 
With !.25 mg/d of tibolone the increase was less pronounced (5.6%) but the same pattern of 
increase in trabecular bone density was seen. Cortical phalangeal bone density. measured with 
radiographic absorption densitometry, also showed a significant increase with both doses of 
tibolone, though the pattern of increase was quite different. Cortical bone density started to 
increase after 6 months and then showed a linear increase throughout the study-period. 
Therefore it is concluded that tibolone in a dose of 2.5 mg/d and !.25 mg/d is capable of 
preventing early postmenopausal bone loss. Preliminary data from two large dose-finding 
studies confirm this observation. Furthermore these studies seem to indicate that !.25mg/d 
tibolone is the preferred dose for prevention of early postmenopausal bone loss. However, one 
should bear in mind that 2.5mg/d and not !.25mg/d of tibolone is effective in alleviating 
vasomotor symptoms. Although it is clearly shown from the present. and other studies that 
tibolone effectively prevents postmenopausal bone loss. data on reduction of fracture risks are 
lacking. In order to establish the effectiveness of tibolone in prevention and treatment of 
postmenopausal osteoporosis. data from a large-scale randomised clinical trial focussing on 
fracture risk are mandatory. Recently. such a trial bas been started so data on magnitude of 
fracture risk reduction will become available within a few years. 
The second objective was to determine the rate of bone loss after discontinuation of 
tibolone treatment. We addressed this issue during a one-year follow-up study in a group of 
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64 postmenopausal women. who completed the initial study. Like in the initial 2-year study. 
the pattern in change of trabecular and cortical bone density is quite different In contrast to 
the decrease of cortical bone density, there was a greater decrease of trabecular bone density. 
compared to the placebo group. These observations suggest that there is an accelerated loss of 
metabolically more active trabecular bone. but not of cortical bone following cessation of 2-
year tibolone intake. Although our follow-up period is short. most of the increase of 
trabecular bone density is lost within one year after cessation of tibolone treatment. It seems 
therefore that replacement therapy with tibolone like with estrogens should be continued into 
late life in order to maintain high bone density. In literature there is controversy about 
whether or not there is an accelerated loss of bone density after HRT. This is partly due to the 
different techniques of bone mass measurements used. as well as skeletal sites measured. Data 
concerning early HRT use and bone density later in live are available from the Framingham 
Study. Only early HRT longer than 7 years resulted in a higher bone density up to 75 years of 
age. Even this duration of HRT in early postmenopause may have little residual effect on 
bone density among women older than 75 years of age. who are at the highest risk for hlp 
fractures. Data from a cross-sectional study also suggests that past estrogen use provides little 
or no long-term benefit for preservation of bone density. It is therefore that the possibility of 
an alternative strategy to start HRT many years after menopause and to continue treatment for 
the rest of woman's lifetime, in order to prevent osteoporotic fractures has been proposed. 
Biphosphonates are the treatment of choice in osteoporotic postmenopausal women. 
However, at present treatment with biphosphonates is limited to a maximum duration of 5 
years. For late postmenopausal women with low bone mass. preventive treatment with a 
tibolone 1.25 mg/d or raloxifene seems promising. 
We also reported on the incidence of vaginal bleeding in early postmenopausal women and 
the effect of tibolone on the endometrium during the 2-year placebo-controlled randornised 
trial. The incidence of vaginal bleeding our study was 51% for 2.5 mg/d tibolone and 44% for 
1.25 mg/d tibolone. In contrast to the incidence of vaginal bleeding the number of bleeding 
episodes was dose related. In women who bled we found no stimulatory effect on the 
endometrium nor could we confirm the earlier suggestion that endogenous estrogen levels 
were related to the occurrence of vaginal bleeding during tibolone treatment. Nevertheless. as 
with any .. bleed-free" HRT regimen, late onset bleeding or recurrent bleeding merits full 
investigation. 
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In respect to the effect of tibolone on breast tissue and cardiovascular system there is 
uncertainty. This is due to lack of epidemiological data or other studies capable of measuring 
clinical events such as myocardial infarction, arteriosclerosis or breast cancer. 
Preclinically data show that tibolone has favourable effects on breast tissue. Tibolone 
decreases cell proliferation, stimulates cell differentiation and apoptosis. In the rat its effect 
with respect to prevention and treatment of D:MBA induced mammary cancer is comparable 
to tamoxifen. Regarding cardiovascular effects. it is yet unknown whether favourable 
metabolic changes with tibolone such as increased fibrinolysis. unchanged coagulation and 
lowering of lipoprotein (a) will counterbalance the potentially negative effect of the decrease 
in high-density lipoprotein cholesterol. These uncertainties need to be addressed by studies 
powered to detect relevant risk. Pethaps the recently started large-scale fracture study will 
provide some answers in the near future. Furthermore, the uncertainties of tibolone treatment 
have to be balanced with known problems of conventional HRT. These include increased risk 
of breast cancer. increased risk of deep venous thrombosis and lack of compliance due to 
bleeding problems, especially in late postmenopausal women. Therefore tibolone can be an 
attractive alternative for conventional HRT in patient-specific situations. 
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6 
Summary I Samenvatting 
Chapter 1 
This chapter aims at providing the reader with a brief overview of the history and 
development of knowledge regarding climacteric complaints and hormonal replacement 
therapy. In more detail, it compares the use of tibolone as hormonal replacement therapy with 
continuous combined regimens of hormonal replacement and raloxifene. 
Chapter2 
Section 2.1 Is there an influence of oral contraceptive use, parity and lactation on early 
postmenopausal bone mass? Is assessment of reproductive history, body weight in combination 
with biochemical markers of bone metabolism suitable to predict lumbar bone mass soon after 
menopause? The present study is a cross-sectional stndy in 94 healthy, nortnal weight, non-
smoking women, 1-3 years after spontaneous menopause. Bone mineral density (BlVID) of the 
lumbar spine was measnred with quantitative computed tomography. Multiple regression 
analysis showed that ouly total dnration of lactation and alkaline phosphatase (AP) levels are 
independently related to trabecular BMD (P=O.OOJ, ?=0.002 respectively). AP was also 
associated with cortical BMD (?=0.003). Assessment of reproductive history, body mass index 
and biochemical markers of bone metabolism could ouly account for 17% of the variation of 
trabecular BMD observed in the study population. This study suggests that total dnration of 
lactation rather than parity is associated with trabecular BMD of the spine. Clinical assessment of 
risk factors unsuccessfully predicts lumbar BMD in healthy early postmenopausal women. 
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Section 2.2 This randomized. double-blind. placebo-controlled. two-year study is the first to 
evaluate the effect of 1.25 mg and 2.5 mg tibolone daily oral administration. on trabecular and 
cortical bone loss in early postmenopausal women. Ninety-four healthy. normal weight. non-
smoking women, 1-3 years following spontaneous menopause. participated. Twenty-three 
subjects were randontised to the placebo group. 36 to the 1.25 mg/d tibolone group and 35 to the 
2.5 mg/d tibolone group. Bone density was assessed at 6 months intervals. Spinal trabecular 
BMD was measured with quantitative computed tomography. Phalangeal cortical BMD was 
measured by radiographic absorptiometry. The 2-year change versus baseline in the placebo 
group for trabecular BMD was -6.4% (95% CI -8.1 to -4.7). Cortical BMD did not change 
significantly. At 24 months both tibolone groups showed a statistically significantly higher 
trabecular [9.4% (6.6 to 12.2) for the 1,25 mg group and 14.7% (95% CI ll.8 to 17.5%) for the 
2.5 mg group] and phalangeal BMD [4.4% (95% CI 1.5 to 7.4) for the 1.25 mg group. and 6.8% 
(95% CI 3.8 to 9.8) for the 2.5 mg group] as compared to the placebo group. After 2 years of 
tibolone in both regimes trabecular and phalangeal BMD was significantly higher as compared to 
pre-treatment values. At 24 mon1hs the 2.5 mg group showed a significantly higher trabecular 
(p<O.OOl) but not phalangeal (p=0.064) BMD compared to the 1.25 mg group. Tibolone prevents 
early postmenopausal bone loss by inducing an increase in trabecular and phalangeal B:rvt:D. 
Section 2.3 This study assessed the loss of BMD one year after a 2 yr period of hormone 
replacement therapy CHRn wi1h two doses of tibolone as compared to placebo in early 
postmenopausal women. Sixty four out of 84 women ( 1-3 yrs following spontaneous 
menopause) who completed a 2 yr randontised. placebo controlled study to evaluate effects of 
tibolone participated in tltis follow-up study. Quantitative computed tomography was used to 
exclusively measure trabecular BMD. nticro densitometry of the ntid phalangeal shaft was 
used for estimation of cortical BMD and biochentical markers of bone metabolism were 
assessed. one year after discontinuation of tibolone. The study group received either placebo 
(n=l6). 1.25 mg/d tibolone (n=25) or 2.5 mg/d tibolone (n=23). Observations revealed a 
significantly greater decrease in trabecular BMD during tile post-trial year in both treatment 
groups compared to the placebo group [for 1.25 mg/d tibolone: -6.0%. (95% CI -8.4 to -3.5): 
for 2.5 mg/d tibolone: -10.0%. (95% CJ:-12.9 to -6.9)). In contrast. 1here was no significant 
difference in loss of phalangeal BMD in both treatment groups compared to placebo. 
Biochentical markers (serum alkaline phosphatase. urinary excretion of hydroxyproline and 
calcium) do not suggest an increased bone turnover comparing tibolone groups to placebo. 
one year after cessation of tibolone. The present study suggests an increased loss of trabecular 
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but not cortical BMD as compared to the placebo group in the first year after cessation of 
HRT with tibolone in early postmenopausal women. 
Section 2.4 This study investigates the potential correlation between vaginal bleeding and 
estradiol (E2) levels/endometrial morphology in early postmenopausal women using tibolone. 
A 2 year randomised placebo-controlled study of 94 healthy women, 1-3 years after 
spontaneous menopause. receiving either placebo (n=23). 1.25 mg/d (n=36) or 2,5 mg/d 
(n=35) tibolone. Episodes of vaginal bleeding throughout the 2 year study period were 
recorded. Age. age of menopause, months since menopause and Body Mass Index were 
recorded. Serum E2 levels were assessed at baseline and at 3 months intervals throughout the 
study period. In case of vaginal bleeding endometrium morphology was assessed by V abra 
Curettage. At least one period of vaginal bleeding occurred in 51% (n::;;;l8. P<0.05) of women 
in the 2.5 mg/d tibolone group and in 44% (n=l6, P=0.07) of the 1.25 mg/d tibolone group. 
compared with 22% (n=5) in the placebo-group. The women who bled in the placebo-group 
were younger (P<O.Ol). had menopause at an earlier age (P<0.05), had an shorter duration 
since menopause (P<0.05) and had a higher median E2 serum level prior to bleeding 
(P<0.05). In contrast. in both tibolone groups no determinants could be found for the vaginal 
bleeding. Ninety percent of the first bleedings occurred within 9 months after starting the 
treatment. At Vabra endometrium sampling there was no evidence of endometrial stimulation. 
In the present study, early postmenopausal women using 1.25 mg/d or 2.5 mg/d tibolone are 
2-2.5 times more likely to present with vaginal bleeding compared to placebo (p<0.05) 
without evidence of higher serum E2levels or endometrial stimulation. 
Chapter3 
This chapter reviews the evidence for the effects of tibolone on bone. Tibolone is a synthetic 
steroid with a mixed (estrogenic/progestagenic/androgenic) hormonal profile. Data suggest a 
complex receptor mediated as well as metabolic regulation of the activity of tibolone at target 
tissue level. It has been shown that tibolone can prevent axial and appendicular bone loss 
induced by ovariectomy and/or low calcium diet in young and mature rats. In addition. 
tibolone increases trabecular and cortical BMD in rats with established osteopenia. In the rat, 
treatment with tibolone results in an increased strength of the femoral neck and of vertebral 
body similar to estrogens. The protective effect on bone can be blocked by anti-estrogens 
indicating that the effect is estrogen-receptor mediated. 
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Clinical trials have shown that loss of bone in the spine and proximal hip can be prevented 
with tibolone 2,5 mg/d in early and late postmenopausal women, In addition, a dose of 1,25 
mg/d seems to be effective as well, especially in late postmenopausal women, In women with 
established osteoporosis, bone density of the axial and appendicular skeleton increases with 
tibolone. In comparative studies. tibolone 2.5mg/d seems as effective as conventional HRT 
regimens. There are no direct comparative studies betv.reen tibolone and biphosphonates or 
raloxifene. Furthermore. to establish the efficacy of tibolone for prevention osteoporotic 
fractures, studies on the magnitude of reduction in fracture risk remain to be conducted. 
Finally. tibolone seems to be effective in preserving bone density in patients treated with 
gonadotropin-releasing hormone agonist. 
Chapter4 
This chapter summarises the conclusions that can be drawn from this thesis and gives 
directions for future research. 
Samenvatting (Dutch) 
Hoofdstuk 1 
Dit hoofdstuk geeft een overzicht van de historie en ontwikkeling van de kennis betreffende 
climacteriele klachten en hormonale substitutietherapie (HST), Tevens wordt het gebruik van 
tibolone als HST vergeleken met substitutietherapie door middel van continu gecombineerde 
oestrogeen-progestageen preparaten en raloxifene. 
Hoofdstuk2 
Paragraaf 2.1 Belnvloedt het gebruik van orale anticonceptiva, pariteit en lactatie de vroeg 
postmenopauzale botmassa? Voorspelt de gynaecologische/obstetrische voorgescbiedenis, 
lichaamsgewicht gecombineerd met biochemische markers van het botmetabolisme de 
botdichtheid van de wervelkolom vlak na de menopauze? Het betreft bier een cross-sectionele 
studie met 94 gezonde. niet rokende, postmenopauzale vrouwen, 1-3 jaar na de spontane 
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menopauze. Trabeculaire botdichtheid van de lumbale wervelkolom werd gemeten met 
behulp van quantitatieve computer tomografie. Uit de multipele regressie-anatyse blijkt dat 
aileen totale duur van lactatie en serumwaarde van het alkalisch fosfatase onafhankelijk van 
elkaar geassocieerd zijn met de trabeculaire botdichtheid van de lumbale wervelkolom 
(respectievelijk: P=O.OOI en P=0.002). Alkalisch fosfatase was ook geassocieerd met de 
corticate botdichtheid (P=0.003). Parameters van de gynaecologische en obstetrische 
voorgeschiedenis. alsmede lichaarnsgewicht en markers van het botmetabolisme verklaren 
slechts 17% van de vatiatie in trabeculaire botdichtheid van de lumbate wervelkolom. De 
gevonden resultaten suggereren dat totale duur van lactatie en niet pariteit geassocieerd is met 
de botdichtheid van de lumbate wervelkolom. Tevens blijkt dat met evatuatie van klinische 
risicofactoren. in een gezonde populatie van vroeg postmenopauzale vrouwen. de lumbale 
botdichtheid van de wervelkolom niet voorspeld ktm worden. 
Paragraaf 2.2 Het effect van twee doseringen tibolone (1.25 mg- en 2.5 mg per dag) op het 
trabeculaire en corticale botverlies wordt geevalueerd. Het betreft een tweejarig prospectief. 
gerandorniseerd, dubbelblind. placebo gecontroleerd onderzoek Vierennegentig gezonde 
postmenopauzale vrouwen. I tot 3 jaar na de spontane menopauze worden in een 2:3:3 ratio 
gerandorniseerd in een placebogroep en twee behandelgroepen. Botdichtheid van het 
trabeculaire bot van de lumbale wervelkolom wordt gemeten met behulp van kwantitatieve 
computer tomografie. Het corticale bot van de phalanx wordt gemeten met behulp van 
radiologische absorptiometrie. In de placebogroep bedraagt het verlies aan trabeculaire 
botdichtheid 6.4 %. over een periode van 2 jaar. Er is geen significant verlies van corticale 
botdichtheid gedurende deze periode. Na 2 jaar is er sprake van een significant hogere 
botdichtheid in de beide behandelgroepen vergeleken met de placebogroep. Voor de 
trabeculaire botdichtheid bedraagt het verschil 9.4% (95% betrouwbaarheidsintervat: 6.6% tot 
12.2%) en 14.7% (95% betrouwbaarheidsintervat: 11.8% tot 17.5%) in respectievelijk de 1.25 
mg behandelgroep en de 2.5 mg behandelgroep. Voor de corticale botdichtheid bedraagt het 
verschil 4.4% (95% betrouwbaarheidsintervat: 1.5% tot 7.4%) en 6.8% (95% 
betrouwbaarheidsintervat: 3.8% tot 9.8%) in respectievelijk de 1.25 mg behandelgroep en de 
2.5 mg behandelgroep. Na 2 jaar is zowel de trabeculaire ats corticate botdichtheid in beide 
tibolone behandelgroepen significant gestegen. In tegenstelling tot de corticale botdichtheid is 
na 2 jaar de trabeculaire botdichtheid in de 2.5 mg behandelgroep significant hoger dan de 
trabeculaire botdichtheid in de 1.25 mg behandelgroep. Uit bovenstaande blijl..-t dat dagelijkse 
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inname van zowel 1.25 mg als 2.5 mg tibolone niet aileen vroeg postmenopauzaal verlies van 
botmassa voorkomt, maar de botmassa zelfs doet toenemen. 
Paragraaf 2.3 Deze studie evalueert het verlies van trabeculaire en corticale botdichtheid na 
behandeling met 1.25 mg of 2.5 mg tibolone. Tevens wordt bet verlies vergeleken met een 
placebogroep. Vierenzestig. van totaal vierentachtig woeg postmenopauzale vrouwen, welke 
bet in paragraaf 2.2 beschreven onderzoek voltooiden, nemen deel aan deze "follow-
up"studie. Een jaar na voltooiing van het eerder beschreven onderzoek wordt de trabeculaire 
en corticale botdichtheid gemeten (voor methode zie paragraaf 2.2). Ook worden markers van 
het botmetabolisme (serum alkalisch fosfatase, in de urine uitgescheiden hydroxyproline en 
calcium) bepaald. Er is sprake van een versneld verlies van trabecnlaire botdichtheid, na 2-
jarige behandeling met 1.25mg of 2.5mg tibolone. vergeleken met de placebogroep. Het 
trabeculaire verlies van botdichtheid bedroeg 6% (95% betrouwbaarheidsinterval: -SA% tot-
35%) in de 1.25 mg behandelgroep en 10% (95% betrouwbaarheidsinterval: -12,9 tot --<J.9) in 
de 2.5 mg behandelgroep. In tegenstelling tot het verlies van trabeculaire botdichtheid kan 
geen significant verschillend verlies van corticale botdichtheid worden aangetoond. Een jaar 
na behandeling met tibolone tonen biochemische markers voor botmetabolisme geen 
verhoogde botombouw in de behandelgroepen vergeleken met de placebogroep. De resultaten 
van deze studie wijzen in de richting van een verhoogd verlies van trabeculaire botdichtheid 
maar niet van corticale botdichtheid. na het staken van HST met tibolone. 
Paragraaf2.4 Deze studie onderzoekt de eventuele relatie tussen vaginaal bloedverlies tijdens 
gebruik van tibolone enerzijds en endogene oestrogeenspiegels en morfologie van het 
endometrium anderzijds. Het betreft een 2 jaar durende gerandomiseerde placebo 
gecontroleerde studie waarin 94 gezonde postmenopauzale vrouwen 1 tot 3 jaar na hun 
spontane menopauze deelnemen. Randomisatie resulteert in een placebogroep (n==23), 1.25 
mg tibolone groep (n=36) en een 2.5 mg tibolone groep (n=35). Episoden van vaginaal 
bloedverlies gedurende studieperiodes worden geregistreerd evenals leeftijd, leeftijd ten tijde 
van de menopauze. aantal maanden na de menopauze en de Quetelet Index. Serum oestradiol 
spiegel wordt voor aanvang van het onderzoek en vervolgens elke drie maanden gedurende de 
studieperiode bepaald. Indien vaginaal bloedverlies optreedt wordt een V abra Currettage 
uitgevoerd. Tennrinste een episode van vaginaal bloedverlies treedt op bij 51% (n=l8. 
P<0.005) van de vrouwen in de 25mg tibolone groep en in 44% (n=l6. P=0.07) van de 
vrouwen in de 1.25 mg tibolone groep, vergeleken met 22% (N=5) van de vrouwen in de 
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placebogroep. De vrouwen bij wie vaginaal bloedverlies optreedt in de placebogroep. zijn 
jonger (P<O.Ol). hebben een jongere leeftijd ten tijde van de menopauze (P<0.05) en de 
mediane oestrogeenspiegel voorafgaand aan de bleeding was hager (P<0.05). In tegenstelling 
tot de placebogroep, kan bij de tibolone behandelgroepen geen significante factoren voor het 
optreden van vaginaal bloedverlies worden gevonden. Negentig procent van de eerste 
vaginale bloedingen tijdens het gebruik van tibolone treedt op in de eerste 9 maanden. De 
verrichte Vabra Curettages lieten geen aanwijzingen zien voor stimulatie van het 
endometrium. In deze studie blijkt de kans op vaginaal bloedverlies. tijdens het gebruik van 
1.25 mg of 2.5 mg tibolone, 2 tot 2.5 maal zo groat vergeleken met het gebruik van een 
placebo (p<0,05), zonder dat er aanwijzingen zijn voor een verhoogde endogene 
oestrogeenspiegel of stimulatie van het endometrium. 
Hoofdstuk3 
Dit hoofdstuk geeft een overzicht van de tot nu toe gepubliceerde studieresultaten met 
betrekking tot het effect van tibolone op het bot. Tibolone is een synthetisch steroid met 
gemengd ( oestrogeenlprogestageenlandrogeen) hormoonprofiel. Studieresultaten over de 
weefselspecificiteit van tibolone wijzen in de richting van een receptor afhankelijk, alsmede 
metabool afhankelijk mechanisme dat de activiteit van tibolone op het niveau van het 
doelorgaan regelt. Uit dierstudies blijl1: dat tibolone in staat is botverlies tengevolge van 
ovariectomie of calcium arme voeding. te verhinderen in zowel jonge als volwassen ratten. 
Bovendien neemt zowel de trabeculaire als corticale botdichtheid toe indien osteopenische 
ratten worden behandeld met tibolone. Uit studies met ratten blijkt dat behandeling met 
tibolone leidt tot een toename in botsterl1:e van het femur en wervellichaarn. Dit effect is 
vergelijkbaar met dat van oestrogenen. Toevoeging van een anti-oestrogeen blokkeert het 
beschermende effect van tibolone op het bot van de rat. Dit suggereert dat het effect van 
tibolone op bot plaatsvindt via de oestrogeenreceptor. Klinische studies tonen aan dat verlies 
van botdichtheid in heup en wervellichaam van vroeg postmenopauzale en oudere 
postmenopauzale vrouwen kan worden voorkomen door behandeling met 2.5 mg tibolone. 
Een dosering van 1.25 mg tibolone bliil1: ook verlies van botdichtheid te kunnen verhinderen. 
met name bij oudere postmenopauzale vrouwen. In vrouwen met osteoporose wordt. tijdens 
de behandeling met tibolone, een toename van botdichtheid van zowel het perifere- als axiale 
skelet gezien. Uit vergelijkende studies blijl.:t tibolone even effectief als conventionele HST te 
126 
zijn. Er zijn geen vergelijkende studies tussen tibolone enerzijds en bifosfanaten en raloxifene 
anderzijds. Om de effectiviteit van tibolone met betrekking tot het verminderen van 
osteoporotische fracturen aan te tonen, moet nog gerandomiseerd onderzoek met 
osteoporotische fracturen als eindpunt, worden verricht. Tot slot lijkt tibolone effectief in het 
voorkomen van botdichtheidsverlies in patienten die worden behandeld met een 
gonadotropin-releasing hormone agonist. 
Hoofdstuk4 
Dit hoofdstuk geeft een overzicht van de studieresultaten van dit proefschrift en doet 
suggesties voor toekomstig onderzoek. 
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